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stAR steroidogenic acute regulatory protein 
STAT3 signal transducer and activator of transcription 3 
SVE synaptic vesicle endocytosis 
T2DM Type 2 Diabetes mellitus 
TBS tris buffered saline 
TBST tris buffered saline tween 
TCF transcription factor 
TH tyrosine hydroxylase 
TNF-α tumour necrosis factor-alpha 
TPKII tau protein kinase II 
TrkB tropomyosin receptor kinase B 
tRNA transfer ribonucleic acid 
TRPV-1 transient receptor potential vanilloid-1 
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VAMP vesicle-associated membrane protein 
v/v volume to volume 
w/v weight to volume 
WFS1 Wolfram syndrome 1 
WT wild type 
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Amino Acid Code Three Letter Code Single Letter Code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ilo I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenyalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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ABSTRACT 
 
The discovery of Cyclin-dependent 5 (Cdk5) added a new member to the mammalian 
Cdks, appearing uncharacteristic of its family members despite strong sequence 
homology. In contrast to the mitotic Cdks, Cdk5 exerts no apparent role in cell cycle 
regulation therefore its potential role in cancer is subject to much controversy.  
 
Cdk5 is heavily depicted as a neuronal-specific kinase, due to its association with 
neuronal activators, and dysregulation of Cdk5 activity is thought to contribute to the 
pathogenesis of several neurodegenerative diseases, including Alzheimer’s disease. 
Nonetheless, the physiological functions of this kinase are being complicated by an 
upsurge in potential substrates that implicate Cdk5 activity in extra-neuronal functions 
and diseases such as cancer. However, the predicted substrates fail to meet a general 
consensus sequence and are yet to be fully validated in vivo. Furthermore, the 
involvement of Cdk5 in pathophysiological pathways is only partially understood. 
Adding further complexity, truncation of the Cdk5 cofactor, p35 is thought to increase 
the catalytic ability of the Cdk5 complex and alter its substrate specificity profile, 
although little evidence has been provided to support this claim.    
 
In the present study, in vitro peptide analysis was performed in an attempt to identify 
a consensus sequence that regulates Cdk5 substrate phosphorylation, as a consensus 
for Cdk5 substrate selection is generally considered degenerative. Despite this theory, 
Cdk5 displayed high peptide selectivity that was shown to be distinct from other 
members of the CMGC family of proteins to which it belongs. While Cdk5 showed a 
preference for basic residues, interestingly, it was the presence of a proline residue 
located N-terminally (-2) relative to the phosphoacceptor residue that appeared to 
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dictate substrate phosphorylation. Further in vitro analysis using full-length proteins 
confirmed a correlation between substrates possessing the optimal consensus residues 
and substrate phosphorylation; those containing these residues were phosphorylated to 
a greater extent in vitro compared to those lacking these residues. Furthermore, both 
Cdk5 complexes displayed similar substrate profiles and inherent catalytic ability, as 
determined by comparison of phosphorylation kinetic parameters between complexes, 
despite the notion of a hyperactive complex with altered substrate specificity 
following activator truncation.  
 
Following manipulation of Cdk5 activity in cell lines and intact tissue, tau and 
CRMP2 were confirmed as Cdk5 targets. Subsequently, a panel of total and phospho-
specific antibodies to each substrate was assessed for compatibility with the 
immunohistochemistry protocol to serve as a surrogate for examining Cdk5 activity in 
tumours. For the first time, this study presents abnormal CRMP2 phosphorylation at a 
Cdk5 sensitive site in the nuclei of lymphoma, lung, and breast tumour cells, 
implicating Cdk5 activity in tumourigenesis. Furthermore, this is the first implication 
of long-form CRMP2 (CRMP2A) in the nucleus and potentially the isoform 
associated with cancer.    
 
Overall, the data presented in this study provides a platform in which to improve 
mechanistic insight into tumourigenesis in specific forms of cancer, which will 
potentially provide new diagnostic and therapeutic strategies for cancer in the near 
future.   
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Protein phosphorylation, mediated by protein kinases and opposed by protein 
phosphatases, is one of the most widespread regulatory mechanisms in eukaryotes, as 
well as being the major molecular mechanism through which protein function is 
regulated in response to extracellular stimuli (Newman et al., 2014). As a 
consequence, protein kinases comprise one of the largest families of evolutionarily 
related proteins and comprise one of the most abundant gene families in humans, 
encompassing ~600 members (Mannin, 2002). Phosphorylation of target substrates 
dynamically regulates protein activity, changes in protein complexes, subcellular 
localisation, marks proteins for degradation, and serves to orchestrate the activity of 
almost all cellular processes (Peck, 2006). Kinases are heavily involved in signal 
transduction and coordination of complex functions such as the cell cycle (Rauch et 
al., 2011).   
 
To ensure signalling specificity in response to a given environmental stimulus, 
phosphorylation networks must be precisely coordinated in cellular space and time 
(Newman et al., 2014). This involves regulation at several different levels, including 
the levels of protein kinase expression, substrate specificity and selection, and 
spatiotemporal regulation of enzymatic activity. Dysregulation can have profound 
effects and contribute to the pathophysiology of many pervasive diseases, including 
cancer (Guha et al., 2008; Deschenes-Simard et al., 2014), diabetes (Guo, 2014; 
Mackenzie & Elliott, 2014; Ortsater et al., 2014), and heart disease (Kooij et al., 
2014; Sciarretta et al., 2014). Therefore, understanding the regulation and effects of 
manipulating kinase activity and isolating the physiological implications of protein 
kinases is of ultimate importance as a therapeutic option. Consequently, therapies 
based on this fundamental mechanism are one of the largest and fastest growing areas 
of drug discovery. 	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1.1 INTRODUCING AN UNUSUAL CYCLIN-DEPENDENT KINASE 
The Cyclin-dependent kinases (Cdks) are a large family of proline-directed serine-
threonine kinases that are well known for their role in the regulation of the eukaryotic 
cell cycle (Figure 1.1). The family has been highly conserved throughout evolution, 
reflecting its key roles in cell growth and division. The Cdk family consists of nine 
small (30 - 35 kDa) kinases, numbered according to their discovery, from Cdk1 to 
Cdk9 (Morgan, 1997). The biological function of these kinases ranges from a 
fundamental role in the control of mitosis through to regulation of key cellular 
processes, such as differentiation, senescence, and apoptosis (Tannoch et al., 2000). 
In proliferating cells, Cdk dysregulation is associated with tumour formation, whereas 
their disappearance/inhibition in neuronal precursors coincides with terminal 
differentiation (Okano et al., 1993). 
 
Cdk activity generally requires association with regulatory subunits, the best known 
of which are the cyclins. Specific Cdks are associated with different phases of the cell 
cycle however their activities can sometimes overlap depending on their binding with 
different cyclins (Morgan, 1997; Nguyen et al., 2002; Nigg, 2001).  
 
Despite strong sequence homology to mouse Cdk1 and human Cdk2 (Hellmich et al., 
2002), Cdk5 is considered the atypical member of the Cdk family of proteins. In 
direct contrast to the mitotic Cdks, Cdk5 exerts no apparent role in cell cycle control 
and is most active in postmitotic neurons (Lew et al., 1992). This is attributed to high 
expression of its specific activators in the nervous system and together the Cdk5 
complex plays an important role in neuronal development and neurotransmission. The 
dysregulation of Cdk5 activity is thought to contribute to the pathogenesis of 
neurodegenerative diseases, including Alzheimer’s disease (AD) (Cruz & Tsai, 2004). 
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Figure 1.1. Regulation of cell cycle progression by Cdk-Cycln complexes. As a cell progresses though 
the cell cycle, successive waves of Cdk activity rise and fall as cyclins are synthesised and then 
degraded by the proteasome after ubiquitylation. In response to mitogenic signals, D-type cyclins are 
synthesised and subsequently direct Cdk4 (and/or Cdk6) to phosphorylate pocket proteins such as the 
retinoblastoma (Rb) tumour suppressor. At the G1/S transition, the cyclin E/Cdk2 complex functions to 
trigger chromosomal DNA replication and to initiate centrosome duplication. The cyclin A/Cdk2 
complex collaborates with cyclin E/Cdk2 to regulate DNA replication both positively and negatively to 
ensure that DNA is only replicated once. Finally, cyclin B/Cdk1 activity reorganises the cell for mitosis 
(Moore, 2013).  
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1.2 DISCOVERY AND CHARACTERISATION OF CDK5  
In the early 1990s, a novel Cdk family member was described by four independent 
groups: firstly, an activity termed brain proline-directed kinase (BPDK), was purified 
from bovine brain based on the ability to phosphorylate a synthetic peptide containing 
the phosphorylation consensus sequence for yeast p34cdc kinase, a protein kinase 
integral to the eukaryotic cell cycle (Lew et al., 1992); simultaneously, a sequence 
termed PSSALARE (alpha C helix) was identified using reverse-transcriptase 
polymerase chain reaction (RT-PCR) of HeLa cell mRNA with degenerate primers 
corresponding to conserved regions of Cdc2 (Meyerson et al., 1992); thirdly, a cDNA 
was cloned from a rat brain cDNA library as an enzyme that could phosphorylate 
lysine-serine-proline motifs of neurofilaments and was, subsequently, termed 
neuronal cdc-2-like kinase (nclk) due to strong sequence homology to mouse Cdk1 
(58%) and human Cdk2 (61%) and its high expression in terminally differentiated 
neurons no longer in the cell cycle (Hellmich et al., 1992); finally, a kinase that 
associated with microtubules and phosphorylated the Alzheimer’s related protein Tau 
(Tau protein kinase II (TPKII)) was identified (Ishiguro et al., 1992). Following the 
identification of the 33 kDa protein non-cyclin regulatory subunit and the 
confirmation of the high homology with Cdks, the consensus nomenclature for these 
four activities became Cdk5 (Kobayashi et al., 1993).  
 
The chromosomal location of the Cdk5 gene was mapped to 7q36 using a genomic 
clone encoding human Cdk5 (Demetrick, 1994). The Cdk5 protein is encoded by a 
3.95kb stretch of DNA with 12 exons encoding for the 987bp kinase, a regulatory 
subunit of molecular mass 33 kDa that displays enzymatic activity when it becomes 
bound to activators.  
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The transcription factor ΔFosB regulates the transcription of Cdk5. Elevated Cdk5 
mRNA and protein levels are seen following dopamine or cocaine administration, 
both of which are known to increase ΔFosB. Furthermore, an elevation in the levels of 
Cdk5 mRNA and protein levels is witnessed in transgenic mice that overexpress 
ΔFosB (Bibb et al., 2001; Cyr et al., 2003). Cdk5 is found at the highest expression 
levels in the brain of adult mice and in low or undetectable levels in all other tissues 
(Tsai et al., 1994). 
 
 
1.3 CDK5 CATALYTIC DOMAIN STRUCTURE 
Along with the other members of the Cdk family, Cdk5 belongs to the CMGC group 
of eukaryotic protein kinases (ePKs) (Hanks & Hunter, 1995; Kannan & Neuwald, 
2004; Manning et al., 2002). The CMGC group, whose name is derived from an 
acronym of Cdk, MAP kinase, GSK3, and Cdk-like kinase (Clk), principally consists 
of proline-directed kinases that phosphorylate serine or threonine (S/T) residues in 
close proximity to a proline (P) residue. As is the case for the Cdk and Erk (MAP) 
kinase family, this requirement take the form of a phosphate residue situated N-
terminally adjacent to a proline residue. For GSK3, however, the requirement for a 
proline residue is not absolute and co-exists with an additional phosphate-priming 
mechanism (Dajani et al., 2001; ter Haal et al., 2001).  	  
The presence of a proline residue located immediately C-terminal to either a serine or 
threonine residue is a critical requirement for phosphorylation by all members of the 
Cdk family. The presence of a hydrophobic pocket near the catalytic site 
accommodates the proline residue, formed as a result of the unusual peptide backbone 
(at valine 164, numbering in Cdk2), and dictates the strong preference for S/TP 
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motifs. The structure alleviates the requirement for the peptide substrate to provide a 
hydrogen bond donor and correctly positions the side chain of the phosphoacceptor 
residue for phosphate transfer (Brown et al., 1999). 
 
In addition to the proline requirement, Cdk5 is reported to favour substrates that 
contain a basic residue, either lysine (K), arginine (R), or histidine (H), following the 
phosphoacceptor residue at the +3 position, defining the current Cdk5 consensus as 
(S/T)PX(K/R/H), where X is any amino acid (Beaudette et al., 1993; Shetty et al., 
1993). Despite this consensus, a plethora of substrates has been identified for Cdk5 
that fail to meet the requirements of this consensus sequence and, as a result, a 
consensus sequence that governs Cdk5 substrate selection is generally considered 
degenerative. 
 
At present, it remains unclear how Cdk5 specifically recognises and discriminates 
between substrates. Recently, biochemical and structural studies have revealed subtle 
differences in substrate preferences between the Cdk family members (Echalier et al., 
2010). For example, Cdk2 shows a very strong preference for a basic residue at the +3 
position (Brown et al., 1999) whereas Cdk4 will phosphorylate SPXX motifs with 
similar efficiency to SPXK/R motifs (Takiki et al., 2009). This information suggests 
that differences in substrate recognition between the Cdks lies within the primary 
sequence surrounding the phosphoacceptor residue and therefore needs to be 
examined more thoroughly.   
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1.4 REGULATION OF CDK5 ACTIVITY 
While the regulation of classical Cdks has been investigated extensively, regulation of 
Cdk5 activity is yet to be elucidated. However, it is clear that Cdk5 requires a 
regulatory subunit, and at least two distinct genes, namely p35 and p39, are known. 
Thus the synthesis and degradation of these subunits could be a major mechanism for 
regulation of Cdk5 activity. Similarly, pathways that regulate the interaction of Cdk5 
with regulatory subunits, or alter inherent activity (e.g. through phosphorylation of 
Cdk5), or modify the association of the regulatory subunits with membranes could all 
contribute to Cdk5 control. In addition to these physiological regulations of Cdk5 
activity, dysregulation of Cdk5 activity can occur subsequent to pathological p35 
cleavage leading to hyperactivation/mis-localisation of Cdk5 (Dhavan & Tsai, 2001).  	  
1.4.1 Cdk5 activation by regulatory subunits 
Cdk5 is the catalytic subunit of an active heterodimeric complex consisting of Cdk5 
bound to either p35 or p39, two largely similar Cdk5 cofactors encoded for by two 
different genes (Tsai et al., 1994; Tang et al., 1995) (Figure 1.2). These regulatory 
subunits are, at most, distantly related to the cyclins, with little sequence similarity, 
however they do possess three-dimensional domains similar to the Cdk-binding motif 
of cyclins (Tang et al., 1997; Morgans, 1995) and are selective in their binding of 
Cdk5 (Poon et al., 1997). It is likely that p35 folds into a similar rigid tertiary 
structure and interacts with Cdk5 through both N-terminal and C-terminal domains 
(Tang et al., 1995). This complex is predominantly found in post-mitotic cells and 
astrocytes but absent in mitotically active cells. Protein expression and mRNA studies 
indicate that p39 is most abundant in the posterior part of the brain and appears with a 
delay after p35 in the forebrain (Zheng et al., 1998; Takahashi et al., 2003). 
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Figure 1.2. Genes encoding the Cdk5 activators, p35 and p39. Schematic representation of the genes 
encoding the Cdk5 activator proteins. Each numbered box represents a coding exon. A) The gene 
encoding CDK5R1 (p35) is located on chromosome 17. B) The gene encoding CDK5R2 (p39) is 
located on chromosome 2.  
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1.4.1.1 Regulatory subunit, p35 
Identification of the regulatory subunit activating Cdk5 kinase activity followed 
shortly after the discovery of the catalytic subunit (Tsai et al., 1994). The Cdk5 
cofactor termed p35, which shares no homology to cyclins, was cloned and 
characterised by virtue of its association and regulation of Cdk5 activity. 
Subsequently, p35 was shown to exhibit a neuronal-specific pattern of expression in 
vivo, with expression of p35 mRNA identified in postmitotic cells and developing 
axonal tracts in the brain (Patrick et al., 1998). Transcription of p35 is stimulated by 
laminin in cerebellar macroneurons (Paglini et al., 1998), and p35 is a short-lived 
protein with a half-life (t1/2) of 20 to 30 minutes (Patrick et al., 1998). 
 
The minimum region of p35 that can induce Cdk5 activity spans from residues 138 – 
291, and has an approximate molecular weight of 16 kDa (Amin et al., 2002). Within 
this region, three separate domains (N-, C-, and central domain) associate and interact 
with Cdk5, each of which is essential for Cdk5 activation (Amin et al., 2002) as the 
absence of any one of these domains prevents p35 induction of Cdk5. Furthermore, 
polypeptides that lack these domains can also behave as dominant negative inhibitors 
of Cdk5 activity (Amin et al., 2002).   
 
Within the cell, timely activation of Cdk5 kinase activity at the precise site of 
substrate localisation is critical for the precise functioning of Cdk5. Cdk5 kinase 
activation is controlled through signalling by various changes in the cellular and 
external medium and the role of p35 is pivotal in maintaining the spatial activation of 
Cdk5. Association with p35 tethers Cdk5 to the membrane by hanging through a 
myristoyl residue linked to the N-terminal glycine and facilitates access of Cdk5 to 
membrane protein targets. Direct interaction of p35 with the substrates of the kinase is 
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not common. In addition, myristoylation of p35 regulates the access of Cdk5 to the 
nucleus by increasing the amount of kinase retained by the cytoplasmic and plasma 
membranes (Asada et al., 2008).  
 
1.4.1.2 Regulatory subunit, p39 
The discovery of another Cdk5 activator, p39 was made based on its high sequence 
homology to p35 (Tang et al. 1995). The p39 isoform contains around 150 amino 
acids in the Cdk5 activation domain (Cdk5-AD) in its C-terminal two-thirds, sharing 
~70% sequence homology with p35 (Tang et al., 1995; Zheng et al., 1998) (Figure 
1.3). In contrast, the N-terminal one-third displays a low sequence homology (37%) 
with p35, except for the extreme nine N-terminal amino acids that include a 
myristoylation signal (Patrick et al., 1999) and the lysine cluster in amino acids 75-85. 
At the C-terminus following the Cdk5-binding region, p39 has a domain that interacts 
with muskelin, a protein regulating cytoskeleton organisation in adherent cells (Ledee 
et al., 2005).  
 
Isolating active p39/Cdk5 from brain extracts or cultured cells has proved problematic 
therefore purification of p39/Cdk5 from Sf9 cells using Ni-beads was used to 
characterise the kinase properties of Cdk5 complexed to p39 (Yamada et al., 2007). 
The p39/Cdk5 complex showed similar specific activity towards histone H1 when 
directly compared to p35/Cdk5. Additionally, both complexes phosphorylated tau, 
MAP2, neurofilament H subunit, inhibitor 1, mDab1, p35, and p39 (Ohshima et al., 
2005; Yamada et al., 2007). It is perhaps not surprising that p35 or p39 have similar 
substrate preferences given the high homology of possible substrate-docking sites in 
both activators (Tarricone et al., 2001), however it is remains to be established 
whether either complex has alternative selective substrate targeting mechanisms. 
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Figure 1.3. Molecular structure of Cdk5 activators and their C-terminal fragments generated by 
calpain cleavage. Comparison of the structure of p35 (307 amino acids) and p39 (369 amino acids). 
Both 35 and p39 contain a myristoylation site at Gly2 in the N-terminal common 9 amino acids 
(Green), and a lysine cluster at residues 61-67 in p35 and at residues 75-85 in p39 (Orange). Calpain 
cleaves p35 between residues 98 and 99 to generate p25, and cleaves p39 between residues 99 and 100 
to generate p29. The Cdk5 activation domain (Cdk5-AD) is present in the C-terminal two-thirds 
encompassing about 150 amino acids (Blue). An insertion after the Cdk5 activation domain (Purple) is 
present in p39.   
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1.4.1.3 Proteolytic fragments of p35 and p39 also induce Cdk5 activity 
Under normal physiological conditions, Cdk5 activity is tightly regulated by p35 and 
p39. However, under conditions such as oxidative stress, Aβ toxicity, inflammation, 
and others that led to increased levels of intracellular calcium (Ca2+), proteolytic 
cleavage of both activators occurs and results in truncated fragments that can bind to 
and induce Cdk5 activity.  	  
Elevation of intracellular Ca2+ induces activation of the calcium-dependent protease, 
calpain which then cleavages p35 between residues 98 and 99 to generate a 25 kDa N-
terminally truncated proteolytic fragment (p25) and a 10 kDa proteolytic fragment 
(p10) (Figure 1.3). Calpain directly cleaves p35 in vitro to release a fragment with 
relative molecular mass 25, 000 daltons and the sequence of the calpain product 
corresponds precisely to that of p25 isolated from cells; hypoxic stress, excitotoxins, 
and Ca2+ influx promotes production of p25 in primary cortical neurons; furthermore, 
cleavage of p35 to p25 was promoted in fresh brain lysates treated with Ca2+ and 
prevented by specific inhibitors of calpain activity (Lee et al., 2000). More recent 
research has implicated calpastatin as a critical regulator of calpain activity and, 
hence, the truncation of p35 into p25 (Sato et al., 2011).  
 
The proteolytic cleavage of p35 results in the release of a more stable protein 
expressing a half-life that is 5-10 fold greater than that of p35, which has a half-life of 
20-30 minutes (Patrick et al., 1998; Patrick et al., 1999). Additionally, the p25 
cofactor is not readily degraded and therefore considered to maintain Cdk5 in a state 
of hyperactivation. Furthermore, regulation of enzymatic activity by p25 reportedly 
alters substrate specificity and cellular localisation of Cdk5 (Patrick et al., 1999).   
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Analogous to the cleavage of p35, calpain is additionally responsible for the 
generation of p29, a truncation of p39 (Patzke et al., 2003) (Figure 1.3). In vitro, 
calpain cleavage of p39 generates a C-terminal p29 fragment, and high levels of 
calpain activity lead to the production of p29 in vivo. Consistent with the increased 
stability of p25, the p29 fragment is also more stable than p39. Moreover, p29 
activation of Cdk5 results in the redistribution of Cdk5 in primary cortical neurons 
(Patzke et al., 2003).  
 
The prolonged activation of Cdk5 following association with p25 coupled with the 
reported mislocalisation of the Cdk5 complex is often associated with neurotoxicity 
and has been implicated as a potential regulatory mechanism underpinning several 
neurodegenerative disorders, including Alzheimer’s disease (AD). The alteration in 
subcellular localisation of the p29/Cdk5 complex together with a prolonged activity 
suggests that the conversion of p39 to p29 may also contribute to neurotoxic injury 
although this remains to be proven. 
 
1.4.1.4 The theory of aberrant Cdk5 activity following activator truncation 
In addition to the evidence that p35 truncation promotes hyperactivation of Cdk5 with 
potential altered substrate specificity and cellular localisation, the pathophysiological 
significance of p25/Cdk5 is largely supported by the fact that p25 accumulates in AD 
brains (Patrick et al., 1999; Tseng et al., 2002).  
 
Neurofibrillary tangles (NFTs) are present in some neurons in AD and p25, but not 
p35, was found in neurons containing NFTs as demonstrated by AT8 antibody 
counterstaining (Augustinack et al., 2002). Hyperphosphorylation of tau in AD 
tangles has been attributed, at least in part, to p25/Cdk5 activity, reducing the ability 
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of tau to associate with microtubules (MT) (Hashiguchi et al., 2002). Consistent with 
this hypothesis, p25/Cdk5 overexpression in primary neurons results in cytoskeletal 
disruptions and, ultimately, apoptotic cell death evident by fragmented nuclei (Patrick 
et al., 1999).  
 
These studies highlight a potential association between p25 and neurodegenerative 
disease by suggesting that the unique properties associated with p25/Cdk5 
hyperactivation may exert a critical role in the pathogenesis of NFTs and neuronal 
death. However, despite being heavily depicted as a ‘hyperactive’ complex when 
bound to p25, very few, if any, studies have actually demonstrated that the p25/Cdk5 
complex has inherent higher specific activity, or even enhanced activity toward 
specific substrates in vitro. 
 
1.4.2 Regulation of Cdk5 activity by synthesis and degradation of p35 
The kinase activity of Cdk5 relies primarily on the availability of p35 or p39, evident 
by the excess of Cdk5 relative to cofactor in brain tissue proposing p35 or p39 
availability as the limiting factor in determining Cdk5 activity (Qi et al., 1995; Zhu et 
al., 2005). The level of p35 or p39 is controlled through a balance between synthesis 
and degradation. 
 
In the brain, Cdk5 kinase activity starts to increase, along with neuronal 
differentiation, at about day 13 (E13) when the synthesis of p35 initiates (Tsai et al., 
1994; Wu et al., 2000). The p35 and p39 genes are reported targets for heat shock 
factor 2 (HSF2) during cortical development (Chang et al., 2006), and the expression 
of p35 is induced by brain-derived neurotropic factor (BDNF) in cultured cortical 
neurons and medium-sized spiny neurons (Tokuoka et al., 2000; Bogush et al., 2007). 
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The increase in p35 expression in medium-sized spiny neurons is prevented by 
phosphatidylinositol 3-kinase (PI3K) inhibitors suggesting that BDNF signals to the 
gene promoter through the PI3K pathway (Bogush et al., 2007). 
   
Inactivation of Cdk5 activity is achieved through degradation of Cdk5 regulatory 
subunits by the proteasome (Patrick et al., 1998; Saito et al., 1998; Patzke & Tsai, 
2002) and this is, in part, mediated by autoregulation. Cdk5 phosphorylates p35 
resulting in its ubiquitination and degradation by the proteasome (Patrick et al., 1998). 
In p35 mutants that lack the Cdk5 phosphorylation sites, Ser8 and Thr138, p35 
becomes more stable, with an extended half-life, suggesting a negative feedback loop 
and implicating Cdk5 phosphorylation of p35 as essential component for the 
ubiquitination of the regulatory subunit (Kamei et al., 2007).  
  
1.4.3 Regulation of Cdk5 activity by phosphorylation 
Consistent with the majority of eukaryotic protein kinases, Cdk5 possesses a catalytic 
domain flanked with additional domains essential for activation. The catalytic domain 
is comprised of an ATP binding site between an N-terminal lobe of β-sheet and a α-
helical C-terminal (C-lobe) domain (Manning et al. 2002). The α-helical domain is 
termed PSAALRE based on the polypeptide sequence. The activation loop consists of 
20 amino acids between the N-terminal and C-terminal domains and acquires a 
conformation competent of phosphate transfer. Despite sharing structurally 
similarities with the Cdks, the activation of Cdk5 is atypical from the other family 
members (Mapelli & Musacchio, 2003). 	  
Regulation of Cdk5 activity can be modulated through specific phosphorylation 
events. Three distinct phosphorylation sites on Cdk1, Thr14, Tyr15, and Thr161, are 
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conserved in Cdk5 (Thr159 in Cdk5 corresponds to Thr161 in Cdk1). Despite this, the 
effect of Cdk5 phosphorylation at these sites differs entirely from the other members 
of the Cdk family. Cdk1 requires T-loop phosphorylation at Thr161 to induce the 
active conformation however the crystal structure of p25/Cdk5 (Figure 1.4) indicates 
that T-loop phosphorylation of Thr159 on Cdk5 is not essential for activation of the 
kinase. The association with p25 forces the activation loop to adopt an extended 
conformation, typical of active proline-directed kinases, in the absence of loop 
phosphorylation (Tarricone et al., 2001). 
 
Phosphorylation of Thr14 and Tyr15 in Cdk1 by Wee1 or Myt1 reduces its activity 
(Fattaey & Booher, 1997). Conversely, Cdk5 kinase activity is stimulated following 
its phosphorylation at Tyr15 by nonreceptor tyrosine kinases, c-Abelson (Abl) and 
Fyn, or receptor-type tyrosine kinases, Eph4 and TrkB (Zukerberg et al., 2000; Sasaki 
et al., 2002; Fu et al., 2007; Cheung et al., 2007). Cables, a Cdk5-binding substrate, 
stimulates phosphorylation of Cdk5 by Abl at Tyr15 (Zukerberg et al., 2000). 
Phosphorylation of Tyr15 is detected when a growth cone encounters Sema3, a 
repellent cue (Sasaki et al., 2002). Ephrin A1 stimulates Eph4 receptor kinase 
activation and subsequent phosphorylation of Cdk5 at Tyr15 is observed (Fu et al., 
2007). Furthermore, following BDNF stimulation, Cdk5 is recruited to the TrkB 
receptor and subsequently phosphorylated at Tyr15 by TrkB which results in 
enhanced Cdk5 activity that promotes the phosphorylation of TrkB at Ser478 (Cheng 
et al., 2007). In contrast, phosphorylation of Thr14 has an inhibitory effect on Cdk5 
(Matsuura & Wang, 1996). A 43 kDa protein kinase was purified that phosphorylated 
Cdk5, as well as Cdk1 and Cdk2, and inhibited Cdk5 kinase activity (Matsuura & 
Wang, 1996).    
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Figure 1.4. Structure of the p25/Cdk5 complex. cleavage. Cdk5 (green – pale blue) binds Cdk5 
(yellow – red) in the region of the PSSALRE helix (dark blue) in the kinase small lobe. There are 
extensive interactions with the activation loop. Image taken and adapted from the RCSB PDB 
(www.rcsb.org) of PDB 1H4L (Tarricone, C., Dhavan, R., Peng, J., Areces, L.B., Tsai, L.H., 
Musacchio, A (2001) Structure and regulation of the CDK5-p25(nck5a) complex Mol.Cell 8:657) 
created with PQS software.  
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Finally, the cyclin kinase inhibitors (CKIs), p21 and p27 inhibit mitotic Cdks by 
inactivating the cyclin Cdk complex, however they have little or no effect on Cdk5 
activity (Lee et al., 1996). This, again, provides a contrast in the regulation of Cdk5 to 
that of the classical Cdk family members, and suggests that there is no co-ordination 
of Cdk5 activity with that of Cdk1 or Cdk2.  
 
1.4.4 Pharmacological inhibition of Cdk5 activity 
Olomoucine (Vesely et al., 1994) and roscovitine (Meijer et al., 1997) are both ATP 
competitive inhibitors of Cdk activity, however they do not discriminate between 
individual family members. Whilst these inhibitors do remove Cdk5 activity from 
cells, more selective approaches are required in order to dissect the functional role of 
Cdk5 over other Cdks. For example, overexpression of a dominant-negative mutant of 
Cdk5 or silencing Cdk5 via siRNA should be used in addition to the available 
pharmacological tools. 
 
 
1.5 FUNCTIONAL DIVERSITY OF CDK5 SUBSTRATES 
The functional implications of kinases arise largely due to the identification of 
substrates that have been identified as direct targets of that kinase. Since the initial 
identification of Cdk5 as a brain kinase (Lew et al., 1992) that directly phosphorylates 
tau (Ishiguro et al., 1992), the past two decades have seen a dramatic increase in the 
number of substrates that are reportedly regulated by Cdk5. Cdk5 has been reported to 
phosphorylate a large number of proteins in vitro, however it is not clear how many of 
these proposed substrates are regulated by Cdk5 in vivo and, furthermore, these 
substrates fail to meet a common consensus. 
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Currently, a compendium of substrates exists for Cdk5, each with varying functional 
significance, and their number is continually increasing (Table 1.1). As a result, the 
physiological functions of Cdk5 are becoming more complex, extending its functions 
beyond the nervous system and into extra-neuronal tissues. In addition, the 
involvement of Cdk5 in pathophysiological pathways is only partially understood. 
The physiological and pathophysiological implications of Cdk5 are discussed in 
greater in sections 1.6 and 1.7.  
 
In order to fully understand the function and significance of Cdk5, particularly under 
pathophysiological conditions, proposed substrates must be confirmed as bona fide 
Cdk5 substrates and greater understanding of Cdk5 substrate selection is required to 
identify novel substrates of Cdk5. This, in turn, will contribute to the understanding of 
the regulatory signalling networks involved, help dissect the consequences of 
manipulating Cdk5 activity, and increase interest in Cdk5 as a therapeutic target in 
drug development.  
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Substrate 
 
Functional Outcome 
 
Phosphorylation Sites 
 
References 
N
eu
ro
na
l M
ig
ra
tio
n 
β- Catenin N-cadherin-mediated cell 
adhesion, binding following 
dissociation 
 
Multiple Kwon et al., 2000 
Kesavapany et al., 2001 
Disabled 1 Control of neuronal 
positioning, reelin interaction 
 
S491 Keshvara et al., 2002 
Dixdc1 Allows interaction between 
DISC1 and NUDEL 
 
S250 Singh et al., 2010 
DISC1 Switch between progenitor 
proliferation and migration 
 
S710 Ishizuka et al., 2011 
Doublecortin Lowered affinity to 
microtubules, reduced effect 
on polymerization 
 
S297 Tanaka et al., 2004 
FAK Nuclear translocation through 
microtubule fork 
 
S732 Xie et al., 2003 
NUDEL Regulation of dynein and 
axonal transport  
S198, T219, S231 Niethammer et al., 2000 
Sasaki et al., 2000 
p27(kip1) Actin organisation, cortical 
neuronal migration 
 
S10, T187 Kawauchi et al., 2006 
N
eu
ri
te
 O
ut
gr
ow
th
 
Cables Dissociation of 
Cdk5/Cables/c-Abl complex, 
neurite outgrowth 
 
 
Multiple 
 
Zukerberg et al., 2000 
CRMP2 Semaphorin 3A-induced 
growth cone collapse, axonal 
growth and development 
 
 
S522 
Brown et al., 2004 
Cole et al., 2004 
c-Src Neural development, neurite 
outgrowth, function 
 
 
S75 
 
Kato & Maeda, 1999 
MAP1B Regulation of axonal 
formation and elongation 
 
 
Multiple 
Pigino et al., 1997 
Paglini et al., 1998 
p39 Regulation of actin 
cytoskeletal dynamics 
 
Multiple Humbert et al., 2000 
PAK1 Actin polymerisation, 
cytoskeletal reorganization 
 
 
T212 
Nikolic et al., 1998 
RasGRF2 Altered RasGRF2, 
microtubule protein 
accumulation 
 
 
S737 
Kesavapany et al., 2004 
TrkB BDNF-stimulated dendritic 
outgrowth 
 
S478 Cheung et al., 2007 
Sy
na
pt
ic
 V
es
ic
le
 C
yc
le
 
Amphiphysin 1 Regulation of synaptic vesicle 
endocytosis 
 
S262, S272, S276, 
S285, T310 
Floyd et al., 2001 
Liang et al., 2007 
Dynamin 1 Clathrin-mediated synaptic 
vesicle endocytosis 
 
S774, S778 Tomizawa et al., 2003 
Tan et al., 2003 
Munc18 Modulation of synaptic 
vesicle exocytosis 
 
T574 Shuang et al., 1998 
Fletcher et al., 1999 
PCTAIRE1 synaptic vesicle exocytosis 
via NSF interaction 
 
S95 Cheng et al., 2002 
Septin 5 Reduction of sept5 binding to S17 Taniguchi et al., 2007 
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syntaxin 
 
Synapsin 1 Impact on cytoskeletal 
components, actin bundling 
 
S551, S553 Matsubara et al., 1996 
Synaptojanin 1 Interaction with other 
endocytosis components 
 
S1144 Lee et al., 2004 
Sy
na
pt
ic
 tr
an
sm
is
si
on
 a
nd
 p
la
st
ic
ity
 
CASK Promotion of synaptogenesis, 
presynaptic proteins 
 
S51, S395 Samuels et al., 2007 
Cav1.2 Decreased calcium influx 
upon glucose stimulation 
 
S783 Wei et al., 2005a 
Cav2.1 Synaptic plasticity and 
neurotransmitter release 
 
aa724-981 Tomizawa et al., 2002 
DARPP-32 Signal transduction 
modulation in striatal neurons 
 
T75 Bibb et al., 1999 
δ-Catenin Dendritic morphogenesis, 
synaptic activity 
 
S300, S357 Poore et al., 2010 
Kalirin-7 Formation, regulation of 
dendritic spine protrusion 
 
T1590 Xin et al., 2008 
NR2A NMDA current, LTP, 
ischemia-mediated cell death 
 
S1232 Li et al., 2001 
Wang et al., 2003 
NR2B Surface expression levels of 
NR2B and endocytosis 
 
T1472 Zhang et al., 2008 
PP-1 Signalling pathways 
involving PKA, calcineurin 
 
S6, S67 Nguyen et al., 2007 
PP-1 inhibitor Multiple cellular functions 
and signalling pathways 
 
T72 Agarwal-Mawal & Paudel, 
2001 
PSD-95 Clustering size of K+ channels 
at dendritic spines 
 
T19, S25 Morabito et al., 2004 
SPAR Plk2-mediated degradation 
during synaptic scaling 
 
S1328 Seeburg et al., 2008 
TH Presynaptic component in 
dopamine synthesis 
 
S31 Moy & Tsai, 2004 
Kansy et al., 2004 
N
eu
ro
de
ge
ne
ra
tiv
e 
D
is
ea
se
 
APP Potential localisation of the β-
amyloid protein 
 
T668 Iijima et al., 2000 
Huntington Reduction in Huntington 
aggregation and formation 
 
S434, S1181, S1201 Luo et al., 2005 
Anne et al., 2007 
MEF2D Inhibition of transcriptional 
factors and cell death  
 
 
S444 
 
Smith et al., 2006 
NF Regulation of axonal 
transport of NF 
Multiple Lew et al., 1994 
Ackerley et al., 2003 
Gong et al., 2003 
Parkin Modulation of synphilin-1/α-
synuclein inclusions 
 
S131 Avraham et al., 2007 
Prx2 Tuning sensitivity of neuron 
to oxidative stress 
 
T89 Qu et al., 2007 
Rashidian et al., 2009 
Tau Accumulation and disruption 
of axonal transport 
 
Multiple Baumann et al., 1993 
Kobayashi et al., 1993 
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O
th
er
 
Ape1 Involvement in regulation of 
DNA damage, cell death 
 
T232 Huang et al., 2010 
ATM DNA damage, ATM 
activation, neuronal death 
 
S794 Tian et al., 2009 
β-2 syntrophin Regulatory mechanism of 
insulin secretion 
 
S75 Schubert et al., 2010 
Bcl-2 Neuroprotective effect, 
neuronal survival  
 
S70 Cheung et al., 2008 
Cdh1 Mediates cyclin B1 
accumulation in 
excitotoxicity  
 
S40, T121, S163 Maestre et al., 2008 
ErbB3 Nrg-induced AChR 
expression at NMJ 
 
  
GR Regulates glucocorticoid 
receptor transcriptional 
activity 
 
S203, S211, S232, S246 
and others 
Kino et al., 2007 
Adzic et al., 2009 
JNK3 Inhibition of JNK activity and 
reduced apoptosis 
 
T131 Li et al., 2002 
MEF2A Regulates apoptosis S408 Gong et al., 2003 
 
MEK1 Down-regulation of MAPK 
signalling  
 
T286 Sharma et al., 2002 
mSds3 HDAC transcriptional co-
repressor complex 
 
S228 Li et al., 2002 
p35 Promotion of ubiquitin-
mediated proteolysis 
 
S8, T138, S170, T197 Tsai et al., 1994 
Patrick et al., 1998 
p53 Increased cell cycle arrest or 
cell death genes 
 
S33, S315 Zhang et al., 2002 
Paxillin Involvement in 
oligodendrocyte 
differentiation 
 
S244 Miyamoto et al., 2007 
PIPKIγ Blocked PI(4,5)P2 synthesis 
at synapses and at focal 
adhesions 
 
S650 Lee et al., 2005 
PPARγ Obesity-linked 
phosphorylation in fat cells 
 
S273 Choi et al., 2010 
Rb Cellular growth, 
differentiation, apoptosis 
 
Multiple Lee et al., 1997 
Hamdane et al., 2005 
S6K1 Regulation of S6K1 catalytic 
activity 
 
S411 Hou et al., 2007 
STAT3 Transcription of target genes 
c-fos and junB 
 
S727 Fu et al., 2004 
Talin Regulation of Smurf1-
mediated talin ubiquitination 
 
S425 Huang et al., 2009 
TRPV-1 Modulation of nociceptive 
signalling in DRG 
T407 Pareek et al., 2007 
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Table 1.1. Identified Cdk5 substrates and their functional categories. Abbreviations: AChR, 
acetylcholine receptor; Ape1, apurinic/apyrimidinic endonuclease 1; APP, amyloid precursor protein; 
ATM, Ataxia telangiectasia mutated; Bcl-2, B-cell CLL/lymphoma 2; BDNF, brain-derived 
neurotropic factor; Cables, Cdk5 and Abl enzyme substrates; CASK, calcium/calmodulin-dependent 
serine protein kinase; Cav1.2, L-type voltage-gated calcium channel; Cav2.1, P/Q-type voltage-gated 
calcium channel; Cdh1, cadherin-1; CRMP2, collapsing response mediator protein 2; c-Src, non-
receptor tyrosine kinase; DARPP-32, Dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa; 
DISC1, Disrupted in Schizophrenia 1; Dixdc1, Dix-domain containing 1; DRG, dorsal root ganglion; 
ErbB3, receptor tyrosine-protein kinase erbB3; FAK, focal adhesion kinase; GR, glucocorticoid 
receptor; HDAC, histone deacetylase; JNK3, c-Jun N-terminal kinase 3; LTP, long-term potentiation; 
MAP1B, microtubule-associated protein 1B; MEK, MAP kinase kinase-1; MEF, myocyte enhancer 
factor; Munc18, mammalian uncoordinated 18; NF, neurofilament; NMJ, neuromuscular junction; 
NR2A, N- methyl D-aspartate receptor subunit 2A; NR2B, N-methyl D-aspartate receptor subunit 2B; 
Nrg, neuregulin; NSF, N-ethylmaleimide sensitive factor; NUDEL, nuclear distribution protein nude-
like; p27(kip1), cyclin-dependent kinase inhibitor; p35, regulatory activator of cyclin-dependent kinase 
5 Mr 35 kDa; p39, regulatory activator of cyclin- dependent kinase 5; p53, tumour protein 53; PAK1, 
p21-Activated Kinase; paxillin, focal adhesion- associated adaptor protein; pctaire1, cyclin-dependent 
kinase 16 (cdk16); PIPKI, phosphatidylinositol(4) phosphate 5 kinase type I gamma; PPARγ, 
Peroxisome proliferator-activated receptor gamma; Plk2, polo- like kinase 2; PP-1, protein 
phosphatase-1; Prx2, peroxiredoxin 2; PSD-95, Postsynaptic density protein 95; RasGRF, ras guanine 
nucleotide releasing factor 2; Rb, retinoblastoma protein; S6K1, S6 kinase 1; SPAR, spine-associated 
Rap guanosine triphosphatase activating protein; STAT3, signal transducer and activator of 
transcription 3; TH, tyrosine hydroxylase; TRPV-1, Transient Receptor Potential Vanilloid-1.  
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1.6 THE ROLE OF CDK5 IN NORMAL PHYSIOLOGY 
Cdk5 has been extensively described as a multifaceted kinase exerting a diversity of 
functions on brain physiology, ranging from neuronal development and migration, 
through to synaptic plasticity and pain signalling (Figure 1.5). More recently, studies 
have extended these investigations to include key functional roles for Cdk5 in extra-
neuronal tissues.	  	  
1.6.1 Functional implications of Cdk5 in the nervous system 
Transfection of p35 and p39 into cortical cultures and immortalised hippocampal cells 
stimulated neurite outgrowth, and, conversely, dominant-negative mutants of Cdk5 or 
antisense p35 and p39 constructs inhibited neurite outgrowth (Nikolic et al., 1996; 
Xiong et al., 1997). These results, taken together with the severe disruption of the 
cytoarchitecture of the brain cortex in both Cdk5 knockout (KO) and double KO 
p35/p39 null mice (Chae et al., 1997), implicated Cdk5 activity as a key component 
of the central nervous system (CNS). Therefore, the CNS has formed the basis of 
many of the physiological systems investigated when studying Cdk5 cellular 
functions. Subsequently, identification of a vast array of potential Cdk5 substrates has 
added complexity to the role of Cdk5 in the nervous system but most likely explains 
the severe phenotype of the Cdk5 KO animals. 
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Figure 1.5. The multifaceted role of Cdk5. Currently, Cdk5 is reported to play a role in a large number 
of physiological functions and impacts various cellular processes. Following activation by 35, Cdk5 
regulates multiple events including neuronal migration, neurite outgrowth, cytoskeletal dynamics, in 
addition to roles in a number of pathways such as pain signalling, neuromuscular development, and 
adult neurogenesis (Su & Tsai, 2011).  
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1.6.1.1 Cdk5 activity in the developing CNS 
1.6.1.1.1 Cdk5 exerts a critical role in neuronal cytoarchitecture 
Whole body Cdk5 knockout mice (Cdk5 -/-) display perinatal lethality owing to CNS 
lesions (Ohshima et al., 1996). In particular, there are neuronal migration deficits in 
multiple brain compartments including the cerebral cortex, hippocampus, and 
cerebellum: the laminar organisation of neurons within the cerebral cortex is inverted 
with a superficial ectopic subplate; the pyramidal neurons of the hippocampus are not 
organised in a discrete layer; the cerebellum lacks foliation and tripartite layering; 
and, motor neurons of the spinal cord and cranial nerve nuclei display enlarged 
perikarya characteristic of chromatolytic changes (Ohshima et al., 1996, 1999; 
Gilmore et al., 1998). 
 
Interestingly, mice deficient in the regulatory subunit p35 are viable and fertile. They 
are, however, prone to seizures and lethality in adulthood. While these mice only 
exhibit mild disruptions in the hippocampus and possess fairly normal cerebella, they 
express lamination defects in the cerebral cortex as well as alterations in cell 
orientation, and dendrite and axon trajectories (Chae et al., 1997; Kwon et al., 1998; 
Wenzel et al., 2001).   
 
The difference in phenotypic severity between the Cdk5 and p35 KO mice is likely 
due to compensation by p39. Mice that are deficient in p39 do not display detectable 
abnormalities in neuronal positioning in the CNS. However, p35 and p39 double-null 
deletion mice express identical phenotypes to Cdk5 (-/-) mice including severe 
disruption of various central nervous system components, an absence of Cdk5 kinase 
activity, lamination defects, and perinatal lethality (Ko et al., 2001). These mice 
highlight p35 and p39 as critical, and potentially the sole, regulators of Cdk5 activity 
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in the CNS. Additionally, mice deficient in the transcription factors Brn-1 and Brn-2 
lack p35 and p39 mRNA in migrating neurons in the cortex and hippocampus. These 
animals display a similar cortical lamination phenotype to Cdk5-null mice linking 
Brn-1 and Brn-2 to regulation of Cdk5 function in the CNS through the regulation of 
p35 and p39 expression (Smith et al., 2001).  
 
Taken together, these gene-targeting experiments demonstrate the critical nature of 
Cdk5 in the CNS and highlight Cdk5 and the cofactors, p35 and p39, as necessary 
components for establishing accurate and fundamental neocortical lamination. 
 
1.6.1.1.2 Neurite development, neuronal migration, and axonal elongation 
Neuronal migration and axon guidance are fundamental mechanisms underlying the 
wiring of the brain. The nervous system has acquired the ability to grow in size and 
complexity, using cell migration as a strategy to position cell types from different 
origins into specific coordinates, enabling the generation of brain circuitries.  
 
Cdk5 expression is ubiquitous however it is most abundant in neuronal cells (Tsai et 
al., 1993). During development of the nervous system, Cdk5 and its associated kinase 
activity increases progressively as increasing number of cells exit the proliferative 
phase of the cell cycle. Cdk5 activity is expressed solely in postmitotic neurons 
(Paglini et al., 2001b) and astrocytes (Gao et al., 2001; Gao et al., 2002) but not in 
mitotically active cells (Paglini et al., 2001b). The p35/Cdk5 complex was found to 
colocalise with axonal growth cones (Nikolic et al., 1996), and Cdk5 activity is 
present in neurite outgrowths (Lin et al., 2003).   
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In situ hybridisation examining the temporal and spatial distribution of p35 mRNA in 
the developing and adult mouse brain demonstrated that young post-mitotic neurons 
begin to express p35 mRNA as soon as they leave the cell cycle and begin to migrate 
to their final destination (Delalle et al., 1997). Additionally, p35 mRNA is also found 
to be present in newly formed axonal bundles. Immunohistochemical studies located 
p35 at the cell periphery in lamellipodial and filiopodial structures, both of which are 
important for neurite outgrowth (Nikolic et al., 1996).  Postnatally, p35 is relatively 
abundant in most areas of the forebrain, in particular, the pyriform cortex and 
pyramidal layer of the hippocampus where high levels of neuronal plasticity are 
retained  (Liu & Green, 2001; Tsai et al., 1994; Delalle et al., 1997; Ino et al., 1994; 
Zheng et al., 1998; Paglini et al., 2001a; Paglini et al., 2001b). Expression of p39 
mRNA is found in the developing and adult CNS with highest expression occurring 
postnatally suggesting that p39/Cdk5 may mediate functions distinct from those 
involving p35/Cdk5 during neurodevelopment. Subcellular distribution studies 
indicate both distinct and overlapping features (Humbert et al., 2000). 
 
In immortalised hippocampal cells, p35 is sufficient but not essential for inducing 
neurite outgrowth. The majority of anti-sense oligonucleotide studies suggest that the 
p35/Cdk5 complex acts as a modulator of axonal elongation, rather than having an 
essential role in process formation (Ko et al., 2001; Dhavan & Tsai, 2001). One 
hypothesis proposes that these effects are essentially the result of neurofilament 
phosphorylation and subsequent slowing of their transport through the cytoplasmic 
extension (Sharma et al., 1999; Grant et al., 2001).   
 
There are many proposed targets of Cdk5 that could mediate its regulation of neurite 
outgrowth. For example, following Tyr15 phosphorylation of Cdk5 when it forms a 
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complex with the tyrosine kinase c-Abl and Cables (Zukerberg et al., 2000). 
Additionally, active Cdk5 hyperphosphorylates PAK1 in a Rac-dependent manner 
that results in the downregulation of PAK1 kinase activity (Nikolic et al., 1998). 
Since the Rho family of GTPases and the PAK kinases are implicated in actin 
polymerisation, Cdk5 phosphorylation of PAK1 is likely to have an impact on the 
dynamics of the reorganisation of the actin cytoskeleton in neurons, thereby 
promoting neuronal migration and neurite outgrowth. Cdk5 phosphorylation of the 
BDNF receptor tyrosine kinase TrkB modulates BDNF-stimulated dendrite outgrowth 
(Cheung et al., 2007), and phosphorylation of ephexin and WAVE1 modulates 
ephrin-A1 mediated spine retraction (Fu & Ip, 2007). Cdk5 interacts with the 
ubiquitin ligase mind bomb 1 (Mib1) during neurite morphogenesis (Choe et al., 
2007). Finally, Cdk5 may affect neurite outgrowth via phosphorylation of 
Microtubule Associated Protein 1B (MAP1B) (Smith, 2003; Grant et al., 2001; 
Nikolic et al., 1996). Therefore multiple players in the regulation of neurite initiation, 
growth and retraction are coordinated by Cdk5 mediated phosphorylation. 
 
Harada and colleagues placed Cdk5 downstream of the Erk-1/2 signalling pathway in 
NGF-dependent neurite outgrowth since activation of Erk-1/2 by nerve growth factor 
(NGF) in PC12 cells induced p35 production (Harada et al., 2001). More recently, S-
nitrosylation of Cdk5 was shown to influence the regulation of neurite growth and 
branching (Zhang et al., 2010), however the upstream regulation of Cdk5 by multiple 
factors that control neurite outgrowth remains poorly defined. 
 
There are a number of additional proposed Cdk5 targets that play key roles in 
neuronal migration. These include the tyrosine kinase FAK, which regulates an MT 
fork to guide proper neuronal migration through nuclear translocation (Xie et al., 
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2003); NUDEL, a Lis-1-interacting protein that cooperates with dynein, an MT-
interacting motor protein (Niethammer et al., 2000; Sasaki et al., 2000); doublecortin 
(Dcx), which regulates cytoskeletal dynamics during neuronal migration (Tanaka et 
al., 2004); Dix-domain containing 1 (Dixdc1), which interacts with the psychiatric 
illness risk factor gene Disrupted in Schizophrenia-1 (DISC1) and NUDEL during 
migration (Singh et al., 2010); and DISC1, which mediates neural progenitor 
migration (Ishizuka et al., 2011). Additional cytoskeletal substrates of Cdk5 include 
NF proteins and the microtubule (MT)-associated protein tau (Baumann et al., 1993; 
Lew et al., 1994; Paudel et al., 1993). Tau phosphorylation by Cdk5 modulates the 
rate of MT polymerisation (De Vos et al., 2011). 
 
Work in embryonically derived primary neurons from the Cdk5-/- mice implicates 
Cdk5 in axonal elongation and this is supported by the high degree of temporal 
correlation in p35 expression and Cdk5 activation with the formation of axonal tracts 
in the developing brain (Paglini et al., 2001; Smith & Tsai, 2002; Delalle et al., 1997). 
During terminal neuronal differentiation, both Cdk5 and p35 localise to axonal 
pathways, such as the corpus callosum and external capsule (Tsai et al., 1993).  
 
Semaphorins are a class of secreted and membrane proteins that act as axonal growth 
cone guidance molecules. Sema3A (collapsin-1) was the first identified vertebrate 
semaphorin and acts primarily as a repulsive axon guidance cue, and can cause 
dramatic collapse of the growth cone lamellipodium (Schmidt & Strittmatter, 2007). 
The collapsin response mediator protein (CRMP) family, composed of five cytosolic 
phosphoproteins (CRMP1-5) of similar molecular size (60-66 kDa) and high (50-
75%) sequence homology, was originally identified as mediators of Sema3A 
signalling and neuronal differentiation (Goshima et al., 1995). Phosphorylation of 
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these proteins at the C-terminal region is considered to be important in Sema3A 
signalling. Members of the class A plexins, PlexA1 and A2 are constitutively bound 
to the src family tyrosine kinase, fyn, in a kinase-independent manner. Stimulation 
with Sema3A results in activation of fyn and leads to the recruitment of Cdk5 into the 
complex and activates it kinase activity (Sasaki et al., 2002). The blockade of Cdk5 
kinase activity attenuates dorsal root ganglion (DRG) growth cone collapse in 
response to Sema3A (Sasaki et al., 2002; Brown et al., 2004; Uchida et al., 2005). 
Cdk5 phosphorylates CRMP1, 2, and 4 at Ser522 and this can occur in response to 
Sema3A in vitro and in vivo (Brown et al., 2004; Uchida et al., 2005). The growth 
cones of neurons overexpressing a mutant CRMP2, in which Ser522 is replaced by 
alanine (S522A), fail to collapse when Sema3A is applied (Brown et al., 2004; 
Uchida et al., 2005).  Furthermore, the phosphorylation of CRMPs at Ser522 by Cdk5 
allows for the subsequent phosphorylation of CRMP2 and CRMP4 at Ser518, Thr509, 
and Thr514 by the serine/threonine kinase GSK3β (Brown et al., 2004; Uchida et al., 
2005; Cole et al., 2007; Yoshimura et al., 2005). Further studies indicate that the 
functions of CRMPs are not restricted to the transduction of a single extracellular 
signal but may be involved in multiple cellular and molecular events in 
apoptosis/proliferation, cell migration, and differentiation.  
 
1.6.1.2 Cdk5 in the mature CNS 
In the mature central nervous system (CNS), Cdk5 regulates multiple steps critical for 
neurotransmitter synthesis, synaptic vesicle exocytosis, vesicle fusion with the 
presynaptic membrane, and endocytosis. Again, this occurs through phosphorylation 
of a variety of substrates associated with neurotransmitter release and synaptic 
plasticity (Benavides & Bibb, 2004; Bibb, 2003; Lagace et al., 2008; Zheng et al., 
1998). 
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1.6.1.2.1 Cdk5 as a critical regulator of presynaptic function 
At the presynaptic terminal, vesicles containing neurotransmitters undergo docking 
and fusion, or exocytosis, at the active zone to enable neurotransmitter release across 
the synaptic cleft (Murthy & De Camilli, 2003; Sudhof, 2004). A presynaptic influx 
of calcium triggers vesicle fusion and exocytosis by the SNARE (soluble N-
ethylmaleimide-sensitive fusion attachment receptor) complex proteins, consisting of 
v-SNARES (synaptobrevin or VAMP) and t-SNARES (SNAP-25 and syntaxin). The 
recycling of synaptic vesicle proteins occurs via clathrin-mediated synaptic vesicle 
endocytosis (SVE). Components of SVE include the accessory protein AP-2, 
dynamin, and amphiphysin proteins to pinch off the vesicle from the active zone using 
GTP hydrolysis; synaptojanin 1 to assist in synaptic vesicle uncoating; and other 
dephosphin proteins. The phosphatase calcineurin removes the phosphate groups from 
the dephosphins in response to calcium influx and enables synaptic vesicle exocytosis, 
and rephosphorylation by protein kinases, including Cdk5, is crucial for continued 
SVE (Nguyen & Bibb, 2003).       
 
In both endocytosis and exocytosis, Cdk5 phosphorylation of presynaptic proteins is 
required for the synaptic vesicle cycle. In vitro, p35/Cdk5 forms a complex with 
Munc18 and syntaxin1A, thought to be an essential complex in vesicle function, that 
is dissociated upon addition of ATP suggesting Cdk5 phosphorylation may allow 
syntaxin 1A to form a SNARE complex and promote neurotransmitter release 
(Fletcher et al., 1999; Shuang et al., 1998). The p35/Cdk5 complex also regulates the 
interaction between syntaxin 1A and Sept5, another protein implicated in exocytosis 
(Taniguchi et al. 2007). 
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The presynaptic protein, CASK becomes phosphorylated by Cdk5 to promote synapse 
development (Samuels et al., 2007) and the P/Q-type voltage-gated calcium channel 
to inhibit its interaction between SNAP-25 and synaptotagmin (Tomizawa et al. 
2002). The field excitatory postsynaptic potential (fEPSP) slope and glutamate release 
from synaptosomes are increased following incubation of acute hippocampal slice 
preparations with roscovitine, suggesting that inhibiting Cdk5 activity results in a 
long-term potentiation (LTP) of synaptic strength. However, roscovitine is not a 
specific Cdk5 inhibitor, indeed it also acts on the extracellular domain of Cav2.1 to 
slow channel deactivation. Therefore further studies are required to confirm that Cdk5 
regulates synaptic transmission (Yan et al., 2002). 
 
Cdk5 is proposed to phosphorylate several components of synaptic vesicle 
endocytosis, including amphiphysin (Floyd et al. 2001), dynamin I (Tan et al. 2003; 
Tomizawa et al. 2003), synapsin I (Matsubara et al. 1996), and synaptojanin I (Lee et 
al. 2004), however the role of Cdk5 in SVE is subject to debate. Whereas one report 
claims that Cdk5 is essential for SVE (Tan et al. 2003), another suggests that Cdk5 
disrupts SVE (Tomizawa et al. 2003). Complicating matters further, Cdk5 is involved 
in the activation of PCTAIRE1, a key component in the phosphorylation and 
regulation of N-ethylmaleimide sensitive fusion protein, which is essential for 
disassembling the SNARE complex (Cheng et al., 2002). It is proposed that Cdk5 is 
required for the activity-dependent slow component of SVE (Evans & Cousin, 2007).  
 
1.6.1.2.2 Postsynaptic transmission 
Cdk5 is described as an important regulator of the activity of at least two major 
neurotransmitter systems, the cholinergic and the glutamatergic (Fu et al., 2001; Fu et 
al., 2005; Hawasli et al., 2007; Li et al., 2001).  
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Initially, colocalisation of Cdk5 and p35 with the nicotinic acetylcholine receptor 
(AChR) was reported on the postsynaptic muscle membrane, where Cdk5 was 
proposed to regulate the trafficking of these receptors (Fu et al., 2001). Subsequently, 
Cdk5 was activated by acetylcholine (ACh) agonists and required for ACh-induced 
dispersion of AChR clusters that had not been stabilised by agrin (Lin et al., 2005). In 
agrin mutants, genetic elimination of Cdk5 or blocking ACh production prevented the 
dispersion of AChR clusters. Therefore, Cdk5 was proposed to negatively regulate the 
formation of synapses at the neuromuscular junction.   
 
Regulation of synaptic function by Cdk5 is additionally associated with the 
glutamatergic neurotransmitter system through modulation of N-methyl-d-aspartate 
(NMDA) receptor activity. The conditional Cdk5 knockout results in enhanced 
synaptic plasticity through an increase in the amount of NMDA receptors containing 
NR2B subunits and in the subsequent excitatory postsynaptic currents (Hawasli et al., 
2007). Furthermore, Cdk5 phosphorylation of the NR2A subunit of NMDA increases 
the activity of the receptor (Li et al., 2001).        
 
The dopaminergic signalling pathways are also a prominent area of Cdk5 research. 
Cdk5 controls dopaminergic signalling through postsynaptic phosphorylation of 32 
kDa dopamine cyclic-AMP regulated phosphoprotein DARPP-32 (Bibb et al., 1999), 
and presynaptic phosphorylation of the N-terminal domain of the dopamine-
synthesising enzyme, tyrosine hydroxylase (Moy & Tsai, 2004). Cdk5 phosphorylates 
DARPP-32 on Thr75 permitting DARPP-32 to become a protein kinase A (PKA) 
inhibitor and, therefore, a protein phosphatase 1 activator, promoting 
dephosphorylation of specific targets (Bibb et al., 1999). Conversely, if DARPP-32 is 
solely phosphorylated at Thr34 by PKA, following its activation by dopamine D1 
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receptor signalling, it inhibits protein phosphatase 1. The mRNA and protein levels of 
p35/Cdk5 are upregulated following chronic cocaine exposure in medium spiny 
neurons and ΔFosB mice (Bibb et al., 2001). PKA activation during acute cocaine 
exposure downregulates phosphorylation of Thr75 however following chronic 
exposure, Cdk5 becomes activated to reduce the locomotor response as a part of a 
novel homeostatic mechanism and the subsequent phosphorylation of Thr75 decreases 
D1/PKA signalling. 
 
1.6.1.2.3 Synaptic plasticity 
Synaptic plasticity describes the ability of synapses to strengthen or weaken 
subsequent responses following synaptic activity. The molecular mechanisms 
underlying synaptic plasticity occur both pre- and post-synaptically and involve the 
regulation of vesicle cycling, changes in ion channel conductance and synaptic 
expression, and modulation of both kinase and phosphatase activities (Dineley et al., 
2001; Vautrin & Barker, 2003). Events outside the synapse that influence plasticity 
include extracellular signalling, cell adhesion, and gene transcription.  
 
The initial evidence implicating Cdk5 in synaptic plasticity came from transgenic 
models. Long-term potentiation (LTP) induced by tetanic stimulation was found to be 
normal in p35 KO mice however impairment of hippocampal long-term depression 
(LTD) was observed in these mice (Ohshima et al., 2005). LTP is thought to correlate 
with memory formation whereas LTD may play a role in weakening synapses and 
perhaps blocking memory formation (Malenka & Bear, 2004). Subsequently, 
hippocampal-dependent spatial memory and contextual fear memory was enhanced in 
a Cdk5 KO line and LTP was greater than that of control mice (Hawasli et al., 2007). 
The evoked excitatory post-synaptic current indicated that the NMDA, but not AMPA 
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(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), receptor-mediated current 
is enhanced in these mice which is attributed to a reduction in NMDA receptor 
degradation and greater surface NR2B levels.  
 
1.6.1.3 The role of Cdk5 in normal adult neurophysiology 
1.6.1.3.1 Learning and memory 
Involvement of Cdk5 in the early stages of memory formation became apparent after	  
treatment with the Cdk5 inhibitor, butyrolactone 1 impaired contextual, but not cued, 
fear conditioning in two different strains of mice (Fischer et al., 2002). Furthermore, 
Cdk5 inhibition in the hippocampus profoundly impaired associative learning and 
memory (Fischer et al., 1997; Fischer et al., 2005). This effect on hippocampal 
learning and memory is partially supported by an absence of spatial memory learning 
strategy in the Morris water maze in p35 null mice (Ohshima et al., 2005). However, 
it should be considered that developmental defects in p35 null mice might result in 
confounding effects on behaviour. 	  
 
The molecular basis of learning and memory are proposed to involve phosphorylation 
and dephosphorylation of proteins. The glutamate receptor, N-methyl-D-asparate 
(NMDA) is well-characterised calcium channel that is key for the development of 
long-term potentiation (LTP) of neurons associated with learning and memory. In 
vitro, Cdk5 has been reported to regulate the NMDA receptor by phosphorylating its 
subunit, NR2A on Ser1232. Suppression of this phosphorylation in vivo prevented the 
LTP of hippocampal neurons (Cheng et al., 2003; Fischer et al., 2005).  
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1.6.1.3.2 Cdk5 and pain perception 
Pain is perceived through stimulation of specialised receptors known as ‘nociceptors’. 
The MAPK and Calcium calmodulin kinase pathway (CAMKII) are two important 
signal transduction pathways involved in nociception and the reported interactions of 
Cdk5 with each of these pathways provides a rationale for how Cdk5 could influence 
pain regulation (Pareek & Kulkami, 2006). In comparison to wild-type mice, there is a 
delayed response to painful thermal stimulation in p35 KO mice, which have reduced 
Cdk5 activity, and mice overexpressing p35 are sensitive to thermal stimulation 
(Pareek et al., 2006). Furthermore, inhibition of Cdk5 activity using roscovitine in rats 
attenuates formalin-induced nocireceptive response (Wang et al., 2005). This data 
places Cdk5 activity within the pathway that senses pain. Cdk5 is proposed to regulate 
mitogen-activated protein kinase kinase 1/2 (MEK1/2) activity through a negative 
feedback loop during the peripheral inflammatory response therefore it can regulate 
the Erk1/2 pathway. Moreover, a differential nociception response is observed after 
chronic morphine exposure in p35-/- and p35-overexpressing mice suggesting that 
Cdk5 activity is important for opioid tolerance (Pareek & Kulkami, 2006). In 
addition, during pain sensation, ΔFosB, a transcriptional regulator of Cdk5, is 
upregulated resulting in subsequent upregulation of the kinase. These results suggest 
molecular roles for Cdk5 in pain signalling and opioid tolerance implicating Cdk5 as 
a potential target for analgesic drug development.  
 
1.6.2 Extra-neuronal functions of Cdk5 
The extensive role of Cdk5 in the CNS and its apparent enriched expression in the 
brain has led to Cdk5 being considered a neuronal specific kinase. However Cdk5 
activity can be detected in virtually all tissues (Rosales et al., 2006) suggesting that 
Cdk5 has functions beyond the nervous system. The presence of Cdk5 in different 
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organs and cell types (Daval et al., 2001, Feldmann et al., 2010; Lin et al., 2009; 
Pallari et al., 2011; Shimomura et al., 2011) has expanded the search for Cdk5 
substrates into non-neuronal cells, and an increasing number of novel substrates that 
mediate unique and critical extra-neuronal functions have since been identified (Table 
1.1). As a result, a new dimension has been added to the functional implications of 
Cdk5 and greater diversity to the physiological function of Cdk5. Although it must be 
noted that most of the studies detailed below claim Cdk5 functions based on the effect 
of chemical inhibitors lacking absolute specificity. 
 
1.6.2.1 Cdk5 and transcriptional regulation 
Cdk5 has been implicated as a critical regulator of gene expression in both neuronal 
and non-neuronal cells and, either directly or indirectly, regulates phosphorylation of 
multiple transcription factors (Contreras-Vallejos et al., 2012). Indeed, Cdk5-
mediated transcription regulation appears critical for many cellular functions and 
deregulation can lead to multiple disease-related pathologies.    
 
Cdk5 reportedly phosphorylates signal transducer and activator of transcription 
(STAT3) at Ser727, altering its activity, and this has been linked to the control of the 
proliferation of medullary thyroid and colorectal cancer cells (Chen et al., 2007; 
Courapied et al., 2010; Fu et al., 2001). In muscle cells, Cdk5 phosphorylation of 
STAT3 is enhanced by neuregulin (NRG) 1, a critical neuregulin family protein that 
acts on the EGFR family of receptors and is essential for development of multiple 
organs. This promotes the expression of STAT3 target genes including c-fos, junB, 
fibronectin, and others (Fu et al., 2004). 
 
Cdk5 directly phosphorylates tonicity-responsive enhancer-binding protein/osmotic 
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response element-binding protein (TonEBP/OREBP), an osmotic stress-responsive 
transcription factor, at Thr135 in renal cells under high osmolarity (Gallazzini et al., 
2011). Phosphorylation results in accumulation of TonEBP/OREBP in the nucleus 
and transcription of osmo-protective target genes, thereby contributing to the 
protection of renal cells from hyperosmotic stress. Cdk5 also modulates transcription 
through phosphorylation of Ser180 of acetylated high mobility group box 1 (HMGB1) 
(Ugrinova et al., 2011). HMGB1 is a ubiquitous and abundant protein in nucleated 
eukaryotic cells that interacts with multiple transcription factors to increase their 
affinity for DNA elements, primarily regulating cellular processes critical for glucose 
homeostasis and inflammation (Thomas & Travers, 2001). 
 
Inhibition of Cdk5 activity by roscovitine blocks NF-κB activation in leukocytes and 
in lung carcinomas (Berberich et al., 2011), while Cdk5 phosphorylates and regulates 
the activity of the androgen receptor (Hsu et al., 2011). In pancreatic β-cells, p35 
expression increases with elevated extracellular glucose (post-prandial), and the 
resultant increase in Cdk5 activity is associated with increased transcription of the 
insulin gene promoter (Daval et al., 2011).  
 
Cdk5 can also negatively regulate transcription. Sds3, a constituent of the mSin3-
histone deacetylase (HDAC) co-repressor complex, is phosphorylated by Cdk5 at 
Ser228, which enhances mSds3-mediated transcriptional repression (Li et al., 2004). 
As a result, Cdk5 is linked to multiple transcription factors with a diverse range of 
cellular outcomes from endocrine/nutrient responses through to cell growth and stress 
protection.  
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1.6.2.2 Cdk5 and translational regulation 
Cdk5 can also regulate translation (Arif et al., 2011). Phosphorylation of glutamyl-
prolyl tRNA synthetase (EPRS) at Ser886 results following interferon-gamma-
mediated activation of Cdk5. EPRS becomes part of the interferon-gamma-activated 
inhibitor of translation complex, which suppresses the expression of pro-inflammatory 
genes in myeloid cells (Mukhopadhyay et al., 2009; Arif et al., 2009). In response to 
inflammatory stimulus, EPRS can recognise and directly bind to target mRNAs 
transcribed in response to the stimulus. EPRS is released from the multi-synthetase 
complex following Cdk5 phosphorylation, which enhances the binding of EPRS to the 
interferon-gamma-activated inhibitor of translation complex to inhibit translation of 
mRNAs associated with the inflammatory response (Arif et al., 2009).  
 
1.6.2.3 Cell migration, adhesion, and angiogenesis 
Angiogenesis involves the formation of new capillaries and plays a physiological role 
in healing injured tissues and in the formation of the placenta. In the development of 
cancer, there is a large requirement for nutrient supply from the blood so angiogenesis 
is vital for tumour growth. Hence, the balance between angiogenic and anti-
angiogenic factors is critical in determining the rate of growth of a tumour (Tonini et 
al., 2003). Inhibition or silencing of Cdk5 prevents angiogenesis implicating Cdk5 as 
a new target for anti-angiogenic therapies (Liebl et al., 2010; Liebl et al., 2011). 
Pharmacological inhibition of Cdk5 with roscovitine reduces endothelial cell 
migration in a dose-dependent manner, in vitro. Additionally, roscovitine treatment in 
vivo produces anti-angiogenic effects, which are reproducible using siRNA or shRNA 
to silence Cdk5. Overexpression of the Cdk5 dominant negative mutant D145N 
reduces endothelial cell migration. Inhibition of Cdk5 also reduces phosphorylation of 
focal adhesion kinase (FAK) at Ser732 without altering the formation of focal 
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adhesions or changing microtubule dynamics. Nonetheless, the overall structure of the 
actin cytoskeleton is differentially organised after Cdk5 inhibition with a subsequent 
increase in RhoA and decrease in Rac1 activities, implicating Cdk5 in controlling the 
actin cytoskeleton in endothelial cells that supports migration and angiogenesis (Liebl 
et al., 2010).    
 
Correspondingly, a correlation between the function of small GTPases and Cdk5 
activity has been described in lens epithelial cells (Tripathi & Zelenka, 2009; Tripathi 
& Zelenka, 2010). Cdk5 suppresses Src activity, resulting in decreased p190RhoGAP 
phosphorylation and subsequent activation of RhoA. Src activity becomes increased 
following inhibition of Cdk5 with olomoucine and decreases Rho-ROCK signalling, 
which is responsible for the phosphorylation of myosin and maintenance of the stress 
fibers that are necessary for cell adhesion. Local activation of Rho is consistent with 
the colocalisation of Cdk5 with contractible stress fibers (Tripathi & Zelenka, 2009). 
In agreement, olomoucine increases the expression of matrix metalloprotease-9, 
which is required for corneal epithelial cell migration, most likely through activation 
of Src to increase the migration of these cells (Tripathi & Zelenka, 2010). 
 
Cdk5 can regulate epithelial cell adhesion and migration in the lens and cornea of the 
eye (Tripathi & Zelenka, 2009; Tripathi & Zelenka, 2010). In these cells, migration is 
inhibited by overexpression of Cdk5 whereas a dominant-negative Cdk5 mutant 
enhanced motility. In a mouse model overexpressing Cdk5, corneal wound closure 
was delayed however wound healing was accelerated following treatment with 
olomoucine (Tripathi & Zelenka, 2009). Activation and localisation of Src was found 
to be dependent on Cdk5 activity and determined as a downstream target of Cdk5 
during epithelial cell migration (Tripathi & Zelenka, 2010).   
	  
 
___________________________________________________________________________________ 
 
1. Introduction 
43	  
1.6.2.4 Apoptosis 
Consistent with the majority of information regarding Cdk5 activity, evidence for a 
role for Cdk5 in apoptosis comes mainly from work in the CNS, however evidence of 
a similar role in non-neuronal cells does exist (Rosales & Lee, 2006). Inhibition of 
Cdk5 activity by either genetic or pharmacological manipulation promotes 
susceptibility to cell death in several cell types (Sharma et al., 2004; Wu et al., 2008; 
Brinkkoetter et al., 2010). In retinal pigment epithelial cells treated with roscovitine, 
expression of pro-apoptotic Bax increased while expression of anti-apoptotic Bcl-2 
decreased (Wu et al., 2008). Under stress conditions, apoptosis is increased 
significantly in immortalised podocytes derived from p35 KO mice in comparison to 
controls. Furthermore, transfection of p35 siRNA into wild-type podocytes results in 
increased apoptosis. The increased apoptosis observed in podocytes from p35 KO 
mice could be rescued by expression of p35 (Brinkkoetter et al., 2010). Finally, 
stimulation of proliferation of bovine aortic endothelial cells by basic FGF is blocked 
by roscovitine and this treatment ultimately induces apoptosis (Sharma et al., 2004). 
 
1.6.2.5 Endocrinology and metabolism 
Besides the brain, highest expression of Cdk5 is observed in the testis (Tsai et al., 
1993). Cdk5 activity is observed in both Sertoli- and Leydig cells (TM4 and TM3, 
respectively), in addition to the developing rat testis (Musa et al., 1998). The 
expression and activity of Cdk5 was hormonally regulated (by luteinising hormone 
(LH), follicle stimulating hormone (FSH), and epidermal growth factor (EGF)) in 
Leydig, but not Sertoli, cells (Musa et al., 2000). In vivo, Cdk5 activity was affected 
by hypophysectomy, which causes a reduction in secretion of LH and FSH (Musa et 
al., 2000). Human chorionic gonadotropin also regulates Cdk5 expression and 
activity, in a time- and concentration-dependent manner, in a pathway that utilises 
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cyclic-AMP (cAMP) to promote phosphorylation and activation of Cdk5 and the 
subsequent phosphorylation of steroidogenic acute regulatory protein (StAR), which 
then accumulates in Leydig cells (Lin et al., 2009).  StAR is critical for 
androidogenesis, and in keeping with regulation by Cdk5, testosterone production was 
reduced when Cdk5 activity was silenced (Lin et al., 2009).  
 
In pancreatic β-cells Cdk5 translocates from the membrane to the cytoplasm upon 
glucose stimulation, coinciding with the resultant increase in insulin secretion and 
insulin gene induction. Simultaneous treatment with roscovitine reduces glucose 
induced insulin secretion (Lilja et al., 2001). Subsequently, p35 and p39 expression 
was confirmed in pancreatic β-cells (Lilja et al., 2004). However, p39, rather than 
p35, was the key regulator of insulin secretion, and Munc 18-1, a key protein in 
vesicle trafficking, was proposed as the Cdk5 target (Lilja et al., 2004). In contrast, 
however, Ubeda and colleagues found that p35 expression and Cdk5 activity were 
regulated in β-cells by glucose, and the main action of this complex was to induce the 
insulin gene promoter (Ubeda et al., 2004). Although, in later work, the same group 
found that Cdk5 inhibition reduces glucotoxicity in INS-1 cells (Ubeda et al., 2006). 
The regulation of insulin secretion by Cdk5 may involve phosphorylation of 
phospholipase D2 (PLD2) and β2-syntrophin. EGF-dependent insulin secretion is 
modulated by PLD2 (Lee et al., 2008a), and activation of PLD2 by EGF requires 
Cdk5 phosphorylation of PLD2 at Ser134 (Lee et al., 2008b). In β-cells, β-syntrophin 
is a central adaptor protein that is phosphorylated at Ser75 and Ser90 by Cdk5 
(Schubert et al., 2010).  
 
The referenced data suggests that there may be at least two distinct mechanisms by 
which Cdk5 contributes to control of glucose-stimulated insulin secretion; firstly, 
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during first phase insulin release it regulates secretion and secondly, it enhances 
production of new insulin polypeptide for second phase insulin release and/or 
replenishing insulin secreting vesicles. In contrast, chronic hyperglycemia associated 
glucotoxicity may involve dysregulated activation of Cdk5. 
 
Insulin stimulates glucose transport into adipocytes by inducing translocation of the 
glucose transporter GLUT4 to the cell membrane. Cdk5 and p35 are expressed in 
differentiated 3T3L1 adipocytes and insulin stimulation of these cells causes rapid 
and transient phosphorylation of Cdk5 at Tyr15 by the upstream kinase Fyn, 
paralleled by an increase in Cdk5 activity (Okada et al., 2008; Lalioti et al., 2009) 
Cdk5 and p35 overexpression reduces translocation of GLUT4 while Cdk5 silencing, 
or inhibition, prevented glucose uptake in adipocytes, suggesting a vital role for Cdk5 
in this process (Okada et al., 2008). TC10α is a Rho family GTPase important for 
vesicle trafficking and GLUT4 translocation to the membrane in adipocytes. Cdk5 
phosphorylates TC10α at Thr197, and this phosphorylation regulates TC10α function 
(Okada et al., 2008). Other work proposes that the synaptotagmin analog E-Syt1, as 
opposed to TC10α, is the substrate of Cdk5 that links it to the control of glucose 
transport. Insulin treated 3T3-L1 adipocytes stimulates Cdk5 activity and E-Syt1 was 
subsequently phosphorylated at Ser314 promoting association with GLUT4 
transporters (Lalioti et al., 2009). Both E-Syt1 phosphorylation and GLUT4 
association are inhibited by roscovitine.  
 
Cdk5 is implicated in other adipocyte processes as it phosphorylates PPARγ, a 
nuclear receptor of great importance for adipogenesis, at Ser273 both in vitro and in 
vivo (Choi et al., 2010). Phosphorylation at this site reportedly alters the transcription 
of certain genes including adiponectin, leptin, and adipsin. Hyperinsulinemia induced 
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by fat feeding mice was accompanied by an increase in PPARγ phosphorylation in 
adipocytes. Additionally, anti-diabetic drugs of the thiazolidinedione class prevented 
phosphorylation of PPARγ in vitro and in subcutaneous biopsies of fat tissue taken 
from drug treated animals. Mutation of Ser273 to Ala altered the transcriptional 
profile of adipocytes suggesting that phosphorylation of this residue modifies the 
profile of PPARγ mediated transcription rather than simply enhancing or inhibiting 
PPARγ (Choi et al., 2010). The same group proposed that obesity induced the 
processing of p35 to p25, thereby activating Cdk5 to modify PPARγ function, and 
that interfering with this process would have similar benefits to PPARγ agonists on 
metabolic disease without the known side effects of the glitazone drugs.  
 
 
1.7 PATHOGENIC IMPLICATIONS OF CDK5 DYSREGULATION 
Cdk5 knockout studies in mice have demonstrated that development and maintenance 
of the central nervous system relies on the precise functioning of Cdk5 activity. 
Therefore, dysregulation of this activity has been implicated in the pathogenesis of 
several neurodegenerative diseases including Alzheimer’s disease (AD), prion-related 
encephalopathies (PRE), Parkinson’s disease (PD), amyotrophic lateral sclerosis 
(ALS) or acute neuronal injury caused by ischemia/stroke (Alvira et al., 2008; Lopes 
et al., 2007; Lopes et al., 2010; Nguyen & Julien, 2003; Slevin & Krupinski, 
2009; Tsai et al., 2004). The emerging functions of Cdk5 beyond the nervous system 
now suggest that Cdk5 dysregulation may have wider health implications, such as in 
the development of cardiovascular disease, diabetes and cancer.  
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1.7.1 Neurodegenerative disease 
The etiology of neurodegenerative diseases such as Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS) is unknown. Each 
disease is characterised by signature pathological hallmarks with different brain 
regions initially, and preferentially, affected however, as a result of disease 
progression, cognitive impairments are profound and neuronal death is severe. The 
generation of p25/Cdk5 in response to neurotoxic agents and speculation regarding its 
heightened activity has implicated Cdk5 as a common culprit in the mechanisms 
underlying neurodegeneration.  
 
1.7.1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease that 
causes dementia, and eventually death, in affected individuals. AD is clinically 
characterised as late-onset, age-dependent cognitive decline as a result of neuron 
degeneration in the cortex and hippocampus. The pathological corollary of these 
symptoms is the formation of extracellular senile plaques and intracellular 
neurofibrillary tangles (NFTs). Accumulation of oligomeric amyloid beta (Aβ) results 
in the formation of senile plaques due to the amyloidogenic processing of the amyloid 
precursor protein (APP) by various secretases. NFTs are produced due to 
hyperphosphorylation of cytoskeletal proteins such as tau, neurofilaments, and 
CRMP2, all proposed substrates of Cdk5, and these are the main components of the 
paired helical filament (PHF), an integral part of neurofibrillary tangles. The PHF 
associates with Cdk5 in AD brain where Cdk5 can be found in the intracellular 
neurofibrillary tangles in neurons of the elderly and in AD (Liu et al., 1995). These 
data implicates Cdk5 in the pathophysiology of Alzheimer’s disease, and formed the 
basis for future investigations into the association between Cdk5 and AD. 
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1.7.1.2 Parkinson’s disease 
Manifestation of tremors, muscle rigidity, and postural instability is symptomatic of 
Parkinson’s disease (PD), a neurodegenerative disorder characterised by α-synuclein-
containing Lewy body inclusions, loss of dopaminergic neurons in the substantia 
nigra pars compacta, and impaired motor skills and cognition (Olanow & Tatton, 
1999). Examination of post-mortem PD brains has revealed elevated levels of 
p35/Cdk5 (Brion & Couck, 1995; Nakamura et al., 1997; Takahashi et al., 2004) 
associating abnormal Cdk5 regulation in the pathogenesis of the disease.  
 
Cdk5 inhibition confers neuroprotection in animal models of PD (Smith et al., 2003). 
The pathological consequences of PD can be induced in animal models via 
application of the chemical compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). Cdks including Cdk2 or Cdk4 are unaffected by MPTP treatment however 
MPTP injection or treatment with MPP+ enhanced p25 levels and Cdk5 activity 
(Wong et al., 2007; Smith et al., 2003; Smith et al., 2006; Qu et al., 2007: Huang et 
al., 2010). Additionally, neuronal death is attenuated subsequent to Cdk5 inhibitor 
treatment or dn-Cdk5 virus application. MPTP treatment also increases levels of 
ΔFosB, a transcriptional regulator of Cdk5 that is upregulated during drug addiction.  
 
Parkin, the gene most frequently implicated in familial PD, is a Cdk5 interaction 
partner and substrate (Avraham et al., 2007). Parkin confers neuroprotection through 
its function as an ubiquitin ligase, with substrates including α-synuclein, synphilin-1, 
and p38MAPK. Phosphorylation of Parkin at Ser131 by Cdk5 reduces the auto-
ubiquitination activity of parkin, which in turn modulates synphilin-1/α-synuclein 
inclusion formation. 
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Cdk5 was also found to interact with and phosphorylate Prx2, another neuroprotective 
protein, resulting in down-regulation of its activity (Qu et al., 2007). Reducing Prx2 
in neurons (both in MPTP mouse models of PD and in cultured cells) promotes 
accumulation of reactive oxygen species, specifically in dopaminergic neurons of the 
substantia nigra pars compacta, resulting in neuronal death (Hu et al., 2011). 
Furthermore, an increase in phosphorylated Prx2 is observed in human PD post-
mortem brain suggesting Cdk5 may have contributed to the development of the 
pathology. 
 
1.7.1.3 Huntington’s disease  
Huntington’s disease (HD) is an autosomal-dominant disorder caused by an expansion 
in the number of CAG-repeats in the Huntingtin gene, leading to abnormally large 
polyglutamine (poly-Q) repeats in the huntingtin (htt) protein (Cattaneo et al., 2001). 
Symptomatic manifestations of HD include involuntary tremors, known as chorea, 
physical impairments, and irreversible cognitive decline. The mutant and poly-Q 
containing htt contains multiple caspase cleavage sites and the processing of htt by 
caspase precedes the development of aggregation and neurodegeneration. This implies 
that enhanced processing of htt by caspase may contribute to the disease process. 
 
In contrast to the evidence suggesting a detrimental role of Cdk5 in AD and PD, the 
literature supports a protective role for Cdk5 in HD. Cdk5 phosphorylates the htt 
protein at Ser434 in cytoplasmic fractions resulting in reduced htt cleavage at residue 
513 by caspase, thus attenuating aggregate formation and toxicity (Luo et al., 2005). 
In the brain of HD transgenic mice, the activity of Cdk5 is reduced (Luo et al., 2005). 
Correspondingly, Cdk5 activity is reduced in late-stage HD patients and the stability 
of the p35/Cdk5 interaction is impaired by mutant htt. This might suggest a late-stage 
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compensation mechanism as reduced Cdk5 activity is in direct contrast to 
observations made in PD patients and mouse models of ALS.  
 
Cdk5 phosphorylation of htt at Ser1181 and Ser1201 promotes a neuroprotective 
effect (Anne et al., 2007). Phosphorylation of these sites can be induced by DNA 
damage both in vitro and in vivo. The state of htt phosphorylation is a critical 
regulator of neuronal cell death; absence of phosphorylation at Ser1181 and Ser1201 
confers toxic properties to wild-type htt in a p53-dependent manner in striatal neurons 
and accelerates neuronal death induced by DNA damage, whereas phosphorylation of 
these sites protects against polyQ-induced toxicity. Furthermore, Cdk5 suppresses the 
formation of mutant htt inclusion bodies in cell lines and primary neurons by 
disrupting the microtubule network (Kaminosono et al., 2008).  Collectively, these 
findings suggest that Cdk5 activity is required to limit mutant htt toxicity and may, 
therefore, serve a protective role in HD. 
 
1.7.1.4 Amyotrophic lateral sclerosis   
Amyotrophic lateral sclerosis (ALS) is an adult onset, rapid, progressive 
neurodegenerative disorder that is characterised by selective demise of motor neurons 
in the brain and spinal cord (Cleveland, 1999) which manifests symptomatically as 
muscle atrophy, paralysis, and ultimately death due to cachexia or respiratory failure 
(Walling et al., 1999). The accumulations of neurafilaments in the cell body and 
proximal axons of the motor neurons hallmark the disease. Hyperphosphorylation of 
tau and neurofilaments, namely the heavy chain subunit (NF-H) is evident in the 
disease, at sites that may be Cdk5 targets, while Cdk5 activity appears enhanced in 
ALS (Nguyen et al., 2001)(Bajaj et al., 1999).     
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1.7.1.5 Niemann-Pick Type C 
Niemann-Pick type C (NPC) is a lysosomal storage disease associated with mutations 
in the NPC gene and is an autosomal-recessive neurodegenerative disorder 
characterised by distorted lipid storage in neurons, dendritic and axonal abnormalities, 
demyelination, and neuronal death (Elleder et al., 1985). NFTs, comprised of PHFs 
with phosphorylated tau are a key feature of NPC disease (Auer et al., 1995).  
 
Enhanced Cdk5 activity was reported in one NPC KO mouse (Bu et al., 2002), but not 
a second (Sawamura et al., 2001). Additionally, Cdk5 inhibitors, roscovitine and 
olomoucine, attenuated tau and neurofilament hyperphosphorylation, cytoskeletal 
lesion formation, and motor defects in the NPC KO model with high Cdk5 activity, 
suggesting that Cdk5 activity is required for the neuropathology and subsequent 
motor impairment in that model (Zhang et al., 2004). More recently, silencing of the 
Cdk5 gene in NPC KO mice significantly attenuated tau hyperphosphorylation, 
delayed neuronal death, and ameliorated motor defects implying a neuroprotective 
effect of the reduction of Cdk5 activity in this model (Hao et al., 2009).  
 
 
1.7.2 Pathology in extra-neuronal tissues 
 
1.7.2.1 Cdk5 and diabetes 
The discovery that Cdk5 promotes insulin secretion from β-cells (Lilja et al., 2001; 
Wei & Tomizawa, 2007) and regulates the insulin gene (Ubeda et al., 2004; Wei et 
al., 2005) prompted investigations into the importance of Cdk5 dysregulation in the 
development of Type 1 and Type 2 diabetes. In addition, the links between Cdk5 and 
glucotoxicity suggested inhibition of Cdk5 might protect pancreatic β-cells in 
hyperglycaemic states such as Type 2 diabetes (Ubeda et al., 2006).  
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Type 2 diabetes mellitus (T2DM) results as a consequence of the inability of cells to 
adequately respond to insulin produced by the pancreas, and is characterised by an 
initial phase of hyperinsulinemia followed by progressive loss of β-cell function. The 
incidence of T2DM is correlated with more than 60 genetic polymorphisms including 
CNJ11, which encodes a potassium rectifying channel, and the transcription factors 
peroxisome proliferator-activated receptor gamma (PPARγ), hepatic transcription 
factor 2 (TCF2), and Wolfram syndrome 1 (WFS1) (Ferguson, 2008). Of note, a 
single nucleotide polymorphism (SNP) in intron 5 of the Cdk5 regulatory subunit-
associated protein 1-like 1 (Cdkal1) gene was also linked to increased risk of Type 2 
diabetes. Cdkal1 is a 65 kDa protein that shares considerable amino acid and domain 
homology with Cdk5RAP1, an inhibitor of Cdk5 activity. This polymorphic variant of 
Cdkal1 is associated with decreased insulin secretion, and one group has hypothesised 
(without any experimental evidence) that this is a result of abnormal Cdk5 activity 
regulation (Chistiakov et al., 2011). 
  
In obese animals, adipocyte secretion of cytokines and adipokines (cytokine-like 
molecules) is altered. These agents modulate glucose homeostasis and deposition of 
free fatty acids (FFAs) in multiple tissues and may contribute to the development of 
insulin resistance and T2DM (Cusi, 2010). Several cytokines, including tumour 
necrosis factor-alpha (TNF-α) (Utreras et al., 2009), can enhance Cdk5 activity 
through the transcriptional up-regulation of p35. PPARs are a family of structurally 
related nuclear receptors that control the expression of several genes and 
physiological processes such as insulin secretion and adipogenesis (Brun et al., 1997; 
Sharma & Staels, 2007). Cdk5 activation by TNF-α, interleukin (IL)-6, and FFAs is 
reported to promote phosphorylation of PPARγ at Ser273 in 3T3-L1 adipocytes (Choi 
et al., 2010). This phosphorylation is proposed to modulate the transcriptional activity 
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of PPARγ toward specific genes such as the fatty acid transporter CD36, adiponectin, 
adipsin, and leptin potentially by modulating PPARγ interaction with transcriptional 
co-regulators. Importantly, treatment of cells and animals with the anti-diabetic drug, 
rosiglitazone (a PPARγ agonist) inhibits Cdk5-dependent phosphorylation of PPARγ 
(Choi et al., 2010). The authors therefore suggest that drugs targeting the Cdk5 
regulation of PPARγ could invoke the anti-diabetic potential of the PPARγ agonists 
without some of the side effect problems that are reducing the clinical use of this class 
of drug. 
 
1.7.2.2 Cdk5 and senescence 
Cellular senescence describes the phenomenon of cell growth arrest due to telomere 
shortening however this term may also be applied to the attrition process in response 
to cellular damage produced by endogenous or exogenous stimuli such as DNA 
damage, oxidative stress, or oncogene activation (Campisi & Fagagna, 2007).  In 
response to such noxious stimuli, cells enter a state of cell arrest that eventually 
results in senescence as an anti-proliferation mechanism. 
 
The retinoblastoma protein (pRB) and tumour suppressor protein p53 are important 
regulators of senescence, and mutations that inhibit activation of these proteins enable 
abnormal proliferation (Mao & Hinds, 2010). In human osteosarcoma SAOS-2 cells, 
ectopic expression of pRB induces Cdk5 activity during senescence thereby 
promoting the phosphorylation of ezrin and suppression of Rac activity, resulting in 
acquisition of a pRB-induced senescent phenotype (Yang et al., 2003; Alexander et 
al., 2004). Also, p35 expression is essential for Cdk5 activation in pRB-induced 
SAOS-2 senescent cells. Conversely, reducing p35 levels with shRNA antagonises 
development of the senescent phenotype in SAOS-2 cells. Notably, the p35 promoter 
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seems to contain no regulatory elements responsive to pRB therefore it seems unlikely 
that RB directly regulates the p35 gene promoter (Mao & Hinds, 2010). 
 
1.7.2.3 Cdk5 and cancer  
Cancer is a genetic and epigenetic disease arising from a single cell that has acquired 
the hallmarks of cancer (Barber et al., 2014). These hallmarks comprise a series of 
distinctive and complementary biological capabilities acquired during the multistep 
development of tumours, enabling tumour growth and metastatic dissemination 
(Hanahan & Weinberg, 2011). The hallmarks constitute an organising principle for 
rationalising the complexities of neoplastic disease and include: (1) Sustaining 
proliferative signalling. Arguably, the most fundamental hallmark of cancer cells 
involves their ability to sustain chronic proliferation. In contrast to normal cells which 
carefully manage the production of growth promoting or inhibiting factors to ensure a 
tight control of cell number, tissue architecture and function, tumour cells show 
deregulated signalling cascades that enable them to be more or less independent of 
proliferation which results in unlimited growth. Cancer cells sustain proliferation 
through autocrine proliferative signals, overexpression of cell-surface receptors and/or 
constitutive activation of signalling pathway components. (2) Evading growth 
suppressors. Normal cells are maintained in a non-dividing state by antigrowth 
signals, which cancer cells evade through genetic changes; (3) Activating invasion 
and metastasis. Cancers cells are involved in the inactivation of a whole series of 
controls that confines a cell to the site and tissue of normal growth enabling tumour 
cells to invade local tissues and metastasise to distal sites. This requires alterations in 
cell morphology, decreased attachment to other cells and the extracellular matrix, and 
an increase in cell motility; (4) Enabling replicative immortality. Most mammalian 
cells can replicate a finite number of times due to progressive shortening of telomeres 
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however cancer cells proliferate indefinitely by activating telomerase. This enzyme 
extends the telomeres enabling cancer cells to progress through multiple cycles of 
growth and division without concern of the imminent collapse of its telomeres; (5) 
Inducing angiogenesis. The process of angiogenesis is critical for almost all cancers. 
In tumour progression, there is an ‘angiogenic switch’ that results in quiescent 
vasculature to promote growth of new blood vessels into the tumour mass, thereby 
providing the tumour with nutrients and glucose and oxygen and evacuating 
metabolic waste and carbon dioxide, sustaining tumour growth; (6) Resisting cell 
death. Although cancer cells are under continual stress as the result of DNA damage 
and oncogenic signalling associated with hyperproliferation, they have devised 
mechanisms to evade apoptosis resulting in the accumulation of aberrant cells 
(Hanahan & Weinberg, 2000). 
 
The potential links between Cdk5 activity and tumourigenesis remain shrouded in 
considerable controversy. Firstly, Cdk5 is considered the atypical member of the Cdk 
family, a family whose role in cancer is well documented, due to an absent role in cell 
cycle regulation and mitotic function coupled with enriched expression in postmitotic 
neurons and glial cells. Additionally, the activity of Cdk5 is regulated by neuronal 
activators, and its extensive role in the development of the central nervous system 
opposes the potential implications of Cdk5 in cancer. However neuronal migration 
during development of the nervous system and cancer cell migration are mediated by 
quite similar processes (Kasemeier-Kulesa et al., 2008), suggesting that the 
involvement of Cdk5 in cancer may not be that surprising. Furthermore, the 
identification of Cdk5 activity in malignancy and expression of Cdk5 and cofactors in 
extra-neuronal tissues is suggesting that role of Cdk5 in tumourigenesis should 
perhaps be reconsidered.    
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Evidence for an association between Cdk5 dysregulation and cancer was first found in 
leukaemia cells (Chen et al., 1999; Sandal et al., 2002). 1alpha, 25-dihydroxyvitamin 
D3 (1,25D3), the biologically active form of vitamin D, induced Cdk5 activity in 
human leukaemia cells (Chen et al., 1999). 
 
More recently, Cdk5 activation promoted medullary thyroid carcinoma (MTC) in a 
conditional MTC mouse model (Pozo et al., 2013). Furthermore, signalling via the 
retinoblastoma protein (Rb) was a critical regulator of MTC tumourigenesis and 
progression. In addition, retinoic acid can modify Cdk5 activity in thyroid cancer cells 
through a mechanism involving the sodium/iodide transporter, a plasma membrane 
glycoprotein that stimulates the uptake of iodide (Jeong et al., 2006). These findings 
suggest that Cdk5 activity may function as a potential molecular diagnostic or 
therapeutic target for the treatment of thyroid cancer.   
 
In the breast cancer cell lines MCF-7 and MDA-MB321, decreased proliferation was 
observed in the presence of either roscovitine or siRNA specific for Cdk5. 
Additionally, application of carboplatin, a known chemotherapeutic drug used in the 
treatment of breast cancer, induced Cdk5 activation by increasing ERK activity in 
response to DNA damage (Upadhyay et al., 2008). An increase in Cdk5 activity 
stimulates p53 stability that can ultimately lead to cell death in response to DNA 
damage caused by carboplatin. This implies that tight regulation of Cdk5 activity may 
be important for normal cell physiology and that local and temporal loss or gain of 
function might result in abnormal cell proliferation.  
 
The p35/Cdk5 complex was active in both nTERT-HPNE and MIAPaCa-2 pancreatic 
carcinoma cells while inhibition of Cdk5 activity using either dominant negative 
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Cdk5 (dn-Cdk5) or pharmacological inhibitors of Cdk5 activity decreased the polarity 
and migration of both cell lines (Feldmann et al., 2010). Cdk5 also regulated cell 
invasion through modulation of the formation of invadopodia (Quintavalle et al., 
2011). In correlation with these effects, inhibition of Cdk5 activity by RNA 
interference (RNAi) reduces tumour growth and metastasis in pancreatic cancer cells 
(Feldmann et al., 2010). The monomeric GTPases RalA and RalB play a fundamental 
role in the development of pancreatic cancer cells (Lim et al., 2006). Blocking RalA 
signalling with KRAS2 mutants inhibited the tumourigenicity of pancreatic cancer 
cells, while expression of dn-Cdk5 in MIAPaCa-2 cells decreased levels of RalA-GTP 
and RalB-GTP (Feldmann et al., 2010). Co-expression of constitutively active forms 
of either RalA or RalB overcame the effect of dn-Cdk5 suggesting that Ral proteins 
are downstream of Cdk5. By controlling the function of RalGEFs and RalGAP, Cdk5 
may regulate the activation of RalA and RalB implicating Cdk5 as a potential target 
for the treatment of pancreatic cancer (Feldmann et al., 2010). Additionally, increased 
Cdk5 kinase activity was also observed in immortalised human pancreatic nestin-
expressing (HPNE) cells expressing a mutant form of K-Ras (G12D) compared with 
HPNE cells expressing native K-Ras (Eggers et al., 2011). Mutant K-Ras elevated 
p35 cleavage to p25, whereas p25 protein levels were decreased following inhibition 
of the signalling cascade downstream of mutant K-Ras which involves mitogen-
activated protein/extracellular signal-regulated kinase, phosphoinositide 3-kinase, or 
Cdk5. This suggests that mutant K-Ras acts in concert with Cdk5 and its activators to 
increase malignant progression, migration, and invasion of pancreatic cancer cells 
(Eggers et al., 2011).   
 
In cervical carcinoma caused by human papilloma virus (hPV), Cdk5 can inhibit cell 
proliferation through phosphorylation of p53 at Ser43 and Ser20, however hPV can 
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overcome this mechanism by inducing p53 degradation. HeLa cells infected with hPV 
do not undergo apoptosis or cell cycle arrest even when p53 is overexpressed, 
however modifying the phosphorylation state of p53, either by promoting the activity 
of protein kinases or inhibiting phosphatases, can induce apoptosis (Ajay et al., 2010). 
In this context, Cdk5-dependent phosphorylation of p53 could increase stability and 
transcriptional activation of p53 (Zhang et al., 2002). 
 
In contrast, Cdk5 activity was essential for control of motility and the metastatic 
potential of prostate cancer cells (Strock et al., 2006). Phosphorylation of the 
androgen receptor at Ser81 by p35/Cdk5 regulates the stability of this protein and 
increases the accumulation of androgen receptors in the nucleus, thereby regulating 
the proliferation of cancer cells (Hsu et al., 2011). Additionally, Cdk5 can increase 
both the expression and secretion of prostate-specific antigen (PSA), perhaps by 
regulating exocytosis, suggesting that Cdk5 may play a critical role in the 
development of prostate cancer (Hsu et al., 2011).  
 
In PC12 pheochromocytoma cells, talin, a β-integrin tail-binding protein required for 
integrin activation, was identified as a Cdk5 substrate under physiological conditions. 
Cdk5 phosphorylates talin at Ser425, which prevents binding to the ubiquitin ligase 
SMURF1 and halts its degradation. In SHSY5Y cells, the talin mutant tal(S425A) is 
resistant to Cdk5 phosphorylation and is intensively ubiquitinylated by SMURF1, 
resulting in an increased focal adhesion turnover and inhibition of cell migration 
(Huang et al., 2009). In glioma and glioblastoma cells, annexin-2 is a gliotropic factor 
upregulated in these cells that contributes to glioma malignancy (Zhai et al., 2011). 
Treatment of the cells with roscovitine abrogated annexin-2-induced migration. 
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In some patients with non-small cell lung cancer there is a significant correlation 
between the expression of p35/Cdk5 and the degree of differentiation and metastasis 
to lymph nodes (Liu et al., 2011). Polymorphisms in the Cdk5 promoter increase the 
risk of lung cancer in a specific Korean population (Choi et al., 2009). Also, 
overexpression of Cdk5 induced by gene amplification in lung cells can enhance 
signalling through the EGF receptor pathway (Lockwood et al., 2008). Decreased 
methylation of the Cdk5 gene has been found in mantle cell lymphoma, a subtype of 
B cell lymphoma, and this is associated with an increase in Cdk5 mRNA levels 
(Leshchenko et al., 2010). However the mechanism of generation of this cancer and 
the link with Cdk5 remains unknown. 
 
Further evidence in support of Cdk5 contributing to cancer initiation and progression 
comes from the study of probable Cdk5 substrates in cancerous tissue. Although 
considered to be neuron-enriched proteins, the CRMP family (Cdk5 targets) have now 
been found in several malignant tumours unrelated to the CNS. For example, 
downregulation of the CRMP1 isoform is associated with poor outcome in lung 
cancer (Shih et al., 2001), while upregulation of CRMP2 is found in colorectal cancer 
(Wu et al., 2008). Phosphorylation of both of these isoforms by Cdk5 is associated 
with enhanced function in neurons (Schmidt & Strittmatter, 2007), however the role 
of phosphorylation of CRMPs by Cdk5 in cancer has not yet been studied. 
Additionally, the CRMP4 isoform functions as a metastasis suppressor in prostate 
cancer (Gao et al., 2010). This isoform may not be a physiological substrate for Cdk5 
(Cole et al., 2004) however it can be phosphorylated by Cdk5 in vitro and this may 
provide a means to upregulate its activity in disease states. 
 
In addition, Cdk5 phosphorylation of STAT3 at Ser727 in medullary thyroid 
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carcinoma cells results in increased cell proliferation and promotion of 
tumourigenesis (Fu et al., 2004). In Cdk5 null mice, tumour growth was delayed in a 
STAT3 phosphorylation-dependent manner (Lin et al., 2007).     
 
Therefore, there is evidence of a potential role of Cdk5 in cancer progression and/or 
as a treatment option. Enhancing Cdk5 action on specific substrates may reduce 
progression/metastasis of specific tumours, while inhibition has potential to 
antagonise others. Similarly, Cdk5 substrates may offer diagnostic or prognostic 
value. It is therefore vital to further our understanding not only of how Cdk5 
dysfunction could occur to affect tumourigenesis but what specific downstream 
substrates confer Cdk5 action (positive or negative) to each specific form of cancer. 
 
 
1.8 AIMS OF THESIS  
The overall main objectives of this thesis were to further explore, and validate where 
possible, a number of proposed Cdk5 substrates as physiological targets. This 
information would be used to reassess the role of Cdk5 activity in tumourigenesis.  
 
1.8.1 Consensus for substrate phosphorylation 
The primary sequence requirements for Cdk5 substrate phosphorylation have not been 
fully established and are generally considered degenerative. This thesis will aim to 
explore the primary amino acid sequences of proposed Cdk5 substrates and generate 
peptides to study the substrate selection profile of Cdk5 based on the primary amino 
acid sequence surrounding the phosphoacceptor residue. This will contribute towards 
establishing a consensus for the targeting of Cdk5 phosphorylation. This consensus 
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will aid in identifying the physiological substrates of Cdk5 and provide a substrate 
profile to investigate in vivo. 
 
1.8.2 Assessing the hyperactivity of the p25/Cdk5 complex 
The current consensus surrounding Cdk5 dysregulation is associated with the 
cleavage of p35 by calpain resulting in a hyperactive Cdk5 complex. Therefore, this 
thesis aims to compare substrate specificities and phosphorylation kinetics of the 
p35/Cdk5 and p25/Cdk5 complexes in order to assess whether different substrate 
phosphorylation rates are likely to occur following cleavage of p35 to p25 in disease.  
 
1.8.3 Validating the tools to study Cdk5 phosphorylation in cancer 
Following in vitro validation of Cdk5 consensus and substrates, these will be 
investigated using a mammalian cell line system to assess substrate phosphorylation 
in intact cells. Tools to monitor regulation of conferred substrates will be developed 
and optimised for the study of Cdk5 substrate phosphorylation in human cancer.  
 
1.8.4 Investigating the role of Cdk5 in cancerous tissue 
Cdk5 is commonly described as an atypical member of the Cdk family, a large gene 
family that contains specific members that are heavily associated with cancer and 
tumour progression. The proposed atypical nature of Cdk5 will be explored in the 
final part of this thesis by investigating Cdk5 substrate phosphorylation within a range 
of human tumours. The information gathered throughout this thesis will contribute to 
the investigation of abnormal Cdk5 activity in cancer, with a view to develop useful 
diagnostic or prognostic reagents, and identify possible avenues for novel 
therapeutics. 
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2.1 MATERIALS 	  
2.1.1 Reagents 
Invitrogen (Groningen, The Netherlands): Streptomycin/penicillin, NuPAGE Bis-Tris 
4-12% pre-cast gels, pCR TOPO 2.1 cloning kit, NuPAGE buffers for SDS-PAGE, 
SeeBlue molecular weight standards, Western blotting Mini Cell apparatus, 
LipofectamineTM 2000, PureLink PCR purification kit, PureLink® Quick Plasmid 
Miniprep Kit, PureLink® HiPure Plasmid Filter Maxiprep Kit, SilverQuestTM staining 
kit, LDS sample buffer.  
 
Sigma-Aldrich (Dorset, United Kingdom): Glycine, Tris-base, imidazole, kanamycin 
sulphate, Tween®20, DMSO, Brilliant Blue G-Colloidal Concentrate, NP-40, BES, 
ethidium bromide, bovine serum albumin (BSA), ethylenediaminetetraacetic acid 
(EDTA), ethylene glycol tetraacetic acid (EGTA), MOPS, ampicillin, 
orthophosphoric acid, myelin basic protein (MBP), glycerol, Triton X-100, Brij® L23 
solution, Igepal CA-630, sodium vanadate, β-mercaptoethanol.  
 
Thermo Fischer Scientific (Massachusetts, United States): Agarose, sodium 
hydroxide, sodium dodecyl sulphate (SDS), calcium chloride, paraformaldehyde, 
Subcellular Protein Fractionation kit for Cultured Cells, Kodak® Biomax MS 
autoradiography film, Ambion® nuclease free water.   
 
Gibco (California, United States): 0.05% (w/v) trypsin-EDTA, 2.5% (w/v) trypsin-
EDTA, penicillin-streptomycin. 
 
Lonza (Switzerland): Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose 
without sodium pyruvate. 
 
Sera Laboratories International (United Kingdom): foetal bovine serum (FBS). 
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PerkinElmer ((Massachusetts, United States)): Ultima GoldTM scintillation fluid, [γ-
32P] adenosine triphosphate (specific activity, 3000Ci/mmol). 
 
Corning (New York, United States): polypropylene tubes. 
 
NUNC (Roskilde, Denmark): tissue culture flasks and plates. 
 
Promega (United Kingdom): All restriction nuclease enzymes, 10 kb DNA ladder.  
 
Bio-Rad (California, United States): Bio-Rad protein assay dye reagent concentrate. 
 
Merck Millipore (Massachusetts, United States): p25/Cdk5 active complex, p35/Cdk5 
active complex, purvalanol A, roscovitine.  
 
Roche Molecular Biochemicals (Lewes, United Kingdom): completeTM protease 
inhibitor tablets (EDTA free).  
 
GE Healthcare (New Jersey, United States): HybondTM Extra-C, protein G-sepharose 
beads. 
 
Vector Laboratories (California, United States): VECTASTAIN® ABC Reagent 
 
VWR International: p81 phosphocellulose paper, microscope slides and coverslips. 
 
Whatman International (Maidstone, United Kingdom): 3 MM chromatography paper.  
 
Kind Gifts: pCMV5 Cdk5, pCMV5 p35, pCMV5 p25 (Dr. Margareta Nikolic, 
Imperial College London). Anti-PPARγ antibody (Professor Colin Palmer, University 
of Dundee), Dynamin 1 constructs (Professor Mike Cousin, University of Edinburgh). 
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2.1.2 Recombinant Proteins 
The Division of Signal Transduction Therapy (DSTT), University of Dundee was 
responsible for the production of all bacterially expressed recombinant proteins. 
Briefly, E. coli were transformed with a plasmid expression vector pGEX6p, 
containing the cDNA of the protein of interest fused to a purification tag (e.g. 
glutathione S transferase (GST) and placed under the control of a bacterial promoter. 
The cells were grown in liquid broth and protein expression was increased using 
isopropyl β-D-1-thiogalactopyranoside (IPTG). The cells were then lysed, the 
insoluble material removed, and the remaining lysate passed through an affinity 
purification column containing the ligand of the tag of interest (e.g. glutathione). The 
protein bound to the column was then washed several times to remove contaminating 
proteins followed by elution by competition or pH change. 
 
2.1.3 Antibodies 
Antibodies used throughout this thesis were obtained either commercially or were 
produced in-house by the Division of Signal Transduction Therapy (DSTT), 
University of Dundee. 
	  
2.1.3.1 In house antibodies  
The Division of Signal Transduction Therapy (DSTT), University of Dundee provides 
an antibody generation service to staff members at the University. Aliquots of all 
antibodies previously generated are made available to colleagues within the 
University after the PI who raised the antibody has published. Table 2.1 lists the 
antibodies used in this thesis that were generated by Division of Signal Transduction 
Therapy, University of Dundee for the Sutherland lab.  
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Antibody Species Dilution Supplier 
anti-CRMP2 Sheep 1:1000 DSTT, University of Dundee 
anti-pCRMP2 Ser522 Sheep 1:1000 DSTT, University of Dundee 
anti-pCRMP4 Ser522 Sheep 1:1000 DSTT, University of Dundee 
anti-PPARγ Ser273 Rabbit 1:1000 DSTT, University of Dundee 
 
 
 
Table 2.1. In-house antibodies. The following antibodies were generated by the Division of 
Signal Transduction Therapy (DSTT), University of Dundee.  
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2.1.3.2 Total CRMP2 antibody  
An antibody recognising both phosphorylated and non-phosphorylated forms of 
CRMP2 was generated in sheep following injection with full-length recombinant 
GST-CRMP2 (Sutherland lab in collaboration with DSTT). Following preclearing on 
GST-sepharose, antiserum was affinity purified on GST-CRMP2-sepharose. Due to 
the high amount of homology between the CRMP isoforms this antibody was further 
purified using GST-CRMP1 and GST-CRMP4 proteins bound to gluthathione-
sepharose in order to remove antibodies that recognised CRMP1 and CRMP4. Each 
purified CRMP2 antibody preparation was routinely tested against GST-CRMP1, 
GST-CRMP2 and GST-CRMP4 protein to ensure efficient purification.  
 
2.1.3.3 pCRMP2 Ser522 antibody 
For generation of a phosphospecific antibody that recognises CRMP2 phosphorylated 
at Ser522, a phosphopeptide based on the sequence surrounding Ser522 
(CASSAKTpSPAKQQA where pS is phosphoserine) was synthesised (Sutherland lab 
in collaboration with DSTT). This was conjugated separately to both bovine serum 
albumin (BSA) and keyhole limpet hemocyanin and then injected into a sheep host 
(Diagnostics Scotland, Penicuik, UK). Antiserum was collected and affinity-purified 
on a CRMP2 Ser522 phosphopeptide antigen sepharose column. Isoform specificity 
and sensitivity was then assessed by SDS-PAGE and Western blotting using WT and 
S522A mutant CRMP isoforms (recombinant phosphorylated and over-expressed 
protein), and was found to be specific for CRMP2 phosphorylated at S522 (Adam 
Cole, personal communication). Additional CRMP phosphospecific antibodies 
recognising other phosphorylation sites were generated by a similar method (Table 
2.2). For immunoblotting, each phospho-specific antibody was diluted in TBS 
containing 5% (w/v) skimmed milk and 1 µM non-phosphorylated peptide. 
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Isoform 
 
Epitope Sequence 
 
Antibody Description 
 
Western blotting Dilution 
 
CRMP2 
 
CEVSVpTPKTVpTPAS 
 
pThr514/509 
 
1:1000 
 
CRMP2 
 
CEVSVpTPKTVTPAS 
 
pThr514 
 
1:1000 
 
CRMP4 
 
GSARGpSPTRPNP 
 
pSer522 
 
1:1000 
 
CRMP4 
 
FDLTTpTPKGGTPAG 
 
pThr509 
 
1:1000 
 
 
 
Table 2.2. Phosphospecific CRMP antibodies. Peptide sequences used to generate CRMP 
antibodies. 
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2.1.3.4 Commercial antibodies 
Primary and secondary antibodies were sourced commercially. For immunoblotting, 
each primary antibody was diluted (at the concentration specified in Table 2.3) in 
Tris-buffered saline (TBS) containing 5% (w/v) skimmed milk or 5% (w/v) bovine 
serum albumin (BSA), dependent on antibody requirements, and incubated overnight 
at 4°C. Secondary antibodies containing a fluorescent conjugate were diluted in TBS 
containing 5% (w/v) skimmed milk and incubated for 1 hr at room temperature.  
 
For immunofluorescence, antibodies were diluted 1:50 in phosphate-buffered saline 
(PBS) containing 5% (w/v) bovine serum albumin (BSA). Incubation time was an 
hour at room temperature followed by secondary antibody incubation at 1:250 for an 
hour. The secondary antibodies used for immunocytochemistry were Cys-3 
conjugated donkey anti-sheep IgG (H+L) and Cys-3 conjugated donkey anti-rabbit 
IgG (H+L) (Jackson ImmunoResearch Laboratories, Inc). Secondary antibodies were 
diluted in PBS containing 5% (w/v) BSA for 1 hr at R.T. 
 
For use with immunohistochemistry (IHC), primary antibodies were diluted in 5% 
(v/v) normal serum in PBS containing 5% (v/v) biotin at overnight at 4°C. 
Biotinylated secondary antibodies (Vector Laboratories, CA, USA) were diluted 1:250 
in 5% (v/v) normal serum and incubated for 30 min at R.T., followed by streptavidin 
complexed with biotinylated peroxidase (Vectastain ABC kit: Vector Laboratories, 
CA, USA) for 30 min at R.T.  
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Antibody Species Dilution Supplier Catalogue No. 
anti-Cdk5 (total) Rabbit 1:1000 Santa Cruz sc-173 
anti-p35/p25 Rabbit 1:1000 Santa Cruz sc-820 
anti-CRMP2 (total) Rabbit 1:1000 Cell Signaling 9393 
anti-TUC4/CRMP4 Rabbit 1:1000 Merck Millipore AB5454 
anti-Tau (total) Rabbit 1:1000 Dako A002401-2 
anti-pTau S235 Rabbit 1:1000 Bioworld BS4193 
anti-pTau S231 Rabbit 1:1000 Merck Millipore AB9668 
anti-pTau S205 Rabbit 1:1000 Invitrogen 44-738G 
anti-pTau S202 Rabbit 1:1000 Cell Signaling 11834 
anti-FLAG Mouse 1:500 Sigma-Aldrich  F3615 
anti-Dynamin 1 S778 Mouse 1:1000 Abcam ab18101 
anti-STAT3 S727 Rabbit 1:1000 Cell Signaling 9134 
anti-Mef2a S408 Rabbit 1:1000 GeneTex GTX79018 
anti-PAK1 T212 Rabbit 1:1000 Abcam ab75599 
anti-Lamin A/C Rabbit 1:1000 Cell Signaling 2032 
anti-Histone H4 Rabbit 1:1000 SeroTec AHP413 
anti-GAPDH Rabbit 1:1000 Abcam ab37168 
anti-ANT Mouse 1:1000 Calbiochem AP1034 
 
 
Table 2.3. Commercial antibodies. List of antibody dilutions and species used for Western 
blot analysis. Antibodies were diluted to the specific dilutions in 5% (w/v) Milk/TBST or 5% 
(w/v) BSA/TBST dependent on antibody specifications.  
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2.2 METHODS 
 
2.2.1 General Use Buffer Preparation 	  
PBS (pH 7.4) (1L)  
Sodium chloride (NaCl) 8 g 
Potassium chloride (KCl) 0.2 g 
Disodium phosphate (Na2HPO4) 1.44 g 
Monopotassium phosphate (KH2PO4) 0.24 g 
ddH2O Fill up to 1L 
 Autoclave to sterilise 	  
TBS 10 x Stock Solution (1L)  
Sodium chloride (NaCl) 87.66 g 
Tris base 12.11 g 
ddH2O 800 ml 
 Adjust pH to 8.0 
 Fill up to 1L with ddH2O 	  
1M Tris Buffer (1L)  
Tris base 121.1 g 
ddH2O 800 ml 
 Adjust pH accordingly with HCl 
Fill up to 1L with ddH2O and autoclave to sterilise 	  
0.5M EDTA (pH 8.0) (1L)  
Na2EDTA 186.1 g 
ddH20 500 ml 
 Adjust pH to 8.0 with 10 M NaOH 
Fill to 1L with ddH2O and autoclave to sterilise 	  
0.5M EGTA (pH 8.0) (1L)  
Na2EGTA 190.2 g 
ddH20 500 ml 
 Adjust pH to 8.0 with 10 M NaOH 
Fill to 1L with ddH2O and autoclave to sterilise 	  
TBE 10 x Stock Solution  
Tris base 108 g 
Boric acid 55 g 
0.5M EDTA 40 ml 
Fill to 1L with ddH2O and autoclave to sterilise 	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2.2.2 Molecular Biology 
	  
2.2.2.1 Agarose Gel Electrophoresis 
Agarose gel electrophoresis separates DNA based primarily on molecular size and 
was used during analysis of DNA digestion patterns by restriction enzymes. An 
agarose gel of 0.8% was used for most applications; a higher percentage gel would be 
used to separate relatively small DNA constructs (e.g. <1 kbp), whereas a lower 
percentage gel was used for relatively large constructs (e.g. > 10 kbp). To prepare a 
100 ml, 0.8% gel, 0.8g of agarose was dissolved in 100ml 1 x TAE buffer by heating 
in a microwave oven. Upon cooling, 2 µg of the intercalating agent ethidium bromide 
was added to enable visualisation of the DNA under ultraviolet (UV) light. The 
solution was then poured into a gel cast with a well separating comb and left to set at 
room temperature. Once set, the gel was placed into a suitable gel tank where it was 
submerged in 1 x TAE buffer. Finally, samples and DNA molecular mass ladder were 
loaded onto the gel and run for 60 min at 60V before examining the gel under UV. 
The ethidium bromide interacts with the DNA in each sample and emits fluoresces 
when exposed to UV allowing the DNA bands to be visualised. The Qiaquick gel 
purification kit (Qiagen) was used as the manufacturer’s instructions for the 
purification of DNA bands from the agarose gel.  
 
2.2.2.2 Restriction enzyme digest of plasmid DNA 
A standard restriction enzyme digest contained 1 Unit of endonuclease enzyme, 1 µl 
of 10 x compatible buffer and 0.2 mg/ml of DNA in a final volume of 10 µl. The 
endonuclease was added last before placing the reaction at 37°C for 2 hrs, unless 
otherwise dictated by specific instructions for the enzyme in question.  
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Plasmid DNA 1 µl (0.2 mg/ml) 
Endonuclease 1 µl (1 Unit) 
10 x Endonuclease buffer 1 µl 
ddH2O  7 µl 
 
2.2.2.3 Production of Chemically Competent Bacterial Cells for DNA 
Transformations 
A starter culture of 5 ml liquid broth (LB) was inoculated with an XL-1 blue glycerol 
stock and incubated on a shaker overnight at 37°C. Subsequently, 1 ml was removed 
from this culture and added to 50 ml LB. This was then incubated at 37 °C for 1-2 hrs 
until an optical density between 0.45 and 0.55 at 550 nm was obtained to ensure 
bacteria were in the log phase of growth. The cells were pelleted via centrifugation at 
4000 x g for 5 min at 4°C, the supernatant discarded, and the pellet resuspended in 10 
ml ice cooled Transformation Buffer 1 (TFB1) buffer for 5 min on ice, followed by 
the addition of a further 70 ml for 5 min. Once again, the cells were pelleted via 
centrifugation at 4000 x g for 5 min at 4°C and then resuspended in 8 ml ice cooled 
Transformation Buffer 2 (TFB2) buffer and stored on ice for 15 min. The cells were 
then aliquoted into pre-cooled 1.7 ml microcentrifuge tubes in 100 µl volumes, snap 
frozen in liquid nitrogen, and stored at -80°C.  
 
TFB1 Buffer  
Potassium acetate (KoAc) 30 mM 
Rubidium chloride (RbCl2) 100 mM 
Calcium chloride (CaCl2) 10 mM 
Manganese chloride (MnCl2) 50 mM 
Glycerol 15% (v/v) 
 Adjust pH to 5.8 with acetic acid 
 Sterile filtration 
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TFB2 Buffer  
MOPS 10 mM 
Calcium chloride (CaCl2) 75 mM 
Rubidium chloride (RbCl2) 10 mM 
Glycerol 15% (v/v) 
 Adjust pH to 6.5 with HCl 
 Sterile filtration 
 
 
 
2.2.2.4 Transformation of Bacteria 
Plasmids that contain a bacterial origin of replication are recognised by the bacterial 
cell DNA polymerases, allowing replication and amplification, and subsequent 
expression of proteins encoded elsewhere on the plasmid. 
 
Routinely, approximately 1-2 µl of plasmid DNA was added to 50 µl of chemically 
competent XL-1 blue cells, avoiding excessive pipetting and disturbance of the cells, 
then incubated on ice for a minimum of 30 min. The cells were then heat shocked at 
42°C for 90 seconds to facilitate DNA uptake and then placed back on ice for a 
further one minute. To allow for the recovery of the bacteria and the expression of 
antibiotic resistance genes, 1 ml of liquid broth (LB) was added to the cells that were 
then incubated and allowed to grow for a minimum of one hour at 37°C. Finally, 
under a burning blue flame of a Bunsen burner to avoid contamination of the samples, 
approximately 50 µl of bacterial culture was plated on agar plates containing either 50 
µg/ml ampicillin or 30 µg/ml kanamycin, dependent on whether the vector contained 
a gene encoding for ampicillin or kanamycin resistance. The plates were placed 
overnight in an incubator set at 37°C. The following day, confirmation of the uptake 
of DNA was confirmed by the growth of colonies.  
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LB Broth (1L)  
Bacto-tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
ddH2O 800 µl 
 Adjust pH to 7.5 with NaOH 
Fill up to 1L with ddH2O and sterile by autoclaving 
 
 
LB Agar (1L)  
Bacto-tryptone 8 g 
Yeast extract 5 g 
NaCl 10 g 
ddH2O 800 µl 
 Adjust pH to 7.5 with NaOH 
 
Agar 
Agar 15 g 
 Melt in microwave 
Fill up to 1L with ddH2O and sterile by autoclaving 
 	  
2.2.2.5 Plasmid DNA Purification 
For plasmid DNA purification, 5ml of LB, containing the appropriate antibiotic, was 
inoculated with bacteria containing the plasmid of interest and incubated at 37°C 
overnight in a shaker rotating at 250 rpm. For larger DNA purification, a 
larger volume of 200 ml LB was inoculated with bacteria. In order to pellet the cells, 
the 5 ml cultures were centrifuged at 5000 x g for 10 min. Plasmid DNA was 
extracted from the bacteria using the PureLinkTM mini prep kit (Invitrogen) following 
the manufacturer’s instructions. Plasmid DNA was eluted from the anion exchange 
resin using 50 µl nuclease free water. For 200 ml cultures, a J-25 Avanti centrifuge 
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(Beckman) was set at 7000 x g for 10 min to pellet the cells and plasmid DNA was 
extracted from the bacteria using the PureLink® HiPure Plasmid Maxiprep Kit (Enzo 
Life Sciences) following the manufacturer’s instructions. The purified plasmid DNA 
was reconstituted with 500 µl of 5 mM Tris pH 8.5 for long-term storage.  
 
2.2.2.6 DNA Concentration Determination 
The optical density of DNA was measured using a Nanodrop® 2000 
spectrophotometer, which calculated the sample absorbance at 260 nm (A260). The 
purity of the DNA was determined by calculating the A260/A280 ratio, which should be 
between 1.8 and 2.0. Ratios smaller than 1.8 indicated major protein contamination 
whereas ratios larger than 2.0 suggested significant RNA contamination.  
 
2.2.2.7 DNA Sequencing and Analysis 
All sequencing reactions were preformed by The Sequencing Service, School of 
Medicine, Ninewells Hospital, University of Dundee. Raw sequencing data was 
analysed using FinchTV (version 1.4) whereas Clustal (www.ebi.ac.uk/clustalw/) 
(version 2.0) was used as an alignment program against Basic Local Alignment 
Search Tool (BLAST) sequences. 
 
2.2.3 Cell Culture 
 
2.2.3.1 Cell Line Maintenance 
Prior to use, all cell culture reagents were warmed for 15 min in a water bath set to 
37°C. Cells were incubated at 37°C in a 5% water saturated atmosphere until passage. 
Once cells reached around 70-90% confluency (usually every 2-3 days) cell passage 
was performed. Cells were seeded at 1 x 105 cells per 10 cm diameter culture dish 
with supplemented Dulbecco’s modified Eagle’s medium (DMEM) (as described 
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below for individual cell lines). All cell culture techniques were preformed in aseptic 
conditions.   
 
2.2.3.1.1 HEK293 Cell Maintenance 
The Human Embryonic Kidney (HEK) 293 cell line is derived from transformed 
human embryonic kidney cells. HEK293 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 4.5 g/l glucose supplemented with 10% (v/v) 
fetal bovine serum (FBS) and a penicillin (100 units/ml)/ streptomycin (100 µg/ml) 
mix. Cells were passaged using trypsin-EDTA (0.05% w/v).   
 
2.2.3.1.2 SHSY5Y Cell Maintenance 
The SHSY5Y cell line is one of three serially isolated neuroblast clones (SHSY, 
SHSY5, and SHSY5Y) of the human neuroblastoma cell line SKNSH, which was 
established from a metastatic bone tumour (Biedler et al., 1978; Biedler et al., 1973). 
SHSY5Y cell lines were cultured and passaged as for the HEK293 cell line. 
 
2.2.3.1.3 HeLa Cell Maintenance 
The human cervix adenocarcinoma HeLa cell lines were cultured and passaged as for 
the HEK293 cell line.  
 
2.2.3.1.4 EBC-1 Cell Maintenance 
EBC-1 is a human lung squamous cell carcinoma cell line (Watanabe et al., 1985) 
obtained from the Japanese Collection of Research Bioresources (JCRB), Tokyo, 
Japan. Cells were maintained in Eagle’s medium (MEM) containing 4.5 g/l glucose 
supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) penicillin (100 
units/ml)/ streptomycin (100 µg/ml) under standard cell culture conditions at 37°C 
	  ___________________________________________________________________________________ 
___ 
2. Materials and Methods 
78	  
and 5% CO2 in a humid environment. Cells were passaged using trypsin-EDTA 
(0.25% w/v).   
 
2.2.3.1.5 A549 Cell Maintenance 
A549 cells are adenocarcinoma human alveolar basal epithelial cells. The A549 cell 
line was first developed in 1972 by D. J. Giard, et al. through the removal and 
culturing of cancerous lung tissue in the explanted tumor a of 58-year-old Caucasian 
male (Giard et al., 1973). Cells were originally sourced from ATCC and provided by 
Dr Colin Henderson, University of Dundee. Cells were passaged and maintained as 
for the HEK293 cell line. 
 
2.2.3.1.6 H460 Cell Maintenance 
A.F. Gazdar and associates derived the NCI-H460 cell line in 1982 from the pleural 
fluid of a patient with large cell cancer of the lung (Banks-Schlegel et al., 1985). Cells 
were originally sourced from ATCC and were provided by Dr Colin Henderson, 
University of Dundee. Cells were passaged and maintained as for the HEK293 cell 
line.  
 
2.2.3.2 Cell Passage 
During cell passage, culture media was removed and cells washed with 10 ml PBS to 
remove the serum and prevent inhibition of trypsin. PBS was completely removed 
prior to addition of 2 ml of trypsin/EDTA and cells were then incubated at 37°C for 5 
min to allow them to detach from the flask. Subsequently, 8 ml of supplemented 
DMEM was added to the flask and the cells were triturated ten times. The cells were 
diluted 1/10 at each passage and re-incubated at 37°C and 5% CO2 until required. 
Cells were maintained in culture until passage 30. 
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2.2.3.3 Cell Storage 
For cell storage, cells were passaged as normal while around 70-80% confluent so that 
the cells were still in the growth phase. Cells were then pelleted; media removed, and 
resuspended in 10% (v/v) DMSO, 40% (v/v) serum and 50% (v/v) media. Cells were 
then placed in the -80°C freezer overnight before being transferred into liquid 
nitrogen for longer-term storage. To revive cells, cells were rapidly thawed in pre-
warmed media and left overnight before media change. Media was changed daily 
until passage where cells were then split as normal.  
 
2.2.3.4 Culturing Primary Cortical Neurons 
Primary cortical neuron cultures were kindly prepared and supplied by Dr. Ritchie 
Williamson, (now at the University of Bradford). The day prior to culturing neurons, 
coverslips were placed in plates and coated with 2 ml poly-D-lysine (PDL) (50 µl in 
10 ml sterile ddH2O) per 6 well or 1 ml per 12 well. Embryos were dissected from a 
pregnant rat and brains removed and submerged in Hanks Balanced Salts Solution 
(HBSS) (w/o Ca and Mg). The cerebellum, optic nerve, and meninges were then 
removed under a dissecting microscope. The cortex was opened out and the midbrain 
removed then transferred to a fresh small dish with HBSS and taken to tissue culture. 
Subsequently, a trypsin/HBSS solution was prepared using 0.5 ml 2.5% trypsin plus 
4.5 ml HBSS w/o Ca and Mg. Tissue pieces plus HBSS from the dish were pipetted 
and transferred to a fresh 15 ml tube and the tissue left to settle. The media was then 
aspirated off and replaced with trypsin/HBSS solution before placing in a water bath 
set at 37°C and mixing occasionally for 20-30 min. Meanwhile, PDL was washed off 
the coverslips/plates that were then rinsed with fresh sterile ddH2O prior to addition of 
fresh neurobasal media (1 ml per 12 well, 2 ml per well of 6 well), before returning to 
the incubator. Subsequently, 10 mg/ml DNase in HBSS was added to the trypsin-
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tissue mix, the tube inverted gently twice and then the tissue left to settle for 10 min. 
The media was aspirated off, 0.5 ml titrating solution was added and the tissue gently 
pipetted up and down 10-15 times with previously flamed glass pipettes. Cells were 
resuspended in neurobasal media so that the suspension was approximately 1 x 106 
cells per ml. For the purpose of immunostaining, 2-5 x 106 cells/well were added.  
 
 
Media  
Neurobasal Medium (Gibco) 500 ml 
B27 Supplement (Invitrogen) 10 ml 
Pen/Strep (Sigma) 5 ml 
L-glutamine (Sigma) 5 ml 
 
Poly-D-Lysine (0.01% w/v)  
Poly-D-Lysine 5 mg 
ddH2O 5 ml 
 Store at -20°C 
 Use at final concentration of 20 µg/ml 
 
DNase I stock solution  
DNase I 7.5 mg 
HBSS (with Ca and Mg 750 ml 
 Vacuum filter and store at -20°C 
 
Trituring Solution  
HBSS (with Ca and Mg) 100 ml 
Trypsin Inhibitor (Sigma) 50 g 
Albumax (Invitrogen) 1 mg 
DNase I (Sigma) 1 mg 
 Vacuum filter and store at -20°C 
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Dissection Solution  
HBSS (without Ca and Mg) 500 ml 
1M HEPES (pH 7.3) 3.5 ml 
1M MgCl2 5 ml 
Penicillin/Streptomycin 5 ml 
 
 
 
2.2.4 Transient Transfection 
 
2.2.4.1 Calcium Phosphate (Ca3(PO4)2)/BES Transient Transfection 
Typically, a DNA precipitation mix consisted of plasmid DNA made up to volume 
using sterile RNAse free water, plus 2 x BES and mixed gently into 14 ml 
polypropylene plastic tubes. Subsequently, 2.5 M CaCl2 (final concentration 0.15 M) 
was added slowly and drop-wise to the mixture, which was then allowed to precipitate 
at room temperature for 20 min (see table for transfection mix volumes). The 
precipitation mix (volume dependent of dish size) was then added drop-wise and 
evenly across the cells after which the dish was gently swirl-mixed to ensure 
homogeneity. The cells were then incubated for 4 hrs at 37°C in a 5% CO2 water 
saturated atmosphere. At the time of transfection, plated cells were ~50% confluent.  
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 6 well plate (3 cm) 6 cm plate 10 cm plate 
2 x BES 150 µl 200 µl 250 µl 
Nuclease free H20 Up to 135 µl Up to 177.5 µl Up to 220 µl 
Plasmid DNA 1 µg 2 µg 3 µg 
CaCl2 15 µl 22.5 µl 30 µl 
Total Volumes 300 µl 400 µl 500 µl 
 
 
Table 2.4. Ca3(PO4)2/BES transfection mix volumes. A minimum volume of 500 µl was 
made and a maximum volume of 1500 µl in a single transfection mix. 
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2.2.4.2 Lipofection Transient Transfection 
LipofectamineTM 2000 (Invitrogen) transfections involved the formulation of 3 
transfection mixes. Mix 1 consisted of DMEM media (serum and antibiotic free) plus 
1 µg plasmid DNA (200 µl total volume per 3 cm diameter culture dish). Mix 2 
consisted of DMEM media (serum and antibiotic free) LipofectamineTM 2000 (1 µl) 
(200 µl total volume). These were mixed gently and incubated at room temperature 
for 5 min. Mix 1 and Mix 2 were combined (Mix 3), mixed gently and incubated for a 
further 20 min at R.T. 1600 µl of DMEM (10% (v/v) FBS with no antibiotics) was 
then added to Mix 3 (final volume 2000 µl), then added to cells to be transfected 
(previous media removed) and incubated for a total of 48 hrs at 37°C in 5% CO2 
water saturated atmosphere. At the time of transfection cells were ~ 50% confluent.  
 
2.2.4.3 Mammalian Expression Constructs 
The cDNA encoding full-length hCRMP2 was amplified by PCR from Image clone 
#6177866 using the primers 5′-GGATCCGCCACCATGGACTACAAGGACGACG-
ATGACAAGTCTTATCAGGGGAAGAAAAATATTCCACGC-3′ and 5′-GAATT-
CTTAGCCCAGGCTGGTGATGTTGGC-3′. The cDNA encoding full-length 
hCRMP4 was amplified by PCR from Image clone #5725550 using the primers 5′-
GAATTCGCCACCATGGACTACAAGGACGACGATGACAAGTCCTACCAAGG
CAAGAAGAACATCCCG-3′ and 5′-GAA-TTCTTAACTCAGAGATGTGATAT-
TAGAACGGCCG-3′. The PCR products were subcloned into pCMV5 vectors for 
mammalian expression. Expression constructs for CDK5, p35 and p25 were generated 
by Dr. Margareta Nikolic, Imperial College, London. All other expression constructs 
were obtained from MRC Protein Phosphorylation Reagents, University of Dundee. 
Constructs used in this study are shown in Table 2.5. 
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Construct 
XXXXXXXXXXXXX 
Expression  
System 
Promoter 
X 
Bacterial 
Resistance 
Features 
XXXX 
pCMV5 FLAG-Mef2a WT Mammalian CMV Ampicillin FLAG-tagged 
pCMV5 FLAG-PAK1 WT Mammalian CMV Ampicillin FLAG-tagged 
pCMV5 FLAG-STAT3 WT Mammalian CMV Ampicillin FLAG-tagged 
pCMV5 FLAG-Dynamin-1 WT Mammalian CMV Ampicillin FLAG-tagged 
pCMV5 FLAG-CRMP2 WT Mammalian CMV Ampicillin FLAG-tagged 
pCMV5 FLAG-CRMP4 WT Mammalian CMV Ampicillin FLAG-tagged 
pCMV5 Cdk5 WT Mammalian CMV Ampicillin None-tagged 
pCMV5 p35 WT Mammalian CMV Ampicillin None-tagged 
pCMV5 p25 WT Mammalian CMV Ampicillin None-tagged 
 
 
Table 2.5. Mammalian expression constructs. 
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2.2.5 Cell Stimulations 
All Cdk5 inhibitor treatments were performed in serum-free media therefore prior to 
treatment serum-containing media was removed from cells and replaced with pre-
warmed serum-free media. 
 
2.2.5.1 Inhibitors 
Stock solutions of roscovitine (Calbiochem) and purvalanol A (Calbiochem) were 
prepared in DMSO (10 mM). Cells were treated with either purvalanol A or 
roscovitine (10 µM final concentration) or vehicle (0.1% DMSO) for 3 hrs, unless 
stated otherwise in figure legends.  
 
2.2.6 Confocal Microscopy 
 
2.2.6.1 Primary Neuron Cell Preparation 
Following 6 days in vitro (6 DIV), primary cortical neurons were fixed in ice-cold 4% 
(w/v) paraformaldehyde (PFA) (in 1.0% (w/v) PBS) for 10 min at 4°C prior to 
washing twice in PBS followed by two washes in 50 mM TBS. Subsequently, neurons 
were permeabolised with 0.1% (v/v) Triton x-100 in TBS for 3 min at room 
temperature, washed thrice in 50 mM TBS, and blocked with 1% (w/v) BSA in TBS 
containing 0.005% (v/v) Tween-20 in for 1 hr at room temperature. Fixed cells were 
then incubated in primary antibodies diluted 1:50 in PBS containing 5% (w/v) BSA 
for 1 hr at room temperature prior to three washes in 50 mM TBS. Secondary 
antibodies conjugated to Cy3-fluorophores were diluted 1:250 in PBS containing 5% 
(w/v) BSA and incubated with neurons for 1 hr at room temperature. Cells were then 
washed three times in 50 mM TBS and subsequently counterstained with 0.5 µg/ml 
DAPI solution (Invitrogen). 
	  ___________________________________________________________________________________ 
___ 
2. Materials and Methods 
86	  
2.2.6.2 Image Analysis 
Image acquisition was performed on a Leica TSC SP-5 laser scanning confocal 
microscope imaging system (version 2.0.2). Images were subsequently viewed using 
Volocity 3D Image Analysis Software (version 6.3) (PerkinElmer) and this software 
was used to insert scale bars into each image.  
 
2.2.7 Protein Isolation and Assay	  
2.2.7.1 Mammalian Cell Lysis Buffer Preparation 
Ions are essential for the function of many enzymes (including most proteases, 
kinases and phosphatases). During cell lysis, a selection of ion chelators are used to 
sequester enzyme cofactors in order to halt cellular activity and therefore ensure 
protein modifications and integrity (e.g. phosphorylation status) is maintained during 
isolation. As such, cell lysis buffer was prepared to contain EDTA to chelate divalent 
cations (+2 charge), such as magnesium, manganese, zinc, and calcium (Mg2+, Mn2+, 
Zn2+, and Ca2+, respectively), whereas EGTA was used to chelate Ca2+ ions. In 
addition to these reagents, sodium fluoride and sodium pyrophosphate were included 
in order to inhibit serine/threonine phosphatases as well as sodium orthovanadate to 
inhibit protein tyrosine kinases. Sodium orthovanadate was prepared by carrying out 
several rounds of boiling and cooling on ice. This was continued until the pH 
remained stable at pH 10, subsequent to boiling. This boiling and pH adjustment 
ensures that sodium orthovanadate is monomeric and will therefore effectively inhibit 
tyrosine phosphatases. Furthermore, β-mercaptoethanol was used as a reducing agent 
in the cell lysis buffer and protease inhibitor cocktail tablets were added to prevent 
protein degradation.  
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Lysis Buffer  
EGTA 0.1 mM 
Triton X-100 0.1 mM 
Sucrose 0.27 M 
Tris- HCL, pH 7.4 50 mM 
NaF 50 mM 
Na3VO4 1 mM 
Na2P2O7 5 mM 
β-mercaptoethanol 0.1% (v/v) 
Protease inhibitor tablets (Gibco) 1 per 10 ml 
 
 
2.2.7.2 Cell Protein Isolation 
Cell transfections were terminated by washing cells twice with 2 ml ice-cold PBS in 
order to remove excess media. Once the PBS was totally removed a small volume 
(typically 50-500 µl) of ice-cold mammalian lysis buffer was added, followed by cell 
scraping using a plastic scraper on ice. Cell lysates were transferred to ice-cooled 
eppendorf microcentrifuge tubes and left on ice for 20 minutes to allow the proteins to 
solubilise. They were then centrifuged at 13,000 x g for 10 minutes in order to remove 
cellular debris. The supernatant (lysate) was removed and snap frozen in liquid 
nitrogen and stored at -80°C until required.  
 
2.2.7.3 Protein Immunoprecipitation  
In order to couple an antibody to protein G-sepharose, beads were washed 3 times in 
lysis buffer followed by centrifugation at 5000 x g for 1 minute. Antibody was then 
incubated with a 50% (v/v) protein G bead slurry in 1 µg: 10 µl antibody to slurry 
ratio, and incubated on a shaking platform for 1 hour at 4°C. The beads are then 
washed x 3 with lysis buffer in order to remove unbound antibody and stored as a 
50% (v/v) slurry at 4°C until required. 
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Typically, proteins were immunoprecipitated following incubation of a cell lysate (1 
mg/ml, 100 µl) with antibody bound agarose beads (10 µl of 50% (v/v) slurry) for 16 
hrs at 4°C on a shaking platform. Sepharose beads were pelleted by centrifugation at 
2000 x g and then washed twice with cell lysis buffer and once with lysis or assay 
buffer dependent on whether they were for SDS-PAGE or kinase assay. 
Immunoprecipitated proteins/agarose beads were either incubated in 1 x SDS sample 
buffer and heated at 95°C for 10 min in preparation for SDS-PAGE, or retained in 
kinase buffer at 4°C for subsequent kinase assay reactions.  
 
2.2.7.4 Subcellular Protein Fractionation 
Adherent cells were harvested with trypsin-EDTA then pelleted in the centrifuge at 
500 x g for 5 minutes. The cell pellet was then suspended in ice-cold PBS in order to 
wash the cells. Then, 1 – 10 x 106 cells were transferred to a 1.5 ml microcentrifuge 
tube and spun at 500 x g for 5 minutes to pellet the cells. The supernatant was 
carefully removed and discarded, leaving the pellet as dry as possible. The 
fractionation protocol was scaled depending on cell pellet volume, maintaining the 
volume ratio of Cytoplasmic Extraction Buffer: Membrane Extraction Buffer: Nuclear 
Extraction Buffer: Pellet Extraction Buffer (CEB:MEB:NEB:PEB, respectively) 
reagents at 200:200:100:100µl, respectively. Following addition of CEB containing 
protease inhibitors to the cell pellet, the tube was incubated at 4°C for 10 minutes 
with gentle mixing before being centrifuged at 500 x g for 5 minutes. The supernatant 
(containing the cytoplasmic extract) was then immediately transferred to a clean pre-
chilled eppendorf on ice. Ice-cold MEB containing protease inhibitors was added to 
the pellet before vortexing the tube for 5 seconds on the highest setting and then 
incubating at 4°C for 10 minutes with gentle mixing. This was followed by 
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centrifugation at 3000 x g for 5 minutes. The resulting supernatant (containing the 
membrane extract) was transferred to a clean pre-chilled eppendorf on ice. In order to 
isolate the soluble nuclear fraction, ice-cold NEB containing protease inhibitors was 
added to the pellet followed by vortexing on the highest setting for 15 seconds. The 
tube was then incubated at 4°C for 30 minutes with gentle mixing before being 
centrifuged at 5000 x g for 5 minutes. The supernatant (containing the soluble nuclear 
extract) was transferred to a clean pre-chilled eppendorf on ice. The chromatin-bound 
extraction buffer was prepared by adding 5µl of 100mM CaCl2 and 3µl of 
Micrococcal Nuclease (300 units) per 100µl of NEB at room temperature. The tube 
was vortexed on the highest setting for 15 seconds after adding this extraction buffer 
to the pellet. The tube was then incubated at room temperature for 15 minutes 
followed by further vortexing for 15 seconds. The tube was centrifuged at 13,000 x g 
and the resultant supernatant transferred to a clean pre-chilled tube on ice. Finally, 
PEB containing protease inhibitors was added to the pellet and then vortexed on the 
highest setting for 15 seconds, prior to incubation at room temperature for 10 minutes 
before centrifuging at 13,000 x g for 5 minutes. The supernatant (containing the 
cytoskeletal extract) was then transferred to a new tube. For same-day use, fractions 
were maintained on ice for downstream applications and analysis. For long-term 
storage, fractions were stored at -80°C.  
 
2.2.7.5 Measurement of Protein Concentration 
Sample protein concentration was determined using the method described by M. 
Bradford in 1976 (Bradford 1976). The Coomassie brilliant blue G-250 dye in the 
Bradford reagent binds to arginine, aromatic amino acids and histidine containing 
proteins. When Coomassie binds to proteins in solution its absorbance shifts from 465 
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nm to 595 nm. An increase in protein concentration correlates with an increase in 595 
nm absorbance.  
 
Briefly, protein lysates were diluted 1:20 in water, and 20 µl was then transferred to a 
plastic cuvette. 1 ml of Bradford reagent was added, vortex mixed and incubated at 
room temperature for 10 minutes, vortex mixed again and the absorbance read at 595 
nm. A serial dilution linear bovine albumin (BSA) standard curve was used to find the 
gradient coefficient value from which an unknown protein concentration can be 
determined. The assay was blanked using 20 µl of water in 1 ml of Bradford reagent 
incubated for 10 min alongside samples.  
	  
2.2.7.6 Sodium Dodecyl-Sulphate Poly-Acylamide Gel Electrophoresis 
Samples were prepared for Sodium Dodecyl-Sulphate Poly-Acylamide Gel 
Electrophoresis (SDS-PAGE) using SDS sample buffer supplemented with 10 mM 
dithiothreitol (DTT) and heated to 70°C for 10 minutes. SDS is an anionic molecule 
that coats proteins with a negative charge in a uniform charge to mass ratio. The 
negatively charged sulphate groups disrupt amino acid hydrophobic interactions while 
DTT reduces disulphide bonds between cysteine residues therefore denaturing any 
secondary structure of the proteins within the sample. Samples were subjected to 1 
dimensional SDS-PAGE (Bio-Rad) using prepoured 4-15% NuPAGE gels 
(Invitrogen). Upon loading of samples onto the gel, a current of 100V for 10 minutes 
was applied followed by 180V for 60 minutes. Negatively charged SDS residues 
greatly outnumber charged amino acid side chain groups of the protein, therefore 
proteins move towards the positively charged electrode and the rate of movement 
through the polyacrylamide matrix is directly related to molecular mass independently 
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of inherent protein charge. SeeBlue molecular weight markers are pre-stained proteins 
of known molecular mass that provide a standard to determine the apparent molecular 
weight of proteins of interest within the gel.  
 
2.2.7.7 Gel Coomassie Staining 
Following SDS-PAGE, protein bands can be visualised using Coomassie stain. The 
gel is immersed in Coomassie Brilliant Blue (CBR-250) stain, heated in a microwave 
for 10 seconds, and incubated on a shaking platform for 10 min at room temperature. 
The gel is de-stained by immersion in 40% methanol (v/v) and 10% acetic acid (v/v). 
De-stain is changed regularly until the gel background is reduced and protein bands 
become visible. The methanol/acid immersion dehydrates the gel, to prevent cracking 
during drying, a final wash with 50 ml distilled water containing 2 ml 50% (v/v) 
glycerol is performed. The gel is placed onto 3 mm Whatman filterpaper, covered 
with clingwrap and placed into a Slab gel dryer at 70°C for 90 min.  
 
Coomassie Stain  
Methanol 40 % (v/v) 
Acetic Acid 10 % (v/v) 
Brilliant Blue R-250 200 mg/L (w/v) 
 
Coomassie Destain  
Methanol 40 % (v/v) 
Acetic Acid 10 % (v/v) 
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2.2.8 Western Blot Analysis 
 
2.2.8.1 Transfer of Proteins to Nitrocellulose Membrane 
Following SDS-PAGE, the gel was assembled into a gel membrane sandwich as 
follows: nylon sponge, 3 mm Whatman paper, polyacrylamide gel containing protein, 
0.45 mm nitrocellulose membrane (HybondTM C-Extra), 3 mm Whatman filterpaper, 
and then filled with nylon sponges until the transfer cassette was tightly packed. Each 
sandwich component was pre-soaked in transfer buffer prior to transfer sandwich 
assembly. Once placed into the transfer tank, the inner chamber was filled with 
transfer buffer and the outer chamber filled with water. A current of 35 V was applied 
across the sandwich for 2 hrs, facilitating the transfer of proteins from the gel to the 
nitrocellulose. After transfer, the nitrocellulose membrane was stained with reversible 
Ponceau S protein staining solution (Sigma Aldrich) for 1 min to assess transfer 
efficiency. Ponceau S staining was removed by washing the membrane in TBST.  
 
NuPAGE® MOPS Running Buffer (20X)  
MOPS 50 mM 
Tris bas 50 mM 
EDTA (pH 7.7) 1 mM 
SDS 0.1% (w/v) 	  
NuPAGE® Transfer Buffer (20X)  
Bicine 25 mM 
Bis-Tris (free base) 25 mM 
EDTA (pH 7.2) 1 mM 
 
TBST (1L)  
10 x TBS stock solution 100 ml 
Tween 20 500 µl 
ddH2O 900 ml 
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2.2.8.2 Immunoblotting 
Immunoblotting of membranes enables visualisation of specific proteins or protein 
modifications (such as phosphorylation) in a complex mixture, and is a semi-
quantitative technique dependent on the quality of antibodies for the target of interest. 
The nitrocellulose membrane from above was blocked for 1 hr at R.T. in TBST 
blocking buffer in order to block non-specific binding of the antibody to the 
membrane. Membranes were incubated with primary antibody (diluted in TBST with 
appropriate blocking agent) overnight at 4°C on a rolling mixer and then washed 3 x 
10 min with TBST at R.T. Primary antibody bound to the target protein was 
visualised by incubation with an appropriate fluorophore-conjugated secondary 
antibody (in TBST plus 1% (w/v) milk) for 1 hr at R.T.  
 
2.2.8.3 Visualisation of proteins on membranes 
Membranes were washed 5 x 10 min in TBST at room temperature before protein-
antibody-dye conjugates were visualised using a LI-COR Odyssey® Infrared Imaging 
System (LI-COR Biosciences, Lincoln, NE).  
 
2.2.8.4 Analysis and Quantification of Western blots  
Densitometric analysis was performed using the LI-COR Odyssey® Infrared Imaging 
System software. In order to determine changes in protein phosphorylation, total 
protein levels corrected for any variation in protein loaded between samples (loading 
control), therefore a ratio between phosphorylated and total protein for each sample 
could be calculated (phosphorylated protein value divided by total protein, from the 
same sample). An inert protein (such as actin) was used as a loading control when 
assessing potential changes in the levels of a specific protein between two samples. 
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2.2.9 Phosphorylation Assay 	  
2.2.9.1 Assay of proline directed kinases 
The inherent specific activity of purified CGMC protein kinases was assessed using 
myelin basic protein (MBP) as a non-specific substrate. Briefly, the kinase of interest 
was incubated in kinase buffer with MBP (0.3 mg/ml) final concentration) in the 
presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) (50 µl final reaction 
volume) for 10 min at 30°C. Reactions were then terminated by absorption onto 
phosphocellulose p81 paper followed by immediate immersion in 75 mM phosphoric 
acid. Papers underwent 5 x 5 min washes in orthophosphate to remove any 
unincorporated negatively charged [γ-32P] Mg-ATP. A final wash in acetone was 
performed to dry papers before they were placed 2 ml scintillation fluid and 
phosphate incorporation measured by scintillation counting in a Wallace 1409 
scintillation counter. MBP kinase specific activity was used to match activities of 
different kinases in subsequent comparisons with protein substrates. 
 
MgATP (10 x stock solution)  
Magnesium chloride 100 mM 
ATP 1 mM 
 
Kinase Buffer (2 x stock solution)  
MOPS buffer (pH 7.5) 50 mM 
EDTA 0.5 mM 
Brij-35 0.01% (v/v) 
Glycerol 10% (v/v) 
 
One unit (U) of kinase activity is the amount required to transfer one nanomole of 
phosphate to substrate in one minute at 30°C. 
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2.2.9.2 Peptide and protein substrate assay 
Protein kinases were assayed by quantifying their ability to transfer radioactive 32P 
from [γ-32P] ATP into a protein/peptide substrate. A reaction 
mixture, typically, contained purified kinase, protein/peptide substrate
, 10 mM MgCl2, 0.1 mM ATP (cold or radiolabelled [γ-32P]) and kinase buffer in a 
total volume of 50 µl. All assays were initiated by the addition of 5 µl of a 10 x 
MgATP (100 mM MgCl2 and 1 mM ATP (for radioactive assays specific activity of 
ATP was around 0.5 x 106 CPM/nmole) solution and incubated on an IP shaker at 
30°C for the times indicated in the figure legend.  
  
For protein substrates, reactions were stopped by the addition of an equal volume of 2 
x SDS loading buffer (containing 10 mM DTT), heated at 100 °C for 10 minutes and 
then subjected to SDS-PAGE. For peptide substrates, 40 µl of the kinase reaction 
(50µl total assay volume) was spotted onto 2cm2 phosphocellulose P81 paper and 
immediately immersed in 75 mM phosphoric acid. The peptides contain a positively 
charged Arginine residue at the C-terminus, which promotes binding to the negatively 
charged P81 paper. Papers were then washed 5 times for 5 min using 75 mM 
orthophosphoric acid which removes any unincorporated negatively charged [γ-32P] 
ATP. After a final wash in acetone, followed by air drying, the papers were then 
individually placed into labelled tubes and 2 ml of scintillation fluid added. The 
radioactivity of the sample was measured by Scintillation counting in a Wallace 1409 
scintillation counter. Substrate proteins such as myelin basic protein (MBP) were also 
analysed using this method due to their high content of basic amino acids promoting 
interaction with the p81 paper. An aliquot of the 10 x MgATP [γ-32P] was also 
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counted in order to calculate the exact specific activity and to permit quantification of 
the molar incorporation of phosphate into the substrate.  
 
2.2.9.3 Kinase Phosphorylation Stoichiometry 
Kinase phosphorylation stoichiometry was calculated as follows: 1µl of 10 x [γ-32P] 
MgATP (100 mM MgCl2 and 1 mM ATP) stock contains 1 nmole of ATP. Therefore, 
the counts per minute (CPM) in 1 µl provide the CPM per nmole (specific activity) of 
the ATP. As the kinase transfers the radiolabelled γ-phosphate the CPM of the 
substrate at the end of the reaction provides the nmoles of phosphate transferred to the 
substrate. The ratio of nmoles of phosphate transferred to nmoles of substrate in the 
reaction gives the phosphorylation stoichiometry (mol/mol). The nmoles of phosphate 
transferred into substrate over time provides the velocity of the reaction and can be 
used to calculate affinity of the substrate for a given enzyme. 
 
2.2.9.4 Phosphorylation Kinetics, Vmax and Km Calculation 
Vmax is the maximal velocity that the reaction can reach (all the enzyme catalytic sites 
are occupied) and Km is the concentration at which half of all the enzyme active sites 
contain substrate (a measure of affinity of the enzyme for the substrate). The 
Michaelis-Menten equation provides a Lineweaver-Burk plot that will give a straight 
line (reciprocal of both substrate concentration and velocity) where the line that 
intercepts the Y axis will give a value for 1/Vmax and the line intercept on the X axis 
will give a value for -1/Km. These laws are only applicable to linear kinetic reaction 
velocities obtained using a constant concentration of enzyme in the reaction whereas 
the substrate concentration is increased.  
 
	  ___________________________________________________________________________________ 
___ 
2. Materials and Methods 
97	  
The phosphorylation kinetics, Vmax and Km were calculated using the Michaelis-
Menton and Lineweaver-Burk equations: 
 
 
Michaelis-Menton Equation: v = Vmax [S]/Km + [S] 
Lineweaver-Burk Equation: 1/vo = 1/Vmax + ((Km/Vmax) x (1/[S]) 
(Linear transformation of the Michaelis-Menton equation) 
 
2.2.10 Histological Techniques 
 
2.2.10.1 Tissue preparation and paraffin embedding 
The aim of tissue processing is to remove water from the tissue and replace it with a 
solidifying medium, mostly commonly used is paraffin wax, to enable cutting of 
sufficiently thin sections for subsequent analysis of morphology and composition. 
Tissue preparation and paraffin embedding was performed by Dr. Phil Coates, 
Tayside Tissue Bank, using the following procedure: Samples that were fixed in 
formalin were loaded into cassettes and processed to wax using a Tissue-Tek Vacuum 
Infiltration Processor (Sakura Finetek Europe, The Netherlands). Briefly, cassettes 
were dehydrated in graded concentrations of ethanol (70%, 90%, 100%, 100% (v/v), 
each for 2 hrs; Fisher Scientifc, United Kingdom), then cleared in xylene (two 
changes, each for 2 hrs; Fisher Scientific, United Kingdom) and, finally, immersed in 
molten paraffin wax at 60°C (three changes, each for 2 hours, Thermo-Shandon, 
United Kingdom). Each step was preformed under vacuum and with agitation to 
accelerate infiltration of solvent/wax. After processing, samples were positioned in 
molten paraffin wax-filled embedding moulds and cooled rapidly on a Tissue-Tek 
Cryo-console (Sakura Finetek Europe, The Netherlands) to form solid blocks.  
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2.2.10.2 Microtomy 
Sections were prepared by Dr. Phil Coates and Dr. Susan Brey, Tayside Tissue Bank 
using the following procedure: Paraffin blocks were cut into sequential 4 µm thick 
sections using a Leica RM 2135 microtome (Leica Microsystems, Germany). 
Immediately after sectioning, ribbons of sections were allowed to float on top of a 
water bath (Sakura Finetek Europe, The Netherlands) set at 40°C to allow the 
sections to expand and smooth prior to mounting on Superfrost Plus electrostatically-
coated microscope slides (VWR International, United Kingdom). Slides were then 
incubated at 37°C overnight to ensure adherence of the sections to the slides.  
 
2.2.10.3 Immunohistochemistry 
Immunohistochemistry (IHC) staining is an antibody-antigen reaction that can be used 
to identify tissue origin such as with tumours of unknown origin that have 
metastasized or are poorly differentiated. The antibody-antigen interaction can be 
visualised by fluorescence or enzymatic development of a chromogenic substrate, 
usually following several amplification steps.  
 
Firstly, slides were incubated in histosol for 10 min to remove the paraffin wax. This 
was followed by an additional 10 min incubation in histosol. The samples were then 
hydrated by incubation in methylated spirits for 10 min. In order to block endogenous 
peroxidase, specimens were treated with methanol containing 0.5% (v/v) hydrogen 
peroxidase before being washed in distilled water. For antigen retrieval, each 
specimen was incubated for 15 minutes in boiling 10 mM citrate buffer, pH 6. Slides 
were left to cool at room temperature prior to blocking. Specimens were then blocked 
in normal serum diluted to 5% (v/v) in PBS containing azide, 1% (v/v) NP-40, and a 
5% (v/v) avidin solution for 30 min at room temperature. The specimens were then 
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washed in PBS before the addition of primary antibodies. Antibodies were diluted in 
normal serum diluted to 5% (v/v) in PBS containing azide plus 5% (v/v) biotin 
solution and incubated at 4°C overnight. Primary antibodies were removed by 3x 5 
minute washes in PBS. The specimens were then incubated in biotinylated secondary 
antibody at a dilution of 1/250 in normal serum diluted to 5% (v/v) in PBS containing 
azide for 30 minutes at room temperature. This was followed by 3x 5 min washes in 
PBS to remove the secondary antibodies.   
 
2.2.10.4 The ABC complex 
The avidin-biotin complex (ABC) method allows for the amplification of detection 
due to the high affinity between avidin and biotin. It involves biotinylated secondary 
antibody and an avidin conjugated enzyme such as horseradish peroxidase (HRP). 
The mechanism of this method entails first the binding of the primary antibody to the 
target antigen in the specimen. Then, the biotinylated secondary antibody binds to the 
primary antibody. This is followed by the enzyme conjugate avidin binding to the 
biotin. Lastly, a substrate chromogen solution is added for colour detection. The 
specimen is incubated in avidin-HRP for 30 minutes at R.T. followed by 3x 5 minute 
washes in PBS and incubation in 3’ diaminobenzidine tetrahydrochloride (DAB) 
solution (peroxidase substrate solution) for 10 minutes at room temperature to turn 
staining brown. The sample is then washed with distilled water.  
 
2.2.10.5 Hematoxylin Staining 
Hematoxylin is isolated from an extract of logwood, Hematoxylin campechuanun 
Linnaeus, whose oxidation product, hematein, produces a blue/purple colour when 
combined with a mordant metallic ion such as aluminium salt. The positively charged 
aluminium hematein complex combines with negatively charged phosphate groups of 
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nucleic acid producing the characteristic blue/purple colour characteristic of 
hematoxylin stains, and providing a simple method to visualise cell nuclei. Following 
incubation in DAB, specimens were counterstained with hematoxylin for 80 seconds 
at room temperature before they were washed in water and placed in PBS for 10 
minutes.  
 
2.2.10.5 Slide preparation for light microscopy 
Specimens were dehydrated in methylated spirits for 10 minutes at R.T. before 
secondary 10 min dehydration in methylated spirits. An additional 10 minute 
incubation in methylated spirits was performed before placing the specimens in 
isopropanol for 10 minutes at R.T. Finally, specimens were incubated in histoclear for 
two ten minute periods before mounting the coverslips with desferrioxamine (DPX). 
The DPX was allowed to set for 24 hrs before detection under the light microscope.  
 
2.2.11 Mass spectrometry 
 
2.2.11.1 Phosphorylation site mapping 
Prior to phosphorylation site mapping, 0.5 µM hTau (WT) and 1 mU of either 
p35/Cdk5 or p25/Cdk5 were incubated at 30°C in buffer containing 25 mM MOPS 
(pH 7.5), 0.05% (v/v) Brij-35, 0.25 mM EDTA, 5% (v/v) glycerol, 10 mM MgCl2 and 
100 µM [γ-32P] ATP in a total reaction volume of 60 µl. This was repeated using 1 
mU of either p35/Cdk5 or p25/Cdk5 that had been pre-incubated with either 10 µM 
purvalanol A or 10 µM roscovitine prior to assay. Duplicate samples were assayed 
using radiolabelled [γ-32P] for autoradiography purposes to enable localisation of the 
phosphoprotein. The reaction was stopped at the 5, 20 and 60 min intervals by 
removing 20 µl and adding dithiothreitol (DTT) and sample buffer (Invitrogen) to 
give final concentrations of 10 mM DTT and 1 x sample buffer. Samples were then 
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heated at 70°C for 10 min before being allowed to cool R.T. for 30 min. 
Subsequently, 6 µl 250 mM iodoacetamide was added to the 30 µl reaction mixture 
and samples were placed in the dark for 30 min. Samples were then separated by 
SDS-PAGE and stained using Brilliant Blue G-Colloidal Concentrate (Sigma 
Aldrich). The destained and alkylated 32P labeled proteins were excised and the gel 
pieces were digested with either endoproteinase Lys-C (50 µl, 2 µg/ml) or 100 µl 2 
µg/ml trypsin in 50 mM TEAB overnight. Digests were extracted with 5 µl 
acetonitrile, supernatants dried and redissolved in 50 µl 5% (v/v) acetonitrile 
(ACN)/0.1% (v/v) trifluoroacetic acid (TFA). Subsequently, 10/50 µl was injected 
onto Biosphere C18 150 x 0.1 mm column (Nanoseparations, Holland) and analysed 
using the CapC1_45minTop10_MSA method. Subsequently, data was searched 
against Contaminant database using Proteome Discoverer 1.3 with either Lys-C or 
trypsin as the enzyme.  
 
Phosphorylation site mapping was performed by Dr. Nicholas Morrice, The Beatson 
Institute for Cancer Research, Glasgow.  
 
2.2.11.2 Mass Spectroscopic Fingerprint Analysis 
Cell lines (EBC-1, HeLa, and HEK293) were fractionated as described in section 
2.2.7.4. Duplicate samples for each cell line were prepared in LDS sample buffer 
(Invitrogen) and DTT to a final concentration of 10 mM DTT and 1 x sample buffer. 
Samples were heated at 70°C for 10 min before being allowed to cool R.T. for 30 
min. Subsequently, 5 µl 250 mM iodoacetamide was added to the 25 µl reaction 
mixture and samples were placed in the dark for 30 min. Samples were then separated 
by SDS-PAGE and the gel was subsequently cut into two halves. One half of the gel 
was subjected to immunoblotting with total CRMP2 and pCRMP2 Ser522 antibodies 
	  ___________________________________________________________________________________ 
___ 
2. Materials and Methods 
102	  
to confirm presence and protein position. The other half of the gel was stained using 
Brilliant Blue G-Colloidal Concentrate (Sigma Aldrich). The destained and alkylated 
bands equivalent to the CRMP2 bands were excised and digested by trypsin to 
generate peptides for Mass Spectroscopic fingerprint analysis. Peptide samples were 
analysed on the Velos Pro (Thermo Scientific Fisher, Boston) Orbitrap mass 
spectrometer coupled to an Ultimate 3000 RSLC nanoflow HPLC system (Dionex, 
Sunnyvale California). Sample volumes of 5 µl were eluted over a 100 min run on a 
15 cm C18 column (75 µm × 15 cm nanoviper column, Thermo Scientific Boston) 
using a 2–40% linear gradient of solvent A (0.1% (v/v) formic acid; 5% (v/v) ACN): 
solvent B (80% (v/v) ACN with 0.08% (v/v) formic acid) at a flow rate of 0.3 µl/min. 
The initial precursor scan (mass range 335–1800, resolution 60,000 and a tolerance of 
10 ppm) was measured in the Orbitrap. The samples were run with an inclusion list to 
search for peptides from CRMP2A and included the N-terminal peptide for the 
truncated version (CRMP2B), as well as the peptide relating to the site that is 
recognised by the pCRMP2 Ser522 antibody. 	  
Mass spectroscopic fingerprint analysis was performed by Mr. Douglas Lamont, 
Fingerprint Proteomics Facility, College of Life Sciences, University of Dundee.  
 
2.2.12 Statistical Analysis 
All statistical analysis was performed using Prism 6.0 software (GraphPad software, 
CA, USA). Calculation of the mean was used to determine central tendency and 
standard error of the mean was calculated to quantify the precision of the mean. For 
comparison of in vitro phosphorylation between peptides (Chapter 3), statistical 
analysis was performed by one-way analysis of variance (ANOVA) with Tukey’s post 
hoc test. For comparison of in vitro peptide substrate phosphorylation following 
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inhibitor treatment (Chapter 3), statistical analysis was performed by one-way 
analysis of variance (ANOVA) with Dunnett’s post hoc test vs. untreated. For 
comparison of substrate phosphorylation following transfection of p35/Cdk5 and 
p25/Cdk5 with untransfected control (Chapter 4), statistical analysis was performed 
by one-way analysis of variance (ANOVA) with Tukey’s post hoc test. A p value of 
<0.05 was considered significant and p values are expressed in relevant figures using 
asterisks where * represents <0.05, ** represents <0.001, and *** represents <0.0001. 
In all in vitro and mammalian cell studies, n refers to the number of experiments from 
which data were acquired. 
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3.1 INTRODUCTION 
Since its discovery, Cdk5 has been associated with a continually increasing 
compendium of substrates, each with varying physiological significance, implicating 
Cdk5 as a fundamental regulator of multiple cellular processes, in multiple tissues 
throughout the body, ultimately defining Cdk5 as a highly versatile protein kinase 
with diverse physiological function. Despite being credited as the phosphorylating 
kinase of these substrates, very few have undergone full substrate validation or meet a 
common consensus. This is further complicated by the existence of different Cdk5 
containing complexes and the potential for altered substrate selection. For that reason, 
a defined consensus sequence for each complex and identification of the true 
physiological substrates of Cdk5 is necessary to validate its physiological functions 
and potential contribution to pathophysiology. Furthermore, this information is crucial 
to develop Cdk5 as a therapeutic target in the treatment of disease.    	  
In this chapter, the consensus substrate sequences that confer Cdk5 substrate selection 
and subsequent phosphorylation will be examined in peptides designed around the 
proposed Cdk5 substrates in order to determine the residues that influence Cdk5 
phosphorylation rate and define a Cdk5 substrate consensus. On obtaining a 
consensus sequence motif for Cdk5 activity, this sequence will be investigated in full-
length human proteins to confirm proposed substrates of Cdk5 and predict likely 
Cdk5 targets. Additionally, the relative hyperactivity and substrate profile of the 
p25/Cdk5 complex will also be addressed by directly comparing phosphorylation 
kinetics with p35/Cdk5. 
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3.1.1 Chapter Aims 
The collective focus of this chapter is to generate a greater understanding of the 
fundamental mechanisms that shape Cdk5 function in health and disease through 
application of a variety of in vitro techniques. There are three major objectives of this 
chapter: firstly, identifying a consensus peptide sequence that could validate proposed 
physiological Cdk5 substrates and also aid in the identification of novel Cdk5 
substrates; secondly, to investigate whether there are basic differences in catalytic 
activity of the two major Cdk5 complexes; and finally, confirming this consensus in a 
selection of proposed Cdk5 substrates, including performing a comparison of the 
phosphorylation kinetics of the best Cdk5 substrates that could allow the development 
of screening tools to accurately access Cdk5 activity in vivo (in particular, in diseases 
such as cancer). 
 
3.1.1.1 Consensus sequence that regulates Cdk5 substrate selection 
The literature depicts Cdk5 as a highly promiscuous protein kinase with a large 
number of proposed substrates, each with varying primary sequences around the Cdk5 
phosphorylation sites. This raises the possibility that Cdk5 can phosphorylate proteins 
with little requirement for specific consensus primary sequence around the 
phosphorylation site or, alternatively, that many of the proposed substrates are 
relatively weak and not physiologically relevant. Currently, a consensus for Cdk5 
substrate selection is not yet defined and is generally thought to be highly degenerate. 
The focus of this section of the thesis is to investigate the importance of amino acids 
flanking the phosphoacceptor residue and determine a consensus that is essential or 
even preferred for Cdk5 activity (when complexed to p35 or p25). This sequence 
information would aid in validating truly physiological targets as well as identifying 
novel in vivo targets of Cdk5. 
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3.1.1.2 Effect of p35 proteolytic cleavage on Cdk5 substrate affinity 
As described in Chapter 1, it is widely accepted that proteolytic cleavage of p35 to 
produce p25 enhances Cdk5 activity and thus alters substrate phosphorylation profile. 
However, there is limited experimental evidence to suggest that the activity of Cdk5 is 
increased following p25 generation. This chapter aims to investigate whether Cdk5 
activity towards substrates in vitro is altered when p35 is replaced by p25 by 
establishing the phosphorylation kinetics for potential Cdk5 substrates with each of 
the major Cdk5 complexes, p35/Cdk5 and p25/Cdk5.  
 
3.1.1.3 Validation and comparison of Cdk5 substrates 
The final part of this chapter sets out to assess the consensus peptide sequence in 
predicting Cdk5 substrates. A selection of Cdk5 substrates will be chosen to 
investigate whether the consensus peptide sequence found in vitro translates into 
better phosphorylation of full-length proteins by comparing phosphorylation kinetic 
parameters for a selection of proposed Cdk5 substrates with diverse primary sequence 
around the phosphoacceptor site. 
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3.2 RESULTS 	  
3.2.1 Defining Cdk5 activity for in vitro analysis  
Robust analysis of physiological phosphorylation events related to a specific protein 
kinase can be difficult due to the transient nature of many phosphorylation events, the 
often low stoichiometry of phosphorylation at a given site, the low copy number of 
phosphoprotein per cell and the large number of protein kinases present in every cell 
(Goodlett et al., 2000). Despite the improvement in global phosphoproteomic 
technology and the availability of animal and cell models with conditional genetic 
ablation of specific kinases, these limitations still necessitate the use of in vitro assays 
using recombinant protein in order to provide fundamental information on kinase-
substrate interactions. In addition, in vitro approaches allow simple direct comparison 
of the rates of phosphorylation of a given substrate with related kinases. Hence, 
detailed enzyme kinetic analysis in vitro is a useful first step in the investigation of 
the kinase-substrate interactions that are likely to occur in vivo. 
 
Here, Cdk5 substrate phosphorylation was investigated in an in vitro assay system 
using radiolabelled 32P and defined assay conditions in order to accurately calculate 
phosphate transfer from ATP into substrate. In order to directly compare the major 
Cdk5 complexes, p35/Cdk5 and p25/Cdk5, the activity of each complex was assessed 
against a generic substrate and then an equivalent amount of enzyme activity was 
used in all studies. Thus, kinetic information obtained for each substrate was relative 
to that generic substrate. 
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3.2.1.1 Quantification of the specific activity of commercial Cdk5 
The major Cdk5 complexes, p35/Cdk5 and p25/Cdk5, were sourced commercially 
(Merck Millipore). Both Cdk5 complexes were produced by co-transfection of Sf21 
insect cells with two baculoviruses: one that codes for full-length human Cdk5 with 
an N-terminal His6-tag; and, a second that codes for recombinant full-length human 
p35 or p25 containing an N-terminal GST-tag. A complex of recombinant kinase was 
then purified from the cell suspension using Ni-NTA agarose. Upon arrival, the 
commercial kinases were routinely aliquoted, to minimise freeze thaw cycles, and 
stored at -80°C.  The certificate of analysis accompanying each complex contained an 
estimate of kinase activity as measured against histone H1 and kinase preparations 
were diluted to 50 mU/µl based on the reported histone H1 kinase activity. The 
specific activity of both kinases was re-measured against myelin basic protein (MBP) 
in vitro. MBP is readily phosphorylated by numerous kinases and contains multiple 
proline-directed phosphorylation sites hence it is often used to assess the specific 
activity of CDKs. Kinase activity was re-assessed with every aliquot on the day of use 
in case the activity of one complex degraded at a different rate to the other. 
 
Each complex was incubated with 0.3 mg/ml MBP in the presence of MgATP [γ32-P] 
for 10 min (Figure 3.1). The [γ32-P] incorporation into MBP was assessed as 
described in Chapter 2.2.9.1. Consistently, the measured activity of p25/Cdk5 was 
relatively higher than p35/Cdk5 activity when assessed against MBP suggesting that 
p25/Cdk5 has a relative preference for MBP over histone H1 compared to p35/Cdk5. 
Alternatively the p35/Cdk5 complex may be more unstable to transport or freeze thaw 
compared to p25/Cdk5. In the subsequent experiments, this MBP measure of activity 
was used to match the kinase preparations prior to assay. In general, a 1:1.7 dilution 
was preformed on p25/Cdk5 to match the specific activity prior to in vitro analysis.  
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Figure 3.1. Comparison of the major Cdk5 complexes activity against MBP. Myelin basic protein 
(MBP), containing serine residues immediately followed by a proline, was used as a standard substrate 
to compare and subsequently match Cdk5 activity. Specific activity of each complex was assessed by 
incubating either p35/Cdk5 or p25/Cdk5 with MBP (0.3 mg/ml final concentration) in the presence of 
Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for 10 min followed by scintillation counting to 
measure phosphate transfer. Data expressed as mean + SEM, n = 12.  
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3.2.1.2 Investigation of the purity of the commercial Cdk5 preparations 
As the commercial Cdk5 preparations would be used for detailed kinetic comparisons 
of Cdk5 activity, both kinase preparations were assessed for the presence of other 
contaminating kinase activities that could influence the in vitro analysis data. For 
example, dual-specificity tyrosine-regulated kinase (DYRK) 1A possesses an inherent 
His-tag sequence capable of binding to nickel and, as a result, often contaminates 
commercial kinase preparations prepared using Ni-agarose purification. This is of 
particular importance to analysis of Cdk5 activity as DYRKs have an overlapping 
consensus sequence (proline-directed) and are therefore likely to target many of the 
same substrates in vitro.  
 
Inhibitors selective for either Cdk or DYRK were used to establish their ability to 
repress the commercial Cdk5 activity. The Cdk5 complexes were pre-incubated with 
either 10 µM purvalanol A, an inhibitor of Cdk activity, or 10 µM harmine, an 
inhibitor of DYRK activity, for 30 min prior to in vitro phosphorylation assay with 
MBP. Kinase activity was determined by incubating inhibitor treated complexes, in 
direct comparison with vehicle, with MBP in the presence of MgATP [γ32-P] for 10 
min, as described in Chapter 2.2.9.1. 
 
Following treatment with harmine, no apparent reduction in the specific activity of 
either p35/Cdk5 or p25/Cdk5 was observed confirming that DYRKs were not isolated 
with the Cdk5 complexes during Ni-agarose purification (Figure 3.2A). Incubation 
with purvalanol A resulted in almost complete ablation of p35/Cdk5 and p25/Cdk5 
specific activities confirming that the Cdk5 complexes were the major, if not only, 
kinase in the preparations (Figure 3.2B). 
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Figure 3.2. MBP kinase activity of the Cdk5 preparations is dramatically decreased in vitro 
following treatment with purvalanol A but not harmine. A) Both p35/Cdk5 and p25/Cdk5 were pre-
incubated with or without 10 µM harmine for 30 min prior to performing an MBP kinase assay. 
Phosphate transfer (pmol/min) was determined by scintillation counting. B) Both p35/Cdk5 and 
p25/Cdk5 were pre-incubated with or without 10 µM purvalanol A for 30 min prior to performing an 
MBP kinase assay. Phosphate transfer (pmol/min) was determined by scintillation counting. Data 
expressed as mean + SEM, n = 2.  
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3.2.2 Investigating the consensus for Cdk5 substrate phosphorylation 
The consensus proposed for p35/Cdk5 phosphorylation is defined as (S/T)PX(K/H/R)  
(Beaudette et al., 1994; Shetty et al., 1999) however many of the proposed in vivo 
substrates of Cdk5 do not fit this consensus. Additionally, proteolytic cleavage of p35 
to generate p25 reportedly alters Cdk5 substrate specificity (Patrick et al., 1999). 
Therefore, the substrate consensus for Cdk5 was investigated further in order to 
examine the importance of certain residues flanking the phosphoacceptor residue on 
the rate and extent of phosphorylation by each Cdk5 complex.  
 
3.2.2.1 C-terminal basic residues confer Cdk5 substrate affinity 
The current substrate consensus indicates that a negatively charged residue positioned 
three residues C-terminal to the phosphoacceptor residue (+3) is required for Cdk5 
substrate recognition however not all of the proposed Cdk5 protein substrates include 
this specific residue, although most have basic residues within 5 positions in either 
direction of the phosphorylated residue. As an initial investigation of the significance 
of the +3 basic residue, the phosphorylation of a series of synthetic peptides based on 
the Cdc2-kinase/Cdk2 substrate peptide, PKTPKKAKKL (originally derived from 
Cdk2 in vitro phosphorylation of histone H1) were compared directly for 
phosphorylation by each Cdk5 complex. The sequences of the peptides compared to 
the original Cdk2 peptide were as follows: PKTPKAAKKL, PKSPKARKKL, and 
PKTPKKRKKL. The peptides are referred to as TPKAA, SPKAR, and TPKKR in 
figures for simplicity.  
 
 
Both p35/Cdk5 and p25/Cdk5 (1 mU) were independently incubated with three 
peptides, TPKAA, SPKAR, and TPKKR, (50 µM final concentration) in the presence 
of MgATP [γ32-P] for up to 20 min prior to measuring phosphate transfer to each 
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peptide (pmol/min). All three peptides were phosphorylated to some extent by both 
Cdk5 complexes (Figure 3.3). The phosphotransferase activity with each peptide was 
not dramatically different between the Cdk5 complexes and the relative peptide 
preference profile was also the same between the two major complexes. Both Cdk5 
complexes exhibited lowest phosphotransferase activity towards TPKAA, the peptide 
containing the least basic residues. Substituting Ala (+4) for a basic residue (SPKAR) 
resulted in an increase in Cdk5 phosphotransferase activity (~3-fold), although a 
contribution from changing the Thr for a Ser cannot be ruled out (peptides were gifted 
from Professor Sakamoto therefore TPKAR was not compared in this analysis). The 
increase is most likely due to the addition of the basic residue however as substituting 
both Ala residues for basic residues (TPKKR) dramatically increased phosphorylation 
of the peptide substrate (~10-fold). This is consistent with the basic residue at the +3 
position having a profound effect on Cdk5 activity, although comparing 
phosphorylation of additional sequences where the +3 Lys was the only basic residue 
in the peptide in the peptide would indicate whether the effect was synergistic with 
the basic residues at +2 and +4.  
 
These results confirm that the presence of C-terminal basic residues enhances the rate 
that Cdk5 will phosphorylate peptide substrates in vitro, and proposed substrates of 
Cdk5 lacking such basic residues need to be scrutinised very carefully. 
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Figure 3.3. Contribution of C-terminal basic residues to Cdk5 substrate phosphorylation in vitro. 
The influence of C-terminal basic residues to peptide substrate recognition and phosphorylation for 
each Cdk5 complex was assessed by incubating 1 mU A) p35/Cdk5 or B) p25/Cdk5 with the indicated 
peptides (50 µM final concentration) for 20 min and measuring phosphate transferred to each peptide. 
C) Phosphotransferase activity (pmol/min) of each complex was directly compared in a single assay. 
Data expressed as mean values + SEM, n = 2.  
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To determine whether the basic residues increased phosphorylation by altering the Km 
of the substrates, the Cdk5 complexes (1 mU) were incubated with each of the 
different peptides in the presence of MgATP [γ32-P] at varying concentrations of 
peptide (0 µM, 2.5 µM, 5 µM, 10 µM, 25 µM, 50 µM final concentration) for 20 min. 
Lineweaver-Burke plots were generated for both complexes against each peptide and 
Vmax and Km values calculated for each peptide (Figure 3.4A-B). As expected, the 
values for p35/Cdk5 were very similar to those obtained for p25/Cdk5 indicating that 
these two complexes do not have inherently different kinetic properties based on 
immediate sequences around the phosphoacceptor sites of the substrate. Interestingly, 
the presence of a basic residue at +3 in the sequence did not alter Km as dramatically 
as it altered Vmax (Figure 3.4C). This may indicate that the rate of phosphorylation of 
the more basic peptides is higher without a large change in affinity for the substrate 
peptide and requires further investigation.  
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Figure 3.4. Optimisation of Cdk5 substrate peptides containing basic residues, phosphorylation 
kinetics. Substrate saturation curves were established by incubating 1 mU A) p35/Cdk5 or B) 
p25/Cdk5 with the indicated peptides (0 µM, 2.5 µM, 5 µM, 10 µM, 25 µM, 50 µM final 
concentration) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for the times 
indicated and measuring phosphate transfer to each peptide. C) Phosphorylation kinetics, Vmax 
(pmol/min) and Km (µM), were determined for each Cdk5 complex for the indicated peptides. Data 
expressed as mean + SEM, n = 2. 
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3.2.2.2 Comparison of Cdk5 activity towards peptide substrates with 
sequences related to proposed protein substrates of Cdk5 
Evidently, a basic residue at +3 relative to the phosphoacceptor site of substrates 
influences Cdk5 phosphorylation, however many proposed substrates do not have this 
important sequence requirement. Therefore, the position and number of basic residues 
relative to the phosphoacceptor site was used to classify a spectrum of reported Cdk5 
substrates (Chapter 1, Table 1.1). Proteins that contained basic residues on both the 
N-terminal and C-terminal (within +5) side of the phosphoacceptor residue were 
designated as Class 1 substrates. Substrates containing basic residues only towards the 
C-terminus (within +5) were defined as Class 2, while substrates containing basic 
residues only towards the N-terminus of the phosphoacceptor residue (within -5) were 
classified as Class 3. Absence of basic residues  + 5 residues of the phosphoacceptor 
residue defined the substrates as Class 4.  
 
Five peptides were designed to provide a representation of these variations in amino 
acid sequence (± 5 residues), the core sequence being based on an amalgamation of 
the sequence of a number of the best characterised Cdk5 substrates, allowing variation 
only in the position and number of the basic residues (Table 3.1). In short, the 
peptides were each twelve amino acids long containing a central serine residue 
directly followed by a proline residue, flanked on both sides by 5 amino acids. Two 
additional lysine residues were placed at the N-terminus of each peptide sequence to 
ensure binding to the negatively charged p81 paper during in vitro phosphorylation 
assays. Although not comprehensive, this study was designed to provide a general 
comparison of the contribution of the position of basic residues in substrates on the 
regulation of phosphorylation by each Cdk5 complex. 
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Designation 
 
Peptide Sequence 
 
Basic Residues 
 
Class 1.1 
 
KKASAKKSPRKPRS 
 
N-terminal, C-terminal 
 
Class 1.2 
 
KKASAPKSPRKPRS 
 
N-terminal, C-terminal 
 
Class 2 
 
KKASAPVSPPRDRK 
 
C-terminal 
 
Class 3 
 
KKPKSRRSPPSIPT 
 
N-terminal 
 
Class 4 
 
KKENNVLSPLPSQA 
 
None 
 
 
 
 
Table 3.1. Peptides designed to investigate the role of basic residues for Cdk5 phosphorylation. Five 
peptides were designed to provide a representation of variations in amino acid sequence around 
proposed Cdk5 substrates (± 5 residues), the core sequence being based on an amalgamation of the 
sequence of a number of the best characterised Cdk5 substrates, allowing variation only in the position 
of the basic residues. Basic residues are highlighted in blue.  
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Both complexes were assayed against each peptide (Table 3.1) to quantitatively 
compare the effect of the primary sequence differences on the rate of phosphorylation 
by each of the Cdk5 complexes. Recombinant Cdk5 with a specific activity of 1 mU 
was incubated with each of the five peptides at the following concentrations: 0 µM, 
2.5 µM, 5 µM, 10 µM, 25 µM, 50 µM, 100 µM in the presence of MgATP [γ32-P] for 
20 min. The [γ32-P] incorporation into each peptide was assessed as detailed in 
section 2.2.9.2.  
 
Surprisingly, Cdk5 exhibited a highly selective peptide substrate profile, 
preferentially phosphorylating only one of the five peptides (Figure 3.5). This profile 
was identical for both Cdk5 complexes. Class 3 and Class 4 peptide substrates do not 
contain a basic residue at +3; indeed they lack any C-terminal basic residues, which 
may explain the lack of phosphorylation of these peptides. This, again, indicates the 
importance of C-terminal basic residues within the substrate sequences to Cdk5 
activity and suggests that this cannot be replaced by the presence of N-terminal basic 
residues (Class 3 peptide had basic residues at -1, -2 and -4). More surprising was the 
low activity towards peptides KKASAKKSPRKPRS (1.1) and KKASAPVSPPRDRK 
(2). The Class 2 peptide contains a basic residue at +3 and this indicates that a proline 
at +1 and a basic residue at +3 are not sufficient to direct phosphorylation by Cdk5. 
Although, the lack of phosphorylation may be related to the presence of the proline 
residue at +2 or the asparate at +4, both of which would introduce major structural 
changes. The Class 3 peptide also possesses a proline residue at +2. It is more difficult 
to understand the inability of Cdk5 to phosphorylate Class 1.1 as it only differs from 
the Class 1.2 peptide by a single amino acid (proline at -2 in 1.2 instead of lysine at -2 
in 1.1). This suggests that the N-terminal sequence of substrates also has a major 
contribution to Cdk5 substrate specificity. 
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Figure 3.5. Phosphorylation of peptides with varying basic residue content by Cdk5. The contribution 
of basic residues to peptide substrate recognition and phosphorylation was assessed by incubating 1 
mU A) p35/Cdk5 or B) p25/Cdk5 with the indicated peptides (100 µM final concentration) in the 
presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for 20 min and measuring phosphate 
transfer to each peptide. C) The substrate profile between complexes was compared in a single assay. 
Data expressed as mean + SEM, n = 3. Statistical analysis was performed by one-way ANOVA with 
Tukey’s post hoc test, ***p<0.001. 
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3.2.2.3 N-terminal residue required for Cdk5 substrate recognition 
The data in Figure 3.5 suggested that Cdk5 may exhibit a preference for substrates 
with a proline residue located at the -2 position yet prefer not to have a proline at the 
+2 position relative to the phosphoacceptor residue (compare Class 1.1 with Class 1.2, 
and Class 1.2 with Class 2). 
 
To further elaborate on the importance of these proline residues (+2 and -2), an 
additional set of peptides were generated with minor deviations from the Class 1.2 
peptide KKASAPKSPRKPRS (1.2) in order to assess the key residues of this peptide 
for Cdk5 phosphorylation (Table 3.2). Again, the new peptides were twelve amino 
acids long containing a central serine residue directly followed by a proline residue, 
along with two additional N-terminal lysine residues to aid interaction with p81 paper 
during assay.  
 
The rate of phosphorylation of peptides KKSSAPKSPARPRS (Class A), 
KKSSAPVSPRKPRS (Class B), KKASAAKSPPKPRS (Class C), and 
KKASAPKSPPRPRS (Class D) by Cdk5 was assessed by incubating each of the 
peptides (100 µM final concentration) with either p35/Cdk5 or p25/Cdk5 at a specific 
activity of 1 mU in the presence of MgATP [γ32-P] for 20 min (Figure 3.6). The 
[γ32-P] incorporation into each peptide was assessed as described in section 2.2.9.2.   
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Designation 
 
Peptide Sequence 
 
Basic Residue Changes 
 
Class 1.2 
 
KKASAPKSPRKPRS 
 
Parent peptide 
 
Class A 
 
KKSSAPKSPARPRS 
 
Reduced C-terminal 
 
Class B 
 
KKSSAPVSPRKPRS 
 
Reduced N-terminal 
 
Class C 
 
KKASAAKSPPKPRS 
 
Reduced C-terminal plus removed N-terminal Pro 
 
Class D 
 
KKASAPKSPPRPRS 
 
Reduced C-terminal plus added C-terminal Pro 
 
 
 
 
Table 3.2. Further investigation of the role of basic residues in Cdk5 substrate phosphorylation. 
Four further peptides were designed to investigate the role of additional basic residues in Cdk5 
phosphorylation. Amino acid variations from Class 1.2 are highlighted in red. 
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Once more, the rate of phosphorylation of these peptides by p35/Cdk5 and p25/Cdk5 
was identical. Consistent with the previous result, Cdk5 phosphorylates the peptides 
that contain a proline residue situated at -2 position (Class A and Class B) whilst 
failing to phosphorylate the peptide that contains an alanine residue at this position 
(Class C) (Figure 3.6), indicating the importance of this proline residue. There 
appears to be little difference in the phosphotransferase activity observed with 
peptides Class A and B. The basic residue at the +2 position in Class 1.2 was 
substituted to an alanine in Class A and the basic residue at the -1 position in Class 
1.2 was substituted to a valine in Class B. Altering the amino acid either side of the 
SP motif does not appear to alter Cdk5 phosphorylation as dramatically as substituting 
the proline residue in the -2 position. Interestingly, despite containing a proline 
residue at the -2 position, Cdk5 failed to phosphorylate peptide D. This peptide 
contains a single amino acid difference compared to Class A, a proline residue at the 
+2 position instead of an alanine. This suggests that the presence of this proline 
residue has a negative impact on Cdk5 phosphorylation. 
 
These findings suggest that the presence of proline residues may be important in 
aiding Cdk5 substrate recognition and subsequent phosphorylation. In addition to the 
proline residue that is already known to be critical to Cdk5 phosphorylation (+1), the 
presence of an N-terminal proline residue (-2) appears to guide Cdk5 phosphorylation 
whereas the presence of an additional proline residue (+2) appears to abolish Cdk5 
phosphorylation. Evidently, the amino acid sequence directly surrounding the 
phosphoacceptor site is critical to Cdk5 substrate recognition and phosphorylation. 
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Figure 3.6. Cdk5 regulation is dependent on proline residues. The contribution of proline residues to 
peptide substrate recognition and phosphorylation was evaluated by incubating 1 mU A) p35/Cdk5 or 
B) p25/Cdk5 with the indicated peptides (100 µM final concentration) in the presence of Mg [γ-32P] 
ATP (10 mM MgCl and 0.1 mM ATP) for 20 min and measuring phosphate transfer to each peptide. 
C) The substrate phosphorylation profile of each complex was directly compared in a single assay. 
Data expressed as mean + SEM, n = 3. Statistical analysis was performed by one-way ANOVA with 
Tukey’s post hoc test, **p<0.01. 
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3.2.2.4 Establishing the optimal Cdk5 substrate motif 
 
In order to obtain more information regarding the influence of the sequence 
surrounding the phosphoacceptor site on the rate of substrate phosphorylation by 
Cdk5, phosphorylation kinetic parameters were determined and directly compared 
between the peptides optimally phosphorylated by Cdk5 (Class 1.2, A, and B). 
 
Peptides (0 µM, 2.5 µM, 5 µM, 10 µM, 25 µM, 50 µM, 100 µM final concentration) 
were incubated with recombinant p35/Cdk5 and p25/Cdk5 (1 mU) in the presence of 
MgATP [γ32-P] for 20 min. The [γ32-P] incorporation into each of the peptides was 
assessed as described in section 2.2.9.2 and allowed quantification of the number of 
moles of phosphate incorporated per unit time (Figure 3.7). Substrate saturation 
curves were fitted by non-linear regression to the Michaelis-Menton model (Figure 
3.8). Subsequently, reciprocal values were plotted and phosphorylation kinetic 
parameters, Vmax (pmol/min) and Km (µM) calculated using the Lineweaver-Burke.  
 
Both Cdk5 complexes display highest phosphotransferase activity towards the Class 
1.2, being ~2-fold greater in comparison to Class A (reduced C-terminal) or Class B 
(reduced N-terminal) (Figure 3.7). In this case, increased phosphorylation seems to 
be due to a lower Km when basic residues are present upstream and downstream of the 
phosphoacceptor site as substitution of either of these basic residues reduces 
phosphotransferase activity to a similar magnitude and affinity does not differ greatly 
suggesting that an N-terminal basic residue at -1 is as important for Cdk5 
phosphorylation as a C-terminal basic residue at +2. The data presented here extends 
the understanding of the sequence determinants for optimal Cdk5 phosphorylation of 
substrates, where we can suggest that the optimal consensus would be P-K-S-P-R-K. 
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Figure 3.7. Determination of Cdk5 optimal substrate motif. The optimal residues for Cdk5 
recognition and phosphorylation was examined by incubating 1 mU A) p35/Cdk5 or B) p25/Cdk5 with 
the indicated peptides (100 µM final concentration) in the presence of Mg [γ-32P] ATP (10 mM MgCl 
and 0.1 mM ATP) for 20 min and measuring phosphate transfer to each peptide. C) The substrate 
profile between complexes was compared in a single assay. Data expressed as mean + SEM, n = 3. 
Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test, *p<0.05. 
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Figure 3.8. Determining the optimal Cdk5 peptide substrate motif. Substrate-velocity graphs were 
established by incubating 1 mU A) p35/Cdk5 or B) p25/Cdk5 with the indicated peptides (0 µM, 2.5 
µM, 5 µM, 10 µM, 25 µM, 50 µM, 100 µM final concentration) in the presence of Mg [γ-32P] ATP 
(10 mM MgCl and 0.1 mM ATP) for the times indicated and measuring phosphate transfer to each 
peptide. C) Phosphorylation kinetics, Vmax and Km, were determined for each Cdk5 complex for the 
indicated peptides. Data expressed as mean + SEM, n = 3. 
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3.2.2.5 Cdk inhibitors abolish Cdk5 peptide substrate phosphorylation  
To confirm that the observed phosphorylation of peptides KKASAPKSPRKPRS 
(1.2), KKASAPKSPARPRS (A), and KKSSAPVSPRKPRS (B) was due to the 
enzymatic activity of Cdk5, both major complexes of Cdk5 were pre-incubated with 
either 10 µM purvalanol A or 10 µM roscovitine for 30 min prior to assay. Peptides 
(50 µM final concentration) were then incubated with treated Cdk5 complexes in the 
presence of MgATP [γ32-P] for 30 min. The [γ32-P] incorporation into each peptide 
is expressed as the number of moles of phosphate incorporated into each peptide 
substrate per min (Figure 3.9). 
 
As expected, incubation with Cdk5 resulted in a similar phosphate incorporation 
profile to that observed previously. However, pre-incubation with puravalanol A 
robustly reduced all p35/Cdk5 activity (>95%) towards Class 1.2 (p < 0.001), Class A 
(p = 0.002) and Class B (p = 0.005) peptides. A similar decrease in peptide 
phosphorylation was observed with roscovitine pre-incubation which resulted in a 
significant reduction in the phosphorylation of peptide Class 1.2 (p < 0.0001), Class A 
(p = 0.0003), and Class B (p = 0.0007) by p35/Cdk5. Similarly, purvalanol A 
treatment significantly reduced all p25/Cdk5 activity (>95%) towards peptide Class 
1.2 (p < 0.0001), Class A (p = 0.0002), and Class B (p = 0.0005). Roscovitine 
treatment also decreased peptide Class 1.2 (p < 0.0001), Class A (p = 0.0003), and 
Class B (p = 0.0007) phosphorylation by p25/Cdk5 by >90%. 
 
This data confirms Cdk5 is responsible for the observed kinase activity in each 
preparation and the differences in kinetics with each substrate are not influenced by a 
contaminating activity.  
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Figure 3.9. Inhibition of Cdk5 activity results in loss of peptide phosphorylation.  Prior to kinase 
assay, 1 mU A) p35/Cdk5 and B) p25/Cdk5 was pre-incubated with or without 10 µM purvalanol A or 
10 µM roscovitine for 30 min before being incubated with the indicated peptides (50 µM final 
concentration) for 30 min and measuring the phosphate transferred to each peptide. Data expressed as 
mean + SEM, n = 3. Data analysed by two-way ANOVA with Dunnett’s post hoc test vs. no treatment, 
***p<0.0001. 
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3.2.2.6 Cdk5 substrate phosphorylation in comparison to other members of 
the CMGC family of protein kinases 
The CMGC family is a large and important group of protein kinases that are present 
in all eukaryotes, and include the Cdk-like kinases, Mitogen-activated protein kinases 
(MAP kinases), Glycogen synthase kinases (GSK), and the Cyclin-dependent kinases, 
of which Cdk5 is a member.  
 
The majority of the CMGC family prefer substrates to contain a proline residue at the 
+1 position relative to the phosphoacceptor site, although the degree of requirement 
varies across the family. As described previously, Cdk5 exhibits a high degree of 
selectivity for the presence of specific residues around the phosphoacceptor site in 
addition to the proline residue at +1.  To determine if the other aspects of selectivity 
determined in the previous experiments were also important for other members of the 
CMGC group, peptide preference was examined for a selection of kinases, chosen to 
represent different branches of this protein kinase family (Figure 3.10, selected 
kinases shown in red).  
 
The peptides selected for comparison included the three peptides that were previously 
shown to be phosphorylated by Cdk5 in vitro (KKASAPKSPRKPRS (1.2), 
KKASAPKSPARPRS (A) and KKSSAPVSPRKPRS (B)), as well as the peptide 
KKASAPKSPPRPRS (D) that was not phosphorylated by Cdk5 despite possessing 
the critical proline residue at +1 and an Arg at +3. Prior to the kinase comparison 
assay, the specific activity of all kinases was matched against MBP. Subsequently, 
peptides (50 µM final concentration) were incubated with 1 mU CLK2, PCTAIRE, 
HIPK1, DYRK2, SPRK1, SAPK4, JNK3, Cdk5, or ERK8 in the presence of MgATP 
[γ32-P] for 30 min and phosphate incorporation measured (Figure 3.10). 
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Figure 3.10. Schematic representation of the CMCG group and selected members for substrate 
comparison. Kinases highlighted in red indicate the kinases selected for comparison against Cdk5 in 
peptide analysis screen.   
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Once more, Cdk5 phosphorylated peptides KKASAPKSPRKPRS (1.2), 
KKASAPKSPARPRS (A), and KKASAPVSPRKPRS (B) but failed to phosphorylate 
peptide KKASAPKSPPRPRS (D). Interestingly, none of the peptides targeted by 
Cdk5 (Class 1.2, A and B) were phosphorylated to an appreciable extent by any of the 
other CMGC kinases tested, at least under these conditions where their activities were 
matched against MBP. This suggests that these peptide sequences are highly specific 
for Cdk5 phosphorylation. In contrast, one kinase (PCTAIRE) was able to 
phosphorylate KKASAPKSPPRPRS (D) at a much higher rate than Cdk5, confirming 
that this peptide was soluble. PCTAIRE did weakly phosphorylate all the peptides but 
to <15% of that seen with Cdk5 and the relative preference for the peptides was 
distinct from that of Cdk5 (Cdk5: 1.2>B=C>>>D, while PCTAIRE: 1.2 = D = A = B).  
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Figure 3.11. CMGC kinase screen using Cdk5 substrate peptides. The rate of phosphorylation of the 
indicated peptides by selected members of the CMCG kinase family was compared by incubating each 
peptide (50 μM final concentration) with 1 mU (as assessed against the generic substrate MBP) CLK2, 
PCTAIRE, HIPK1, DYRK2, SPRK1, SAPK4, JNK3, Cdk5 and ERK8 in the presence of radiolabelled 
ATP for 30 min and measuring phosphate transfer. Data expressed as mean + SEM, n = 2. Graphs are 
formatted to a scale that best displays the variation across the kinase panel. 
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3.2.3 Investigating peptide consensus in full-length substrates 
There is a clear preference for particular amino acids surrounding the 
phosphoacceptor residue to regulate the rate that Cdk5 phosphorylates short peptides. 
Basic residues flanking the phosphorylatable residue were found to enhance 
recognition by Cdk5 whereas other inputs were found to be antagonistic (e.g. proline 
at +2 or the aspartate at +4). In an attempt to further investigate the importance of 
such sequences to Cdk5 function in health and disease, Cdk5 phosphorylation was 
further examined in a range of full-length protein substrates.  
 
3.2.3.1 Basic residues flank the phosphoacceptor site in CRMP isoforms 
and lack of these residues diminishes phosphorylation 
Previous work within the lab established that Cdk5 phosphorylates CRMP1, CRMP2, 
and CRMP4 at Ser522 in vitro converting the CRMP isoforms into substrates for 
GSK3, which then phosphorylates at Ser518, Thr514 and Thr509 (Cole et al., 2004) 
(Figure 3.12A). These isoforms share reasonable homology surrounding the Ser522 
site (Figure 3.12B). In contrast, CRMP3 contains no SP motif at 522, only a single 
TP motif at Thr84 surrounded by no basic residues (PVLGMTPADDFC) and a single 
SP motif at Ser304 containing a proline at +2 and flanked by non-basic residues 
(AAFVTSPPVNPD) suggesting that CRMP3 would be a very weak substrate of 
Cdk5, if phosphorylated at all. Likewise, CRMP5 lacks an equivalent Ser522 residue. 
Upstream of this residue, there are three TP motifs: RGVDRTPYLGDV (Thr490), 
PLADTPTRPVTR (equivalent to Thr514 in CRMP2) and KKEMGTPLADTP 
(equivalent to Thr509 in CRMP2). In CRMP2 Thr509 and Thr514 are phosphorylated 
by GSK3 rather than Cdk5. However, Thr514 in CRMP5 has a basic residue at +3, 
not present around Thr514 in CRMP1, CRMP2 or CRMP4 therefore it is possible that 
Cdk5 primes CRMP5 at Thr514 allowing GSK3 to phosphorylate at Thr509. 
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Figure 3.12. CRMP phosphorylation sites and sequence alignment of the CRMP isoforms. A) 
Schematic representation of CRMP1, CRMP2, and CRMP4 phosphorylation sites and the 
phosphorylating kinases. B) Sequence alignment of residues 501-529 of human CRMP1, CRMP2, 
CRMP3, CRMP4, and CRMP5. Residues Ser518, Thr514, and Thr509, on CRMP1, CRMP2, and 
CRMP4 are phosphorylated by GSK3 following Cdk5 phosphorylation of the Ser522 priming site, 
which is outlined in green. The Cdk5 required SP motifs are outlined in blue. Basic residues 
surrounding the Ser522 phosphorylation site are highlighted in red. A potential Cdk5 site on CRMP5 is 
underlined in blue and basic residues that may confer Cdk5 recognition are in red. 
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In direct comparison, 1 mU p35/Cdk5 and 1 mU p25/Cdk5 were independently 
incubated with recombinant human WT GST-CRMP1, 2, 3, 4 or 5 (0.5 µM final 
concentration) in the presence of MgATP [γ32-P] for the times indicated (Figure 
3.13). The [γ32-P] incorporation into each substrate was assessed as detailed in 
section 2.2.9.2.   
 
Incubation of p35/Cdk5 with each of the CRMP isoforms resulted in a similar 
maximal stoichiometry (0.5-0.6 mol/mol) for CRMP1, 2, and 4 however CRMP5 
(~0.2 mol/mol) and CRMP3 (<0.1 mol/mol) were relatively weakly phosphorylated 
by p35/Cdk5 (Figure 3.13A). Despite showing slightly lower stoichiometry than 
p35/Cdk5, the isoform specificity of p25/Cdk5 was identical to that of p35/Cdk5. 
Again, similar phosphorylation stoichiometries were reached for CRMP1, 2, and 4 
after 60 min and a relatively lower stoichiometry was reached for CRMP3 and 
CRMP5, with CRMP3 very weakly phosphorylated by p25/Cdk5 (Figure 3.13B). 
 
These results show that the optimal CRMP isoforms were those that contained basic 
residues on both the N- and C-terminal side of the phosphoacceptor residue. 
Interestingly, CRMP1, 2 and 4 isoforms contain a basic residue positioned at -2 and 
+3, the sites found to be important by the peptide analysis. The degree of 
phosphorylation increased when a lysine was substituted for an arginine at both of 
these positions (compare CRMP4 with CRMP1 and CRMP4 with CRMP2).  It would 
appear that a basic residue at the -2 position rather than a proline does not prevent 
Cdk5 phosphorylation and it may be interesting to investigate whether a Lys520Pro 
mutant CRMP2 would be a better substrate for Cdk5. Meanwhile, previous work in 
the lab had established that a Lys520Ala CRMP2 mutant was a weaker substrate for 
Cdk5 in comparison to wild-type CRMP2 (Cole et al., 2006). 
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Figure 3.13. p35/Cdk5 and p25/Cdk5 display identical CRMP isoform specificity. Recombinant WT 
GST-hCRMP-1, -2, -3, -4, or -5 (0.5 µM final concentration) was incubated with 1 mU of A) p35/Cdk5 
or B) p25/Cdk5 in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for the times 
indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE loading buffer 
to terminate the reaction. Aliquots were then heated at 70°C before being subjected to SDS-PAGE. 
Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and exposed to 
autoradiography film. The radiolabelled bands were excised and radioactivity incorporated measured 
by scintillation counting. Data expressed as mean + SEM, n = 2.  
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3.2.2.1.1 Ser522 is the major Cdk5 site in vitro 
CRMP isoforms 1, 2, and 4 were better substrates for Cdk5 compared to CRMP3 and 
CRMP5. Due to the relatively poor phosphorylation observed for CRMP3 and 
CRMP5, these substrates were not included in the subsequent kinetic analysis. Firstly, 
to confirm that Cdk5 phosphorylated CRMP primarily at Ser522 the phosphorylation 
of a Ser522Ala mutant CRMP was also studied in vitro. 
 
Recombinant human WT GST-CRMP1, 2, and 4 (0.5 µM final concentration) was 
independently incubated with p35/Cdk5 or p25/Cdk5 (1 mU) in the presence of 
MgATP [γ32-P] for 30 min. In direct comparison, recombinant human CRMP1 
S522A, CRMP2 S522A, and CRMP4 S522A (0.5 µM final concentration) was 
independently incubated with p35/Cdk5 and p25/Cdk5 (1 mU) in the presence of 
MgATP [γ32-P] for 30 min. Following the assay, samples were subjected to SDS-
PAGE and then autoradiography (Figure 3.14). 
 
The degree of phosphate incorporated into each wild-type CRMP with both p35/Cdk5 
and p25/Cdk5 was substantially greater (>10-fold) than the amount of phosphate 
incorporated into the cognate CRMP S522A mutant. These results confirm that the 
major p35/Cdk5 and p25/Cdk5 phosphorylation sites on wild-type human CRMP1, 
CRMP2, and CRMP4 is Ser522 during in vitro phosphorylation assays.  
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Figure 3.14. The major Cdk5 phosphorylation site is Ser522. Recombinant A) GST-hCRMP1 (WT) 
or GST-hCRMP1 (S522A) (0.5 µM final concentration), B) GST-hCRMP2 (WT) or GST-hCRMP2 
(S522A), and C) GST-hCRMP4 (WT) or GST-hCRMP4 (S522A) was incubated with 2 mU of either 
p35/Cdk5 or p25/Cdk5 in the presence of radiolabelled ATP for 30 min before reactions were subject 
to SDS-PAGE and autoradiography.  
A
B
C
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3.2.2.1.2 p35/Cdk5 phosphorylates CRMP isoforms to a greater extent than 
p25/Cdk5 in vitro  
To establish the optimal assay parameters for kinetic analysis, initial stoichiometric 
values were determined by incubating either p35/Cdk5 or p25/Cdk5, at specific 
activities of 0.2 mU and 2 mU, with each isoform (0.5 µM final concentration) in the 
presence of MgATP [γ32-P] for the following time points: 5, 10, 20, 30, and 60 min. 
Following the assay, samples were subjected to SDS-PAGE and then autoradiography 
(Figure 3.15 – Figure 3.17). Stoichiometry was calculated as described in section 
2.2.9.3. The phosphorylation kinetics, Km (half the active sites possessing substrate) 
and Vmax (the maximal velocity that the reaction can reach when all the enzyme 
catalytic sites are occupied) were calculated as described in section 2.2.9.4.  
 
3.2.2.1.2.1 Collapsin response mediator protein 1 (CRMP1)  
The maximum stoichiometry achieved following 1 hr incubation with p35/Cdk5 and 
CRMP1 was 0.75 mol/mol (Figure 3.15B). In comparison, a maximum stoichiometry 
of 0.58 mol/mol was achieved following incubation with p25/Cdk5 during this time 
period (Figure 3.15D). Phosphorylation kinetic parameters were determined for each 
complex by incubating 0.2 mU of either p35/Cdk5 or p25/Cdk5 with CRMP1 in the 
presence of radiolabelled ATP for 10 min. The calculated Vmax for the p35/Cdk5 
complex (0.7349 pmol/min) was dramatically higher than the Vmax calculated for 
p25/Cdk5 (0.2 pmol/min). In contrast, the Km values obtained for each of the 
complexes did not differ dramatically, with p35/Cdk5 having a Km value of 1.3 and 
p25/Cdk5 a Km value of 1.5. This suggests that the affinity of the Cdk5-CRMP1 
interaction does not differ between p35 and p25 but that the p35/Cdk5 complex can 
phosphorylate CRMP1 to a faster rate (which may be related to product off rate rather 
than substrate on-rate), at least when compared to the generic MBP substrate. 
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Figure 3.15. Kinetic analysis of CRMP1 phosphorylation with the major Cdk5 complexes. 
Recombinant CRMP1 (0.5 µM final concentration) was incubated with 0.2 mU or 2.0 mU of p35/Cdk5 
(A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) 
for the times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE 
loading buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to 
SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and 
exposed to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n = 3. 
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3.2.2.1.2.2 Collapsin response mediator protein 2 (CRMP2)  
CRMP2 was phosphorylated to a greater extent by p35/Cdk5 compared to p25/Cdk5, 
reaching a maximal stoichiometry of 0.698 mol/mol after 1 hr incubation with 
p35/Cdk5 (Figure 3.16B). A maximal stoichiometry of 0.31 mol/mol was achieved 
for CRMP2 following 1 hr incubated with p25/Cdk5 (Figure 3.16D). Phosphorylation 
kinetic parameters were established by incubating 0.2 mU of either p35/Cdk5 or 
p25/Cdk5 with CRMP2 in the presence of radiolabelled ATP for 10 min. As with 
CRMP1, the calculated Vmax values were higher for p35/Cdk5 compared to p25/Cdk5. 
The p35/Cdk5 complex had a calculated Vmax value of 0.72 pmol/min whereas the 
p25/Cdk5 complex had a lower value of 0.18 pmol/min. However, the calculated Km 
values were the same for the p35/Cdk5 (1.65 µM) and p25/Cdk5 complex (1.66 µM) 
suggesting that the affinity of the Cdk5-CRMP2 interaction does not differ when 
Cdk5 is complexed to p35 or p25. 
 
3.2.2.1.2.3 Collapsin response mediator protein 4 (CRMP4)  
As with both CRMP1 and CRMP2, p35/Cdk5 phosphorylated CRMP4 to a greater 
stoichiometry than p25/Cdk5 following 1 hr incubation. The p35/Cdk5 complex 
achieved a maximal stoichiometry of 1.035 mol/mol (Figure 3.17B), much greater in 
comparison to the 0.68 mol/mol stoichiometry achieved for the p25/Cdk5 complex 
(Figure 3.17D). Once again, there is a large difference between the calculated Vmax 
values calculated for each complex. Calculated Vmax for the p35/Cdk5 complex was 
0.665 pmol/min compared to a lower Vmax of 0.155 pmol/min for p25/Cdk5. 
However, as with the other isoforms, the Km values do not differ dramatically 
between p35/Cdk5 (0.4 µM) and p25/Cdk5 (0.3 µM) suggesting that the affinity of 
the Cdk5-CRMP4 interaction does not differ between p35 and p25. 
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Figure 3.16. Kinetic analysis of CRMP2 phosphorylation with the major Cdk5 complexes. 
Recombinant CRMP2 (0.5 µM final concentration) was incubated with 0.2 mU or 2.0 mU of p35/Cdk5 
(A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) 
for the times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE 
loading buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to 
SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and 
exposed to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n = 3. 
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Figure 3.17. Kinetic analysis of CRMP4 phosphorylation with the major Cdk5 complexes. 
Recombinant CRMP4 (0.5 µM final concentration) was incubated with 0.2 mU or 2.0 mU of p35/Cdk5 
(A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) 
for the times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE 
loading buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to 
SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and 
exposed to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n =3.  	  
 
0 20 40 60
0.0
0.5
1.0
1.5
Time (min)
M
ol
 p
ho
sp
ha
te
/ M
ol
 p
ro
te
in
p35/Cdk5
0 20 40 60
0.0
0.2
0.4
0.6
0.8
M
ol
 p
ho
sp
ha
te
/ M
ol
 p
ro
te
in
Time (min)
0.2 mU p35/Cdk5
2.0 mU p35/Cdk5
p35/Cdk5 p25/Cdk5
0 20 40 60
0.0
0.2
0.4
0.6
0.8
M
ol
 p
ho
sp
ha
te
/ M
ol
 p
ro
te
in
Time (min)
0.2 mU p25/Cdk5
2.0 mU p25/Cdk5
A C
B D
Mr  
(x103) 
0.2 mU 
2.0 mU 
Incubation Period (min) 
60 30 20 5 0 
97 
97 
10 
p35/Cdk5 
0.2 mU 
2.0 mU 
Incubation Period (min) 
60 30 20 5 0 
Mr  
(x103) 
97 
97 
10 
p25/Cdk5 
0 20 40 60
0.0
0.5
1.0
1.5
Time (min)
M
ol
 p
ho
sp
ha
te
/ M
ol
 p
ro
te
in
p25/Cdk5
0 20 60
0.0
0.2
0.4
0.6
0.8
M
ol
 p
ho
sp
ha
te
/ M
ol
 p
ro
te
in
Ti  ( i )
0.2 mU p35/Cdk5
2.0 mU p35/Cdk5
p35/C p25/Cdk
20 40 60
0.
0.2
0.4
0.6
0.8
M
ol
 p
ho
sp
ha
te
/ M
ol
 p
ro
te
in
Time (min)
0.2 mU p 5/Cdk5
2.0 mU p25/Cdk5
A C
B D
Mr  
(x103) 
0.2 mU 
2.0 mU 
Incubation Period (min) 
60 30 20 5 0 
97 
97 
10 
p35/Cdk5 
0.2 mU 
2.0 mU 
Incubation Period (min) 
60 30 20 5 0 
Mr  
(x103) 
97 
97 
10 
p25/Cdk5 
0.2 mU 
2.0 mU 
Incubation Period (min) 
60 30 20 5 0 
Mr  
(x103) 
97 
97 
10 
p25/Cdk5 
Mr  
(x103) 
0.2 mU 
2.0 mU 
Incubation Period (min) 
60 30 20 5 0 
97 
97 
10 
p35/Cdk5 
A C
B D
	  
 
___________________________________________________________________________________ 
 
3. In vitro analysis of Cdk5 substrate phosphorylation 
146	  
3.2.3.2 Cdk5 in vitro tau phosphorylation site is a class 1 substrate 
Multiple phosphorylation sites on tau are proposed as possible targets for Cdk5: 
Thr153, Thr181, Ser195, Ser199, Ser202, Thr205, Thr212, Ser214, Thr231, Ser235, 
Ser396, Ser404 (Hanger, D. Tau phosphorylation sites. Retrieved October 24, 2012, 
from http://cnr.iop.kcl.ac.uk/hangerlab/tautable). In order to identify the primary 
Cdk5 in vitro phosphorylation sites on tau, recombinant WT human tau (0.5 µM final 
concentration) was incubated with each Cdk5 complex in the presence of MgATP 
[γ32-P] for the times indicated and the phospho-tau subjected to phosphopeptide 
mapping (Figure 3.18A). To affirm that any phosphopeptides detected during mass 
spectrometry (MS) analysis were attributed to Cdk5 phosphorylation, p35/Cdk5 and 
p25/Cdk5 were also pre-incubated with Cdk inhibitors, purvalanol A and roscovitine, 
prior to incubation with tau. Incubation of recombinant WT human tau in the absence 
of either complex served as a negative control.  
 
Following in-gel digestion with trypsin and MS analysis of Cdk5 phosphorylated tau; 
two phosphopeptides were identified for both Cdk5 complexes corresponding to sites 
Ser202 and Thr205, while no phosphopeptides were detected in the tau alone sample 
or those that had been treated with Cdk inhibitors. However, there was poor sequence 
coverage following the tryptic digestion of all samples and thus the analysis was 
repeated using lys-C instead of trypsin. Once again, no phosphopeptides were 
detected in tau alone samples or the samples in which Cdk5 was pre-incubated with 
either purvalanol A or roscovitine. This time, a single phosphopeptide, 
VAVVRTPPKpSPSSAK, corresponding to a single phosphorylation site (Ser235) 
was detected in the samples corresponding to both p35/Cdk5 and p25/Cdk5 
incubation (Figure 3.18B). Ser202 and Thr205 failed to be detected suggesting that 
these may be minor sites compared to Ser235.    
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Figure 3.18. Both Cdk5 complexes phosphorylate tau. A) Recombinant GST-tau (0.5 µM final 
concentration) was incubated with either p35/Cdk5 or p25/Cdk5, with or without purvalanol A or 
roscovitine pre-incubation, in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for 
the times indicated then subjected to SDS-PAGE followed by Colloidal Coomassie blue staining and 
autoradiography. B) Following the aforementioned methods, tau bands were digested with Lys-C and 
phosphopeptides isolated and identified as described in Chapter 2.2.11.1.  
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3.2.3.2.1 Both Cdk5 complexes phosphorylate tau to the same extent 
The degree of tau phosphorylation by p35/Cdk5 and p25/Cdk5 was directly compared 
by incubating recombinant WT human tau (0.5 µM final concentration) with either 
0.2 mU or 2.0 mU of each complex in the presence of MgATP [γ32-P] for the times 
indicated (Figure 3.19).  
 
Over 1 hr incubation period, tau was phosphorylated to the same extent by both Cdk5 
complexes. A maximal stoichiometry of 0.55 mol/mol was reached following 60 min 
incubation with p35/Cdk5 (Figure 3.19A), while a similar maximal stoichiometry of 
0.58 mol/mol was reached for p25/Cdk5 in the same time period (Figure 3.19B).  
 
More detailed phosphorylation kinetic parameters were established for both of the 
Cdk5 complexes by incubating p35/Cdk5 or p25/Cdk5 with varying concentrations of 
tau in the presence of radiolabelled ATP for 10 min. The calculated Vmax for 
p35/Cdk5 was 0.63 pmol/min while the Vmax for p25/Cdk5 was 0.26 pmol/min, 
suggesting that p35/Cdk5 can phosphorylate tau to a greater velocity than p25/Cdk5. 
There was a higher Km value calculated for p35/Cdk5 (1.89 µM) compared to 
p25/Cdk5 (1.419 µM). Overall, the Vmax/Km ratios were 0.3 and 0.2, respectively.  
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Figure 3.19. Kinetic analysis of tau phosphorylation with the major Cdk5 complexes. Recombinant 
tau (0.5 µM final concentration) was incubated with 0.2 mU or 2.0 mU of p35/Cdk5 (A and B) or 
p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for the times 
indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE loading buffer 
to terminate the reaction. Aliquots were then heated at 70°C before being subjected to SDS-PAGE. 
Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and exposed to 
autoradiography film (A and C). The radiolabelled bands were excised and radioactivity incorporated 
measured by scintillation counting (B and D). Data expressed as mean + SEM, n = 3. 
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3.2.3.2.2 Cdk5 primes tau for phosphorylation at Ser231 by GSK3 
Phospho-mapping of Cdk5 phosphorylated tau identified Ser235 as the major in vitro 
Cdk5 phosphorylation site. It has been previously proposed that GSK3 requires 
phosphorylation at this residue for subsequent phosphorylation of tau at residue 
Thr231 (Li et al., 2006). 
 
To confirm that Cdk5 can prime tau for subsequent GSK3 phosphorylation, a linked 
assay was performed with Cdk5 and GSK3. Cdk5 (1 mU) was incubated with 
recombinant WT human tau (0.5 µM final concentration) in the presence of non-
radiolabelled ATP for 30 min prior to the addition of GSK3 (1 mU) for an additional 
30 min. Following termination of the reaction, each reaction was subjected to SDS-
PAGE and immunoblotted with phospho-specific antibodies to the Ser235 and Thr231 
phosphorylation sites on tau (Figure 3.20).  
 
Phosphorylation of Thr231 on tau was only observed following incubation with both 
Cdk5 and GSK3 confirming Cdk5 as a priming kinase and providing additional 
evidence that Cdk5 phosphorylates tau at Ser235. As Ser202/Thr205 had been 
identified as minor targets for Cdk5 in the phosphopeptide mapping, phosphorylation 
of these sites by Cdk5 was also investigated using phosphospecific antibodies to anti-
Tau Ser202 and anti-Tau Thr205 (Figure 3.20). Interestingly, Cdk5 did induce some 
phosphorylation at both Ser202 and Thr205 and the phosphorylation of Thr205 may 
prime for additional phosphorylation at Ser202 by GSK3. 
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Figure 3.20. Validation of phospho-tau antibodies. Recombinant GST-hTau (WT) (0.5 µM final 
concentration) was incubated with 1 mU of p25/Cdk5 in the presence of non-radiolabelled ATP for 30 
min. Subsequently, 1 mU GSK3 was added to the reaction and incubated for a further 30 min period. 
Following termination of the reaction, each reaction was subject to SDS-PAGE and immunoblotted 
with antibodies phospho-specific to Ser202, Thr205, Ser235 and Thr231. Blots are representative of 
two independent experiments.  
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3.2.3.3 Cdk5 phosphorylation of dynamin 1 
GSK3 phosphorylation of dynamin 1 at Ser774 occurs following prior 
phosphorylation of Ser778 by Cdk5, modulating activity-dependent bulk endocytosis 
(ADBE) (Clayton et al., 2010). The Ser778 site of this substrate is flanked by both N- 
and C-terminal basic residues (RSPTSpSPSPQRR) but does not conform to the 
optimal sequence identified by peptide analysis above (no basic residue at +2/3). 
 
To investigate dynamin 1 phosphorylation by Cdk5, 0.2 mU and 2.0 mU of either 
p35/Cdk5 or p25/Cdk5 were incubated with dynamin 1 (0.5 µM final concentration) 
and radiolabelled ATP as described in section 2.2.9.3. Dynamin 1 was well 
phosphorylated by Cdk5, approaching a stoichiometry of 0.76 mol/mol after 60 min 
incubation with p35/Cdk5 (Figure 3.21A). The stoichiometry obtained for p25/Cdk5 
was of a similar magnitude, reaching a stoichiometry of 0.69 mol/mol after 60 min 
incubation with p25/Cdk5 (Figure 3.21B). 
 
Subsequently, 0.5 mU of either p35/Cdk5 or p25/Cdk5 was incubated with varying 
concentrations of dynamin 1 in the presence of MgATP [γ32-P] for 10 min. The Vmax 
value of 0.309 pmol/min obtained for p35/Cdk5 was slightly greater than the Vmax 
value of 0.187 pmol/min obtained for p25/Cdk5 however p25/Cdk5 had a lower Km 
value (2.04 µM) than p35/Cdk5 (2.78 µM). Thus, the Vmax/Km ratio did not differ 
between the two complexes with both complexes having a Vmax/Km ratio of 0.1. 	  
 
  
 
 
 
	  
 
___________________________________________________________________________________ 
 
3. In vitro analysis of Cdk5 substrate phosphorylation 
153	  
 
 
 
 
 
 
Figure 3.21. Kinetic analysis of dynamin 1 phosphorylation by the major Cdk5 complexes. 
Recombinant human WT dynamin 1 (0.5 µM final concentration) was incubated with either 0.2 mU or 
2.0 mU of p35/Cdk5 (A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM 
MgCl and 0.1 mM ATP) for the times indicated. At each time point, 5 pmol of protein was removed 
and added to SDS-PAGE loading buffer to terminate the reaction. Aliquots were then heated at 70°C 
before being subjected to SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue 
(CBR-250), dried, and exposed to autoradiography film (A and C). The radiolabelled bands were 
excised and radioactivity incorporated measured by scintillation counting (B and D). Data expressed as 
mean + SEM, n 3. 
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3.2.3.4 Phosphorylation of full-length substrates lacking basic residues 
 
3.2.3.4.1 tumour suppressor protein, p53 
Cdk5 reportedly phosphorylates p53 at two different SP motifs: Ser315 
(NTSSpSPQPKKK) (Class 2) and Ser33 (NNVLpSPLPSQA) (Class 4)(Zhang et al., 
2002). The previous peptide work had suggested Class 2 and Class 4 sequences were 
poor substrates for Cdk5 due to the lack of basic N-terminal residues therefore 
implying p53 would be a relatively weak substrate of Cdk5.  
 
To investigate p53 phosphorylation by Cdk5, both major complexes of Cdk5 were 
incubated with recombinant WT human p53 (0.5 µM final concentration) and 
radiolabelled ATP as described in section 2.2.9.3. The p35/Cdk5 complex 
phosphorylated p53 to a stoichiometry of 0.34 mol/mol after 1 hr incubation (Figure 
3.22A), while p25/Cdk5 phosphorylated p53 to around 0.16 mol/mol in this time 
period (Figure 3.22B). Of course, it is not possible to say whether this 
phosphorylation occurs at more than one site in these experiments but this substrate 
was relatively weak compared to CRMPs, tau, and dynamin 1. 
 
In an attempt to determine Vmax and Km values for p53 for a more direct comparison 
with Class 1 substrates, 2.0 mU of either p35/Cdk5 or p25/Cdk5 was incubated with 
varying concentrations of p53, in the presence of MgATP [γ32-P] for 10 min. 
However, under these assay conditions (comparable to those used with the earlier 
substrates) phosphorylation failed to reach twice above background and therefore it 
was not possible to confidently establish the phosphorylation kinetic parameters.  
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Figure 3.22. Kinetic analysis of p53 phosphorylation by the major Cdk5 complexes. Recombinant 
human WT p53 (0.5 µM final concentration) was incubated with either 0.2 mU or 2.0 mU of p35/Cdk5 
(A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) 
for the times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE 
loading buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to 
SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and 
exposed to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n 3. 
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3.2.3.4.2 Cdk5 phosphorylation of PPARγ  
Cdk5-mediated phosphorylation of PPARγ at serine 273 has been linked to obesity 
induced by high fat feeding in mice (Choi et al., 2010). The amino acid sequence 
surrounding Ser273 (TTDKpSPFVIY) contains an N-terminal lysine residue but no 
C-terminal basic residues therefore it is predicted that PPARγ would not be a substrate 
of Cdk5 phosphorylation based on the prior peptide assay. 
 
In order to evaluate the validity of PPARγ as a substrate of Cdk5, both major 
complexes of Cdk5 were incubated with 0.5 µM of either PPARγ1 or PPARγ2 and 
radiolabelled ATP as described in Chapter 2.2.9.3. Cdk5 phosphorylated PPARγ1 
with relatively low stoichiometry, reaching a maximal stoichiometry of less than 0.15 
mol/mol even after 1h incubation with 2 mU of p35/Cdk5 and only 0.034 mol/mol 
with 2 mU of p25/Cdk5 after 1h (Figure 3.23). The maximal stoichiometry values 
were slightly greater with PPARγ2; stoichiometry reached 0.2 mol/mol after 1h with 2 
mU of p35/Cdk5 and 0.045 mol/mol with p25/Cdk5 (Figure 3.24). 
 
Using the information obtained from the stoichiometric analysis, 2.0 mU of either 
p35/Cdk5 or p25/Cdk5 was incubated with varying concentrations of PPARγ1 and 
PPARγ2, independently, in the presence of MgATP [γ32-P] for 10 min. However, the 
activity in these assay conditions was too low to allow accurate calculation of the 
enzyme kinetics of these reactions. Additionally, work in our lab established that a 
PPARγ2 with Ser273 mutated to alanine was phosphorylated to the same level as WT 
PPARγ2, suggesting that this low level of phosphorylation by Cdk5 is not at Ser273 
(Louise Saul, personal communication). As a result, this substrate was not included in 
further investigations. 
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Figure 3.23. Kinetic analysis of PPARγ1 phosphorylation by Cdk5 complexes. Recombinant human 
WT PPARγ1 (0.5 µM final concentration) was incubated with either 0.2 mU or 2.0 mU of p35/Cdk5 
(A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) 
for the times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE 
loading buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to 
SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and 
exposed to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n 3. 
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Figure 3.24. Kinetic analysis of PPARγ2 phosphorylation by Cdk5 complexes. Recombinant human 
WT PPARγ2 (0.5 µM final concentration) was incubated with either 0.2 mU or 2.0 mU of p35/Cdk5 
(A and B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) 
for the times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE 
loading buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to 
SDS-PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and 
exposed to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n 3. 
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3.2.3.5 The role of proline residues in Cdk5 recognition 
It is well established that Cdk5 requires a proline residue at +1 relative to the 
phosphoacceptor residue to permit phosphorylation to occur. Interestingly, I found 
that Cdk5 phosphorylated peptide substrates that contained a proline residue located 
N-terminally (-2) from the phosphoacceptor residue but failed to phosphorylate such a 
peptide substrate when an additional proline residue was present at +2 (Figure 3.6). 
Such a sequence is contained within the transcription factor Mef2a surrounding 
Ser408 (SEPIpSPPRDR), a residue reportedly phosphorylated by Cdk5 which results 
in inhibition of Mef2a transcriptional activity leading to apoptosis of cortical neurons 
following induction by neurotoxicity (Gong et al., 2003). This site contains the 
proline (-2) beneficial to Cdk5 phosphorylation (as well as a basic residue at +3) 
however it also contains an additional proline (+2) and an asparate (+4), the residues 
found to be antagonistic to Cdk5 phosphorylation during the peptide analysis, 
bringing into question whether Ser408 of Mef2a is really a substrate for Cdk5. 
 
To investigate Mef2a as a Cdk5 substrate, 0.2 mU and 2.0 mU of p35/Cdk5 or 
p25/Cdk5 was incubated with 0.5 µM Mef2a in the presence of MgATP [γ32-P] for 
the times indicated (Figure 3.25). At each time point, aliquots of the reactions were 
removed and subjected to gel electrophoresis to separate radiolabelled ATP from 
protein substrate, and the labelled substrate was visualised by autoradiography, prior 
to excision and quantification using liquid scintillation counting.  
 
The stoichiometry of phosphorylation for Mef2a was relatively poor. Phosphorylation 
of Mef2a by p35/Cdk5 failed to achieve a stoichiometry greater than 0.1 mol/mol 
within 60 min (Figure 3.25A) while phosphorylation of Mef2a by p25/Cdk5 was even 
poorer, <0.05 mol/mol after 60 min (Figure 3.25B). 
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Figure 3.25. Kinetic analysis of Mef2a phosphorylation by the major Cdk5 complexes. Recombinant 
Mef2a (0.5 µM final concentration) was incubated with either 0.2 mU or 2.0 mU of p35/Cdk5 (A and 
B) or p25/Cdk5 (C and D) in the presence of Mg [γ-32P] ATP (10 mM MgCl and 0.1 mM ATP) for the 
times indicated. At each time point, 5 pmol of protein was removed and added to SDS-PAGE loading 
buffer to terminate the reaction. Aliquots were then heated at 70°C before being subjected to SDS-
PAGE. Subsequently, gels were stained with Coomassie Brilliant Blue (CBR-250), dried, and exposed 
to autoradiography film (A and C). The radiolabelled bands were excised and radioactivity 
incorporated measured by scintillation counting (B and D). Data expressed as mean + SEM, n 3. 
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The data in Figure 3.25 was obtained using the 82 kDa band. However, following gel 
electrophoresis and Coomassie staining of the gel, bands corresponding to varying 
molecular weights (82 kDa, 50 kDa, 42 kDa, 40 kDa, and 25kDa) were visible 
suggesting that the recombinant Mef2a may have been degraded and this could have 
contributed to the poor phosphorylation by Cdk5.  
 
To quantify the level of protein degradation, and obtain a more accurate stoichiometry 
for full length Mef2a, a protein standard curve was generated using BSA (1.0 mg/ml, 
0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml). The amount of each Mef2a product could then 
be estimated (Figure 3.26). Less than 20% of the protein in the recombinant Mef2a 
was in the 82 kDa band (expected full length) therefore it is difficult to be confident 
that the phosphorylation observed is representative of full length Mef2a. Thus, 
detailed phosphorylation kinetic parameters could not be determined on these protein 
preparations. 
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Figure 3.26. BSA standard curve for determining protein concentration of Mef2a preparation. A 
standard curve was obtained for BSA by obtaining the absorbance readings of known concentrations of 
BSA. A) BSA at four concentrations (1.0 mg/ml, 0.5 mg/ml, 0.25 mg/ml, and 0.125 mg/ml) was 
subjected to SDS-PAGE and stained with Coomassie Brilliant Blue (CBR-250) along with known 
amounts of Mef2A protein. B) Absorbance readings for the indicated concentrations were obtained 
using the Licor imaging system. Data expressed as mean + SEM, n = 2.   
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3.3 DISCUSSION 
Cdk5 is depicted as a highly promiscuous kinase actively targeting a vast array of 
substrates that are not confined by a specific consensus. As a result of the observation 
that levels of p25 are elevated in Alzheimer’s disease, activation of Cdk5 by the 
truncated cofactor is believed to enhance Cdk5 activity and alter specificity thereby 
contributing to the pathogenesis of neurodegenerative disease however there has been 
little evidence to support either claim. Therefore, the aim of this chapter was to 
establish a consensus for Cdk5 substrate selection and compare the inherent activities 
of the p25/Cdk5 and p35/Cdk5 complexes. 
 
3.3.1 Redefining the Cdk5 consensus 
Most protein kinases that have been studied in detail have a minimum and preferred 
consensus peptide sequence that contributes to substrate specificity. However, the 
multitude of proposed Cdk5 substrates appear to only have a single common primary 
structural feature, a Pro residue at the +1 position relative to the phosphoacceptor site, 
a property shared by the majority of the CGMC family of protein kinases. On the 
contrary, biochemical and structural studies have suggested that the Cdk family 
members discriminate substrates through additional differences in the primary 
sequence surrounding the phosphoacceptor residue  (Echalier et al., 2010; Brown et 
al., 2007) implying that a Cdk5 substrate consensus should exist. Thus, the initial aim 
of this chapter was to isolate residues that are important for Cdk5 phosphorylation 
and, ultimately, redefine the degenerate Cdk5 consensus.  	  
3.3.1.1 Important residues that guide Cdk5 substrate selection 
The current consensus sequence described for the Cdk family members suggests a 
preference for a basic residue towards the C-terminus of the phosphoacceptor residue 
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(Beuadette et al., 1993; Shetty et al., 1993) however many of the substrates proposed 
for Cdk5 do not possess this residue therefore questioning its importance for Cdk5 
specificity. In the present study, in vitro investigation into the primary sequence 
requirements of Cdk5 uncovered an unexpected, highly selective, peptide substrate 
profile for Cdk5. Whilst basic residues towards the C-terminus were found to be 
favourable for Cdk5 phosphorylation, surprisingly, the N-terminal residue at -2 
actually had more influence on the rate of peptide phosphorylation by Cdk5. Peptides 
with a proline residue at -2 had high affinity for Cdk5 phosphorylation whereas Cdk5 
selectively failed to phosphorylate peptides that lacked a proline residue at this 
position. In correlation with this finding, previous work using an oriented degenerate 
peptide library with p35/Cdk5, along with other Ser/Thr protein kinases, determined 
that the optimal sequence for Cdk5 when complexed to p35 contained either a 
histidine (selectivity value = 2.5) or a proline (selectivity value = 2.1) at the -2 
position (Songyang et al., 1996). Taken together, these results suggest that the amino 
acid in the -2 position contributes to Cdk5 substrate selection and the presence of a 
proline or basic residue increases the probability of this substrate being 
phosphorylated by Cdk5.  
 
In addition to having a positive effect on Cdk5 phosphorylation, proline residues were 
also found to have a detrimental effect on substrate phosphorylation. The presence of 
a proline residue directly following the SP motif (+2) resulted in complete ablation of 
Cdk5 phosphotransferase activity, even in peptides containing an N-terminal proline 
residue (-2). The amino acid substitution work in this chapter provides evidence to 
suggest that the primary sequence in direct proximity of the phosphoacceptor residue 
is critical for Cdk5 substrate selection, and the sequence determinants could be used 
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to identify potential novel substrates while providing confidence (or, alternatively, 
questioning) that proposed substrates are Cdk5 targets. 
 
3.3.1.2 Validation of consensus in full-length substrates 
The second goal of this chapter was to investigate whether the primary sequence 
requirements identified in the peptide work were valid in full-length protein 
substrates. Interestingly, the major site on tau found in this study to be phosphorylated 
by Cdk5 in vitro possessed the N-terminal proline (at -2) and basic residues both N- 
and C-terminal within +5 of the phosphoacceptor residue (TPPKSPSSAK). In 
addition, CRMP1 and CRMP2 were excellent substrates for Cdk5 in vitro and both 
contain basic residues N- and C-terminal to the phosphoacceptor site (lysine residues 
at +2 and -2). Interestingly, CRMP4, which contains arginine residues at +2 and -2, 
was found to be the best in vitro substrate of Cdk5 suggesting that even small changes 
in amino acid properties modulate Cdk5 phosphorylation rate. 
 
Substrates that lacked the optimal residues were phosphorylated to a lesser extent. For 
example, PPARγ was a relatively poor substrate for Cdk5 in vitro. These results 
provide further confidence in the optimal Cdk5 consensus and question whether 
potential substrates that do not meet consensus requirements are bona fide Cdk5 
substrates. However, it is important to note that kinases have devised several 
strategies in addition to primary sequence to specifically recognise their substrates. 
For example, additional docking sequences can increase the specificity of kinases 
towards their substrates. This is especially well characterised for the Cdks: an RXL 
motif that is present in many of their substrates binds to a hydrophobic patch on the 
catalytic subunit, increasing the affinity of the kinase for the substrate (Schulman et 
al., 1998). Furthermore, classical MAPKs directly bind to their substrates and do not 
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phosphorylate peptides very well implying that primary sequence motifs may be 
overridden by other mechanisms such as binding. Therefore, further work is required 
to understand Cdk5 substrate recognition and fully validate potential Cdk5 substrates, 
however this work provides evidence to suggest that Cdk5 substrate selection can at 
least be inferred or seriously questioned by studying the primary sequence. 
 
3.3.1.3 Consensus sequence is specific to Cdk5 
Phosphorylation of peptides by Cdk5 was compared with a panel of kinases 
representing different branches of the CMGC family to establish if the Cdk5 peptide 
consensus was conserved across CMGC members. Cdk5 expressed the highest 
phosphotransferase towards most of the peptides studied, with the other kinases 
showing relatively minimal phosphotransferase towards each of the peptides, 
suggesting that Cdk5 substrate selection has primary sequence determinants specific 
to the kinase. The exception was a higher phosphotransferase activity by PCTAIRE 
with a peptide that Cdk5 failed to phosphorylate (KKASAPKSPPRPRS). This result 
provided confidence that this peptide was soluble and that Cdk5 did not phosphorylate 
it, and suggests that the primary sequence around the phosphoacceptor site of 
substrates can provide strong selectivity bias toward even relatively homologous 
protein kinases. In this case, the proline at +2 reduces phosphorylation by Cdk5 to a 
much greater extent than for PCTAIRE. 
 
In hindsight, it would have been interesting to compare Cdk2 with Cdk5 on these 
peptides as the high homology between these enzymes suggests there is likely to be 
some overlap in substrate recognition. It is quite possible that the known Cdk2 
substrates could also be Cdk5 substrates, thereby providing regulation outside of the 
cell cycle (as Cdk5 is active in terminally differentiated cells).  
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3.3.1.4 Perspectives and future directions for a Cdk5 consensus sequence 
The results described here provide evidence to suggest that Cdk5 substrate selection is 
defined, at least in part, at the primary sequence level. Fully elucidating the sequence 
requirements of Cdk5 would require peptide studies covering more sequence 
combinations, as there appears to be multiple contributions to the recognition 
parameters for Cdk5 phosphorylation. The CRMP family of proteins were good in 
vitro substrates of Cdk5 therefore these could serve as a useful substrate to use as a 
template in which to study the effect of substituting residues that we predict to be 
important (positively or negatively) which were determined through peptide analysis. 
For example, substituting lysine residues to arginine residues (CRMP1/CRMP2 to 
CRMP4) enhanced phosphotransferase activity in vitro, and it would be interesting to 
try all 20 amino acid substitutions within this context on each and both of these sites. 
Of course, our previous work found that Cdk5 deletion in neurons reduced CRMP1 
and CRMP2 phosphorylation at Ser522, but did not alter CRMP4 phosphorylation 
(Cole et al., 2007). Thus, although Cdk5 may prefer arginine over lysine it would 
appear that there are other kinases in neurons with an absolute requirement for 
arginine over lysine which means CRMP4 can be regulated independently of Cdk5 
and the other CRMPs. Therefore, it is important to keep in mind that primary 
consensus sequences for kinases have evolved not only to provide the best possible 
target sequence for efficient phosphorylation but also to provide (or not) specificity to 
a given kinase(s). In addition, recognition of the sequence by phosphatases will also 
dictate steady state phosphorylation levels. The pSer522 motif in CRMP2 is highly 
resistant to dephosphorylation in vitro (Cole et al., 2008) and this is related to the 
presence of the same basic residues N- and C-terminal to the phosphoacceptor site 
that make it a better Cdk5 substrate. These may form a structure with the PO42- that 
reduces accessibility for phosphatases and results in relatively high stoichiometry in 
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cells (Cole et al., 2007). This model would predict that other Cdk5 substrates with 
basic charged residues either side of the phosphoacceptor would also be relatively 
highly phosphorylated due to low rates of dephosphorylation. One could then suggest 
that substrates with basic residues to only one side of the phosphorylation site may 
have slower rates of phosphorylation by Cdk5 but allow more access to a phosphatase 
and be more dynamically controlled.     
 
In conclusion, although kinases have devised several strategies to recognise substrates 
and substrate sequences have evolved in an environment where specificity and 
dephosphorylation are also factors for sequence selection, this chapter provides 
evidence to suggest that the primary sequence surrounding the phosphoacceptor 
residue contributes key information to aid in the identification and validation of Cdk5 
substrates. Importantly, substrates that do not meet the minimum requirements for 
phosphorylation in vitro should be heavily scrutinised, while classification of 
substrates by primary sequence could allow modelling of specificity and likely 
stoichiometry of phosphorylation in cells. 	  
3.3.2 Cdk5 as a potential priming kinase for GSK3 on CRMP5 
CRMP5 is highly expressed during brain development and plays an important role in 
the regulation of neuronal polarity by inhibiting dendrite outgrowth at early 
developmental stages (Brot et al., 2013). When expressed in adults, CRMP5 is 
associated with neurological disorders (Brot et al., 2013). Results obtained with 
CRMP5-deficient mice stress the role of CRMP5 in the development, and synaptic 
plasticity, of cerebellar Purkinje cells (Yamashita et al., 2011). However, few studies 
have investigated the regulation of CRMP5 and Cdk5 has not been considered as a 
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CRMP5 kinase due to the lack of conservation around the Ser522 region with the 
other CRMPs. 
 
3.3.2.1 Cdk5 displayed phosphotransferase activity towards CRMP5 
Previous work within the laboratory (Cole et al., 2006) established Cdk5 as the 
priming kinase that allowed subsequent GSK3 phosphorylation of CRMP2. Due to the 
conservation of the 509-522 motif within CRMP1, CRMP2, and CRMP4, only these 
three isoforms were investigated as Cdk5 targets. In the present study, CRMP3 and 
CRMP5 were included in the analysis and it was confirmed that Cdk5 does not 
phosphorylate CRMP3. In contrast, this work demonstrated for the first time that 
Cdk5 was able to phosphorylate CRMP5, albeit at a lower rate and to a lower 
stoichiometry than CRMP1, CRMP2, and CRMP4. Interestingly, the sequence 
surrounding the Thr514 residue on CRMP5 meets some of the requirements for Cdk5 
phosphorylation elucidated in the peptide studies. Of particular note is that, if Thr514 
were the Cdk5 target residue then this would prime CRMP5 for regulation by GSK3 
at Thr509, in a similar fashion to the other CRMPs. This would be relatively 
straightforward to investigate through use of T514A and T509A mutants of CRMP5. 
 
3.3.3 Differential inherent activities of the p25/Cdk5 and p35/Cdk5 
complexes in vitro does not account for the role of p25/Cdk5 in the 
pathogenesis of neurodegenerative disease 
Development of the mammalian central nervous system is dependent on the tight 
regulation of Cdk5 activity, an activity that results following association with its 
regulatory subunit, p35. At present, there is common belief that truncation of this 
cofactor results in an increase in Cdk5 kinase activity, prolonged activation, as well as 
a change in cellular localisation and alteration of its substrate specificity (Patrick et 
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al., 1999), which subsequently promotes pathogenesis of neurodegenerative diseases. 
A major goal of this chapter was to directly compare the p35/Cdk5 and p25/Cdk5 
complexes and establish potential differences in rates of substrate phosphorylation 
that may result from proteolytic cleavage of the p35 regulatory subunit.  
 
3.3.3.1 Substrate profile and inherent activity is similar between complexes 
If proteolytic processing of p35 to p25 results in an increase in inherent catalytic 
activity or an altered substrate specificity profile then it should be possible to confirm 
this through direct comparison of substrate phosphorylation in vitro. However, the 
two Cdk5 complexes phosphorylated a range of peptides and proteins to almost 
identical levels and similar rates (when activities were first matched against a generic 
substrate) (Table 3.3). Additionally, phospho-mapping identified the same 
phosphorylation site on tau for both complexes indicating that both complexes target 
substrates using the same discrimination techniques and we could find no evidence for 
additional sites on tau being hit by p25/Cdk5. These findings indicate that the 
substrate profile of Cdk5 is unaltered by the cleavage of p35 and does not support the 
theory that a greater inherent activity of p25/Cdk5 contributes to its potential role in 
the pathogenesis of neurodegenerative disease. 
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p35/Cdk5 
 
 
p25/Cdk5 
 
Vmax 
 
 
Km 
 
Vmax/Km 
 
Vmax 
 
Km 
 
Vmax/Km 
 
CRMP4 
 
0.67 
 
0.40 
 
1.66 
 
0.16 
 
0.25 
 
0.62 
 
CRMP1 
 
0.73 
 
1.26 
 
0.59 
 
0.19 
 
1.46 
 
0.13 
 
CRMP2 
 
0.72 
 
1.65 
 
0.44 
 
0.18 
 
1.66 
 
0.11 
 
Tau 
 
0.63 
 
1.89 
 
0.33 
 
0.26 
 
1.42 
 
0.19 
 
Dynamin 1 
 
0.31 
 
2.78 
 
0.11 
 
0.19 
 
2.04 
 
0.09 
 
 
 
Table 3.3. Phosphorylation kinetic parameters of Cdk5 substrates and comparison between the 
major Cdk5 complexes. Phosphorylation kinetic parameters were established by incubating equal 
amounts of p35/Cdk5 and p35/Cdk5 with varying concentrations of the indicated substrates in the 
presence of Mg [γ-32P] ATP (10 mM Mg 0.1mM ATP), for 10 minutes at 30°C. Vmax and Km values 
were calculated by plotting the substrate-velocity curves and using the Lineweaver-Burk equation. Vmax 
values are in pmol/min and Km values are in µM. Values are representative of at least two independent 
experiments.    
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3.3.3.2 Perspectives and future directions to delineate the effect of p35 
proteolytic cleavage 
There are two major mechanisms that could not be investigated in the in vitro analysis 
performed in this study. Firstly, if clipping of p35 alters the stability of this subunit 
then it is possible that p25 would accumulate to higher levels than p35. There is some 
evidence that p25 is more stable than p35 (Patrick et al., 1999). Secondly, the 
cleavage of p35 removes a membrane targeting sequence meaning that p25 could 
relocate Cdk5 to a different cellular compartment and thus target an alternative set of 
substrates. This seems an important aspect to investigate and a direct comparison of 
the global phosphoproteome of cells expressing each complex may provide evidence 
as to how great a change occurs when p25 is produced. This latter point may influence 
the interpretation of the in vitro system used in the present study, which compared 
p25/Cdk5 and p35/Cdk5 catalytic activities in a soluble assay. A myristolyation site is 
present on p35, tethering p35/Cdk5 to the membrane, however proteolytic cleavage of 
p35 by calpain results in loss of the myristolyation site and a complex that is no 
longer retained by the membrane. If membrane association alters Cdk5 complex 
structure then this may affect the rate at which it phosphorylates specific substrates. 
The development of a micelle/vesicle assay system to study p35/Cdk5 substrate 
phosphorylation may be required to fully address this issue.  	  
In conclusion, the inherent catalytic affinity of Cdk5 and substrate specificity profile 
of Cdk5 is not dramatically altered upon cleavage of p35 when measured using 
purified components in vitro. However, intracellular protein-protein, protein-lipid 
interactions, or post-translational modifications may differentially affect catalytic 
specificity in vivo. Otherwise, the toxicity of the p25/Cdk5 complex may be attributed 
to its specifically altered subcellular compartmentalisation and accessibility to 
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different substrates. In addition, the prolonged activation of Cdk5 may contribute to 
pathophysiology, if the half-life of p25/Cdk5 is substantially greater than that of 
p35/Cdk5, and the mis-localisation and lapse in the tight regulation of Cdk5 activity 
need further investigation. However, this chapter concludes that the potential role of 
Cdk5 in the pathogenesis of neurodegenerative disease can not be attributed to 
“hyperactivation” of the specific activity of the Cdk5 complex, as measured in vitro.  
 
3.4 SUMMARY 
In summary, in vitro peptide analysis studies were performed to evaluate the 
importance of primary sequence requirements in Cdk5 substrate selection and 
concluded that Cdk5 substrate selection is mediated, to some extent, at the primary 
sequence level. Proline residues at the -2 position relative to the phosphoacceptor 
residue appeared important for guiding Cdk5 substrate selection whereas proline 
residues at the +2 position were antagonist for Cdk5 phosphorylation. The optimal 
consensus sequence was subsequently defined as P-K-S-P-R-K. Further in vitro 
analysis using full-length proteins confirmed that proteins adhering to the consensus 
were phosphorylated to a greater extent, for example tau was phosphorylated to a 
greater extent than PPARγ in vitro. Substrate profile and inherent activity was also 
similar between complexes suggesting that the specific activity of Cdk5 is not 
affected by the cleavage of p35. 
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 4.1 INTRODUCTION  
The work described in the previous chapter examined Cdk5 substrate phosphorylation 
through in vitro analysis. While significant in vitro phosphorylation of a proposed 
substrate is essential in identifying potential substrates, there are additional criteria 
that are required to confidently validate a proposed substrate as a true physiological 
target. Namely, manipulation of kinase activity in cells and in vivo through genetic, 
pharmacological, and physiological methods should alter the phosphorylation of 
specific residues on substrates targeted in vitro. Finally, alteration of phosphorylation 
should result in a change in the function of the substrate. Full validation of kinase 
substrates is important as it aids in understanding the physiological significance of the 
kinase and enables examination of kinase activity in a pathophysiological context. 
Moreover, it allows subsequent assessment of the benefits of manipulating kinase 
activity as a therapeutic option. 
 
In this context, this chapter attempts to further validate the substrate consensus 
sequence and specific substrates identified in the previous chapter by manipulating 
Cdk5 kinase activity in cells and intact tissue, through overexpression and inhibition 
of Cdk5 activity, and subsequently assessing the effect on substrate phosphorylation 
at the sites targeted in vitro. Substrates confirmed as direct targets of Cdk5 by these 
means will then be investigated in human tumours to provide insight into the status of 
Cdk5 activity in cancer. 
 
 
	  
 
___________________________________________________________________________________ 
 
4. Validating tools to assess Cdk5 substrate phosphorylation in cancer 
176	  
4.1.2 Chapter Aims 
The major goal of this chapter was to establish whether specific proposed substrates 
of Cdk5 examined in the previous chapter were indeed physiological substrates and to 
subsequently use these to monitor Cdk5 activity in cancer.  
 
4.1.2.1 Sequence determinants 
Having investigated the phosphorylation of potential Cdk5 substrates in vitro in the 
previous chapter, this chapter sets out to investigate the relationship between the 
degree of substrate phosphorylation observed within a mammalian cell line and the 
preferred substrate sequence determinants identified in the previous chapter. Proposed 
substrates would be confirmed as Cdk5 targets if phosphorylation of these substrates 
was altered following manipulation of Cdk5 activity in cell lines and intact tissue.  
 
4.1.2.2 Tools to study Cdk5 in cells and tissue 
Following the validation of Cdk5 substrates through modulation of Cdk5 activity in 
cell lines and intact tissue, the second aim of the chapter was to establish a phospho-
specific antibody panel that would enable the measurement of phosphorylation of 
these validated Cdk5 substrates, and subsequently validate these tools for use in 
immunohistochemistry.    
 
4.1.2.3 Cdk5 and cancer 
The final aim of this chapter was to screen human tumours for abnormal Cdk5 
substrate phosphorylation to determine if changes in Cdk5 activity may contribute to 
the initiation, progression, or prognosis of human cancer. 
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4.2 RESULTS 
 
4.2.1 Establishing an appropriate cell model system in which to study 
Cdk5 substrate phosphorylation 
Cells provide a physiological system in which to validate and characterise protein 
phosphorylation events identified in vitro. The most appropriate system for 
characterisation of substrate phosphorylation is generally a cell system where both the 
kinase and substrate are known to be endogenously expressed however one of the 
aims of this chapter was to compare the action of each Cdk5 complex on given 
protein substrates, therefore cell systems were developed where each of the Cdk5 
complexes were not endogenously expressed and the p25 and p35 isoforms could be 
ectopically introduced. 
 
4.2.1.1 Investigating Cdk5 substrate phosphorylation within HEK293 cells 
The human embryonic kidney (HEK) cell line has been extensively used for the study 
of recombinant proteins as it is of human origin and is also relatively easy to transfect. 
This cell line expresses relatively little, if any, p35/p25 or Cdk5 and therefore 
provides the opportunity to study the specific effect of each cofactor on Cdk5 activity 
with regard to substrate phosphorylation.   
 
4.2.1.1.1 Transfection of Cdk5 and cofactors results in an active complex in 
HEK293 cells 
As the purpose of transfection was to study the effect of Cdk5 phosphorylation on 
potential substrates it was therefore important to establish if overexpression of Cdk5 
along with either cofactor (p35 or p25) would result in the production of an active 
Cdk5 complex. 
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Equal amounts of Cdk5 and either p35 or p25 expression vectors were co-transfected 
into HEK293 cells using the calcium phosphate precipitation method (refer to 
methods, section 2.2.4.1). Successful overexpression of Cdk5 and p35/p25 protein 
was confirmed by Western blot analysis (Figure 4.1A). In order to isolate complexes 
of Cdk5, immunoprecipitation (IP) was performed using the p35 antibody, which 
recognises both the p35 and p25 cofactors. IP using the Cdk5 antibody was not 
performed as this could isolate recombinant Cdk5 not complexed to a cofactor and, 
furthermore, this antibody can inhibit the activity of the Cdk5 complex (Dr. M. 
Nikolic, personal communication). The efficiency of the p35 IP was assessed by 
immunoblotting (Figure 4.1B). Following successful pull-down, Cdk5 activity was 
examined by in vitro kinase assay using MBP as the standard substrate.  
 
Both p35/Cdk5 and p25/Cdk5 isolated from HEK293 cells showed a substantial 
increase in phosphotransferase activity, compared with control, confirming that 
overexpression of Cdk5 with either cofactor results in generation of an active Cdk5 
complex within HEK293 cells (Figure 4.1C). The phosphotransferase activity of the 
p25/Cdk5 complex was slightly greater in comparison to the p35/Cdk5 complex, 
which may be attributed to a slight difference in expression levels or, alternatively, 
the p25/Cdk5 complex phosphorylating MBP with a slightly greater specific activity. 
The immunoblots did not indicate a major difference in expression levels and thus it 
seems possible that the inherent activity of the recombinant p25/Cdk5 complex 
against MBP is slightly higher than that of p35/Cdk5. However, this theory was not 
explored further. 
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Figure 4.1. Generation of an active Cdk5 complex within a mammalian cell line. Mammalian 
constructs containing cDNA for Cdk5 and either p35 or p25 were co-transfected into HEK293 cells 
using calcium phosphate. A) Successful overexpression was confirmed by Western blot analysis. B) 
Cdk5 complexes were immunoprecipitated using an antibody to anti-p35/25 and pull-down efficiency 
determined by immunoblotting. C) Specific activity of each complex was determined by means of in 
vitro kinase assay using MBP as substrate. The degree of phosphate transfer was measured by 
scintillation counting and used to calculate the specific activity (pmol/min). Data expressed as mean + 
S.E.M, n = 2. 
 
	  
 
___________________________________________________________________________________ 
 
4. Validating tools to assess Cdk5 substrate phosphorylation in cancer 
180	  
4.2.1.1.2 Co-transfection of Cdk5, cofactor and substrate in HEK293 cells  
Having confirmed that overexpression of Cdk5 and either p35 or p25 in HEK293 cells 
resulted in the formation of an active Cdk5 complex, this system was then expanded 
to investigate substrate phosphorylation by Cdk5 following triple transfection of 
kinase, cofactor, and substrate in the cell line. 
 
Consistency of total DNA content in transfections was achieved by including 
appropriate amounts of parent vector plasmid when comparing a single plasmid to 
multiple plasmid transfections. Cells were plated around 24 hrs prior to transfection to 
allow the cells to reach around 60% confluency (Figure 4.2A). Triple transfection of 
constructs was performed using the calcium phosphate precipitation method (refer to 
methods, section 2.2.4.2). Transfection reactions were repeated at least 3 times. In 
every case, Western blot analysis was performed to quantify successful protein 
overexpression (Figure 4.2B).  
 
Although double transfection of both Cdk5 and cofactor consistently produced active 
Cdk5 complexes, triple transfection experiments (to include a substrate) were more 
problematic. Single transfection of substrate expression vectors confirmed the validity 
of these constructs (Figure 4.2B), however all substrates failed to overexpress when 
co-transfected with two other plasmids with expression cassettes (i.e. Cdk5 and either 
p35 or p25). Transfction with PPARγ is given as an example where transfection of 
constructs results in PPARγ overexpressing only in single transfections and not during 
triple transfection (Figure 4.2B). 
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Figure 4.2. Triple transfection in HEK293 cells successfully overexpresses Cdk5 and cofactor but 
fails to overexpress substrate. A) Schematic representation of transfection protocol. HEK293 cells 
were plated 24 hrs prior to transfection to allow the cells to reach the appropriate level of confluency. 
The different number of plasmids transfected was controlled for by including empty vector plasmids 
(a) in transfections with only a single construct to ensure each transfection received the same amount of 
plasmid. Cells were triple transfected with constructs containing the substrate of interest, Cdk5 and 
cofactor (b). Transfection mix was removed after 4 hrs and cells were incubated in fresh DMEM for 24 
hrs to allow protein overexpression. B) Western-blot analysis was performed to confirm 
overexpression.  
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Extensive optimisation of the triple transfection protocol was performed in order to 
overcome the technical issues described above. For example, the ratio of constructs 
was altered per transfection reaction in an attempt to find the minimal amount of each 
plasmid DNA required to generate robust protein expression. Concentrations were 
tested for each plasmid in the range from 1 ng/µl, in intervals of 1, up to 10 ng/µl in 
different ratios of Cdk5 to cofactor to substrate. Unfortunately, no conditions could be 
found that produced robust and consistent expression of all three proteins and hence 
an alternative cell system was approached.  
 
4.2.1.2 Investigating Cdk5 substrate phosphorylation within HeLa cells 
HeLa cells are a human cervix adenocarcinoma used extensively in cell biology 
research since the 1950s. Interestingly, previous work in this cell line suggested that 
HeLa cells contain endogenous Cdk5 but lack either cofactor (Sun et al., 2008). In 
theory, this provides an opportunity to study Cdk5 substrate phosphorylation 
following transfection of either cofactor along with substrate, negating the 
requirement for a triple transfection. 
 
4.2.1.2.1 Cdk5 activity isolated from HeLa cells increases more dramatically 
following overexpression of Cdk5 and cofactor compared to cofactor alone 
To ensure that overexpression of a Cdk5 cofactor resulted in generation of an active 
Cdk5 complex beyond endogenous activity in the HeLa cells, they were transfected 
with either p35 or p25, with or without co-transfection of Cdk5, and a subsequent IP 
kinase assay was performed on the resultant cell lysates. IP reactions were performed 
using the p35/p25 antibody, with untransfected lysate as a control, and successful 
pull-down confirmed by Western blot. The specific activity of each isolated complex 
was determined by performing an in vitro kinase assay with MBP as substrate. 
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No activity was found in beads alone control IP and only a small amount of activity 
was observed from pull-down using lysates from untransfected cells suggesting a low 
level of p35 and Cdk5 endogenous expression (Figure 4.3). Activity isolated from 
lysates generated from cells transfected with either cofactor was greater than 
endogenous activity suggesting Cdk5 is present in the HeLa cells, but by far the 
greatest Cdk5 activity was obtained in lysates from cells transfected with both kinase 
and cofactor (Figure 4.3). This suggests that the endogenous level of Cdk5 is much 
lower than that following transfection of the Cdk5 expression vector. Unfortunately, 
when potential Cdk5 substrates were co-transfected with only p35 or p25, there was 
no enhancement of substrate phosphorylation detected (data not shown). This could 
be due to the very low level of kinase activity in cells transfected with p35 and p25 in 
the absence of Cdk5 or, alternatively, it could mean that these are not truly Cdk5 
substrates. Therefore, triple-transfections were attempted, this time using the HeLa 
cell system in an attempt to distinguish between these two possibilities.   
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Figure 4.3. Kinase activity is dramatically greater following overexpression of Cdk5 and cofactors 
compared to cofactors alone. Mammalian constructs containing cDNA for Cdk5 and either p35 or p25 
were co-transfected into HeLa cells using calcium phosphate. Successful overexpression was 
confirmed by Western blot analysis before Cdk5 complexes were immunoprecipitated using an 
antibody to anti-p35/25 and pull-down efficiency determined by immunoblotting. Specific activity of 
each complex was determined by means of in vitro kinase assay using MBP as substrate. The degree of 
phosphate transfer was measured by scintillation counting and used to calculate the specific activity 
(pmol/min). Data expressed as mean + S.E.M, n = 2. 
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4.2.1.2.2 Overexpression of Cdk5, cofactor, and substrate in HeLa cells 
Previously, triple transfections in HEK293 cells using calcium phosphate proved 
problematic therefore in an attempt to increase the efficiency of triple transfections in 
HeLa cells, the method of transfection was altered from calcium phosphate to 
Lipofectamine (refer to methods, section 2.2.4.2). 
 
HeLa cells were plated around 24 hrs prior to transfection to enable the cells to reach 
around 60% confluency. Subsequently, expression vectors for multiple constructs 
(refer to methods, section 2.2.4.3) were transfected into HeLa cells along with Cdk5 
and either activator using Lipofectamine. Total DNA in transfections was equalised 
by including empty vector plasmids where appropriate. 
 
As with the HEK293 system transfection of three plasmids interfered with the 
overexpression of at least one of the proteins of interest. This mostly affected 
overexpression of the substrate where overexpression was much greater in the 
substrate alone transfections and minimal in the triple transfections, as was the case 
with Mef2a and PAK1 (Figure 4.4A-B), or where overexpression either failed 
completely, as was the case with dynamin 1 and STAT3 (data not shown, the 
constructs were both FLAG-tagged though not detected by the FLAG antibody 
therefore these blots are not shown in Figure 4.4C-D). Additionally, overexpression 
of p25 protein appeared to be dramatically greater compared to p35 overexpression. 
 
Of all the potential Cdk5 substrates investigated by triple transfection in HeLa cells, 
only CRMP2 and tau overexpressed to a robust level when co-expressed with Cdk5 
and a cofactor therefore these are described in greater detail in the next section. 
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Figure 4.4. Triple transfections in HeLa cells results in Cdk5 and cofactor overexpression but 
overexpression of substrate is affected.  HeLa cells were transfected with equal amounts of expression 
constructs for Cdk5, p35 or p25, and substrate of interest to assess Cdk5 phosphorylation of A) Mef2a, 
B) PAK1, C) Dynamin 1, and D) STAT3. Subsequently, cells were lysed, subjected to SDS-PAGE, and 
successful overexpression was determined by Western blot analysis. 
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4.2.1.2.2.1 Co-expression of CRMP2, Cdk5, and cofactors results in 
increased phosphorylation of Ser 522  
The major Cdk5 phosphorylation site on both CRMP2 and CRMP4 was previously 
reported as Ser522 following in vitro analysis experiments (Cole et al., 2004). In 
order to assess these substrates in intact cells and additionally investigate potential 
differences between p35 and p25 regulation of this target, HeLa cells were transfected 
with Cdk5, either cofactor, and CRMP2 or CRMP4.  
 
Transfection reactions were performed at around 60% confluency using 
Lipofectamine (refer to methods, section 2.2.4.2). Cells were harvested after 24 hrs 
and protein expression was confirmed using Western blot analysis (Figure 4.5A, D). 
In the single transfection reaction, expression of either CRMP2 or CRMP4 was 
slightly greater compared to triple transfected cells. In cells where Cdk5 was 
overexpressed with CRMP2, an increase in pCRMP2 Ser522 was observed compared 
to the CRMP2 alone control, confirming that overexpressed Cdk5 results in increased 
phosphorylation of this site (Figure 4.5B). Conversely, Ser522 of CRMP4 was 
phosphorylated when expressed in HeLa cells, even though there is little Cdk5 
activity, and co-expressing Cdk5/cofactor did not increase CRMP4 Ser522 
phosphorylation suggesting that this site is either not an in vivo target of Cdk5 or is 
fully phosphorylated by endogenous Cdk5 kinase (Figure 4.5C). This observation is 
consistent with previous work in a Cdk5 knockout mouse from our lab indicating that 
Cdk5 is required for regulation of CRMP2 but not CRMP4 in vivo (Cole et al., 2006). 
In general, the degree of phosphorylation of CRMP2 was greater with p25 expression 
however expression of p25 was greater than that of p35 in these experiments. This 
may account for differences in CRMP2 phosphorylation between complexes.    
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Figure 4.5. Overexpression of Cdk5 complexes results in increased Ser522 phosphorylation in 
CRMP2 but not CRMP4. HeLa cells were transfected with equal amounts of expression constructs for 
Cdk5, p35 or p25, and CRMP2 or CRMP4. Cells were lysed, subjected to SDS-PAGE, and A) Western 
blot analysis establishing successful overexpression. B-D) Quantification was performed using Licor 
software. Data expressed as mean + SEM, n = 6. Data was analysed by one-way ANOVA with Tukey’s 
post hoc test, *p<0.05. 
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4.2.1.2.2.2 Overexpression of Cdk5, cofactor and tau resulted in increased 
phosphorylation of tau at Ser 202, Thr 205, and Ser 235  
In the previous chapter, phospho-mapping of phosphorylated tau identified Ser235 as 
the major Cdk5 phosphorylation site on tau, with potential minor sites at Ser202 and 
Thr205 (Chapter 3, Figure 3.18). To confirm that Cdk5 phosphorylates these sites in 
a cell system and to investigate the contributions of cofactors, an expression vector for 
tau was co-transfected along with Cdk5 and cofactor expression constructs in HeLa 
cells, as with CRMPs above. 
 
Transfection reactions were performed at around 60% confluency using 
Lipofectamine (refer to methods, section 2.2.4.2) and cells harvested after 24 hrs. 
Protein overexpression of tau, Cdk5 and cofactors was confirmed by Western blot 
analysis, as was the effect of Cdk5 phosphorylation of tau at residues Ser202, Thr205, 
and Ser235 using phospho-specific antibodies to each of these sites (Figure 4.6A).  
 
In the single transfection reaction, overexpression of tau was slightly greater 
compared to the triple transfected cells. In cells where Cdk5 was overexpressed with 
tau, an increase in phosphorylation of tau was observed at sites Ser202, Thr205, and 
Ser235 confirming these are potential Cdk5 phosphorylation sites in intact cells. 
There was not a significant difference in tau phosphorylation at any of the sites when 
p25 expression was compared to p35 expression data suggesting each complex was 
equally able to induce phosphorylation of this substrate. 
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Figure 4.6. Overexpression of Cdk5 complexes results in increased phosphorylation of Tau. HeLa 
cells were transfected with equal amounts of expression constructs for Cdk5, p35 or p25, and tau. Cells 
were lysed, subjected to SDS-PAGE, and A) Western blot analysis which confirmed successful 
overexpression. B-D) Quantification was performed using Licor software and the ratio between 
phospho-tau: total tau calculated for each phospho-tau antibody. Data expressed as mean + SEM, n = 6. 
Data was analysed by one-way ANOVA with Tukey’s post hoc test, *p<0.05, **p<0.01. 
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4.2.1.2.3 Cdk5 inhibitors, purvalanol A and roscovitine, are toxic to HeLa 
cells after transfection using Lipofectamine 
Following overexpression of Cdk5 activity, the effect of inhibition of endogenous 
Cdk5 activity on substrate phosphorylation in HeLa cells was subsequently 
investigated. HeLa cells were transfected with substrates, as described in the previous 
sections, before transfection media was removed and cells incubated for 24 hrs to 
allow protein overexpression. Subsequently, serum-containing media was removed 
from the transfected cells and replaced with media containing either purvalanol A or 
roscovitine (both at 10 µM final concentration) to inhibit endogenous Cdk5 activity. 
However, cell death was apparent within 1 hr of inhibitor treatment on transfected 
cells, therefore the effect of Cdk5 inhibition on overexpressed substrate 
phosphorylation could not be assessed. Inhibitor concentration was lowered to 1 µM 
however this still proved toxic to transfected cells.   
 
4.2.1.3 Examining substrate phosphorylation following Cdk5 inhibition in 
primary neuronal cells 
Primary neuronal cultures derived from rodents are commonly used to study basic 
physiological properties of neurons and, as such, present a useful tool in which to 
study the effect of kinase inhibition on protein phosphorylation. Cdk5 is primarily 
active in post-mitotic neurons therefore primary cortical neurons were used to study 
the effect of inhibition of Cdk5 activity on the phosphorylation of substrates identified 
in vitro in the previous chapter.  
 
The primary cortical neuron cultures used in the following experiments were cultured 
and donated by Dr. Ritchie Williamson, University of Bradford, as described in 
Chapter 2, section 2.2.3.4. 
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4.2.1.3.1 Phosphorylation of CRMP2 at Ser522 but not CRMP4 is reduced in 
primary neurons following Cdk5 inhibition 
Both CRMP2 and CRMP4 are phosphorylated by Cdk5 in vitro (Section 3.2.3.1) 
however only CRMP2 was phosphorylated at Ser522 in cells overexpressing each 
CRMP isoform and active Cdk5 complex (Figure 4.5). Therefore, this site was 
examined in primary neurons following inhibition of endogenous Cdk5 activity.  
 
Following cell suspension preparation (refer to methods, 2.2.3.4), cells were 
maintained in DMEM/F12 culture medium to enable maturation and differentiation. 
Cultures following 6 days in vitro (DIV) were treated with purvalanol A (10 µM final 
concentration) for 3 hrs to inhibit Cdk5 activity, with 0.1% DMSO as vehicle. After 3 
hrs treatment with purvalanol A, cells were fixed for a duration of 3 min with 4% 
(w/v) formaldehyde solution, washed three times with 500 µL PBS then subjected to 
phospho-specific antibody staining to determine the effect of Cdk5 inhibition on 
CRMP2 and CRMP4 phosphorylation. Cells were initially incubated with either an 
anti-pCRMP2 Ser522 or anti-CRMP4 Ser522 antibody followed by incubation with a 
fluorophore-conjugated antibody to mouse IgG (Cys3, absorption 543 nm = red) and 
counter-stained with the DNA-binding dye DAPI (absorption 350 nm = blue) to label 
nuclei. Cells were then mounted and viewed with an automated confocal microscope 
(Figure 4.7).   
 
In the vehicle-treated controls, phosphorylation of CRMP2 and CRMP4 at Ser522 
was apparent throughout the cell body and axons. Treatment with purvalanol A 
resulted in a complete loss of phosphorylated CRMP2 (Figure 4.7A). Conversely, 
pCRMP4 Ser522 immunopositive staining was still apparent in the cell body and 
axons of primary neurons treated with purvalanol A (Figure 4.7B).  
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Figure 4.7. Purvalanol A treatment reduces Cdk5 phosphorylation of CRMP2 but not CRMP4 at 
Ser522. Primary cortical neurons were cultured for 6 days in vitro (6 DIV) then treated with 10 µM 
purvalanol A or vehicle (0.1% DMSO) for 3 hrs prior to fixation, permeabolisation, and staining with 
phospho-specific antibodies to A) pCRMP2 Ser522 and B) pCRMP4 Ser522. Phospho-specific 
antibodies were detected by Cy-3 bound secondary antibodies (red) and nuclei were counter-stained 
with the DNA-binding dye DAPI (blue). Scale bar = 60 µm. 
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4.2.1.3.2 Phosphorylation of Tau is reduced following Cdk5 inhibition 
Phospho-mapping of tau phosphorylated by Cdk5 in vitro identified Ser235 as the 
major Cdk5 phosphorylation site on tau with minor sites at Ser202 and Thr205 
(Section 3.2.3.1). Phosphorylation of each of these sites was increased following 
overexpression of tau protein and active Cdk5 complexes (Figure 4.6). Therefore, 
these sites were investigated in primary neurons following Cdk5 inhibition. 
 
Primary neurons were treated with purvalanol A as described previously for both 
CRMP2 and CRMP4. Subsequent to washing in PBS, cells were incubated with 
phospho-antibodies specific to either anti-pTau Ser202, anti-pTau Thr205 or anti-
pTau Ser235 followed by incubation with a fluorophore-conjugated antibody to rabbit 
IgG (Cys3, absorption 543 nm = red) and then counter-stained with DAPI to label 
nuclei (absorption 350 nm = blue). Cells were then mounted and viewed with an 
automated confocal microscope (Figure 4.8). 
 
Staining was apparent throughout the cell body and axons of primary neurons treated 
with vehicle (Figure 4.8). Following inhibitor treatment, a slight reduction in the 
number of pTau Ser202 immunopositive cells was observed (Figure 4.8A). The 
number of pTau Thr205 immunopositive cells was reduced to a greater extent 
following purvalanol A treatment, with a weaker signal observed in the cell body and 
axons of the primary neurons compared to vehicle treatment (Figure 4.8B). Staining 
of primary neurons with pTau Ser235 appeared weaker when treated with inhibitor 
however staining using this antibody was weak in vehicle cells (Figure 4.8C). This 
was also the case with the HeLa cells were Ser235 only became phosphorylated when 
Cdk5 was co-expressed (Figure 4.6). 
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Figure 4.8. Purvalanol A treatment reduces Cdk5 phosphorylation of tau. Primary cortical neurons 
were cultured for 6 days in vitro (6 DIV) and then treated with 10 µM purvalanol A or vehicle (0.1% 
DMSO) for 3 hrs prior to fixation, permeabolisation, and staining with phospho-specific antibodies to 
A) pTau Ser202, B) pTau Thr205, and C) pTau Ser235. Phospho-specific were detected by Cy-3 bound 
secondary antibodies (red) and nuclei were counter-stained with the DNA-binding dye DAPI (blue). 
Scale bar = 60 µm. 
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4.2.2 Assessing Cdk5 substrate phosphorylation in human tumours 
Treatment of primary neurons with purvalanol A gave promising results that both 
CRMP2 and tau were physiological substrates of Cdk5 that could be monitored by 
immunohistochemistry (IHC). This suggested that these antibodies might be suitable 
to screen human tumours to examine Cdk5 substrate phosphorylation during 
tumourigenesis therefore they underwent preliminary antibody optimisation for IHC.  
 
4.2.2.1 Antibody Optimisation for Immunohistochemistry 
To ensure accurate interpretation of immunohistochemistry results, the following 
controls were performed to demonstrate that the specific antigens were localised to 
the correct specialised tissues, cell types, or subcellular localisation. Optimisation of 
fixation, blocking, antibody incubation, and antigen retrieval steps improves the 
chances of a strong and specific signal. IHC characterisation requires appropriate 
positive and negative controls to support the validity of staining observed and identify 
experimental artefacts. Figure 4.9 shows a schematic representation of the antibody 
validation process.   
 
As substrate phosphorylation could be reduced following Cdk5 inhibition with 
purvalanol A (section 4.2.1.3), primary neurons were used for the initial antibody 
validation to establish compatibility with the IHC protocol. Primary neuron cultures 
(6 DIV) were embedded in paraffin and sectioned as described in Chapter 2, sections 
2.2.10.1 – 2.2.10.2. The antibody panel (including total CRMP2, pCRMP2 Ser522, 
total tau, pTau Ser235, pTau Ser202 and Ser205) to be used for assessing Cdk5 
substrate phosphorylation in human tumours underwent stepwise rounds of 
optimisation and validation, as depicted in Figure 4.9. 
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Figure 4.9. Schematic representation of stepwise antibody validation. A) Antibody panel composed 
of phospho-specific and total protein antibodies for validation. B) Initially, antibodies undergo either 
no antigen retrieval step (see text for definition) or antigen retrieval using citrate buffer. Antibodies that 
failed the IHC protocol would be eliminated at this point. C) Several dilutions would be performed to 
optimise optimal antibody concentration, evident by optimal antibody staining. D) Phospho-specific 
antibodies would then be characterised by observing the effect of Cdk5 inhibitor treatment on 
immunostaining of primary cortical neurons. 
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4.2.2.2 Antigen Retrieval Optimisation 
For preservation of tissue morphology it is essential that fixation of the tissue is 
performed however this process can have a negative impact on IHC detection. The 
fixation process can alter protein biochemistry and, as a result, the epitope of interest 
may become masked thereby preventing binding of the primary antibody. This may 
be due to cross-linking of amino acids within the epitope, cross-linking of unrelated 
peptides at or near the epitope, alteration of the electrostatic charge of the antigen, or 
alteration of the conformation of the epitope. Antigen retrieval refers to any technique 
in which masking of an epitope is reversed and epitope-antibody binding is restored. 
The requirement for antigen retrieval is dependent on multiple variables including, but 
not limited to, tissue type, method and duration of fixation, antibody, and the target 
antigen therefore this technique must be investigated for each individual antibody 
prior to staining of tissue.  
 
During the initial round of antibody screening, all antibodies in the antibody panel 
(Table 4.1) went through either the antigen retrieval step or the IHC protocol omitting 
the antigen retrieval step to establish the requirement for antigen retrieval for each 
antibody. Briefly, during the antigen retrieval step, sections were placed in boiling 
citrate buffer (pH 6.0) and heated in a microwavable oven for 15 min before being 
allowed to cool at room temperature for 30 min and subsequently incubated with each 
antibody in the antibody panel. Following this initial round of screening, it was 
apparent that all of the antibodies tested favoured the antigen retrieval step (Table 
4.1), expressing better staining after antigen retrieval. Following this, all antibodies 
used in the subsequent experiments were subjected to the antigen retrieval step prior 
to antibody incubations during immunohistochemical staining of tissue.   
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Protein 
 
 
Residues 
Surrounding 
 
 
Source 
 
 
Antibody 
 
 
Detects 
 
Antigen 
Retrieval 
by HIER 
 
 
CRMP2 
 
 
total protein 
 
 
Sheep 
 
 
Polyclonal 
 
Recognises phosphorylated 
and unphosphorylated human, 
mouse and rat CRMP2 protein 
 
 
Yes 
 
 
pCRMP2 
Ser522 
 
 
Ser 522 
 
 
Sheep 
 
 
Polyclonal 
 
Recognises human, mouse, 
and rat CRMP2 protein 
phosphorylated at Ser 522 
 
Yes 
 
 
Tau 
 
 
total protein 
 
 
Rabbit 
 
 
Polyclonal 
 
Reacts with phosphorylated 
and non-phosphorylated forms 
of human, mouse and rat tau 
 
 
Yes 
 
 
pTau 
Ser235 
 
 
Ser 235 
 
 
Rabbit 
 
 
Monoclonal 
 
Detects human, mouse and rat 
tau phosphorylated at 
threonine residue 235 
 
 
Yes 
 
 
pTau 
Thr205 
 
 
Thr 205 
 
 
Rabbit 
 
 
Polyclonal 
 
Detects human, mouse and rat 
tau phosphorylated at 
threonine residue 205  
 
 
Yes 
 
 
Cdk5 
 
 
total protein 
 
 
Rabbit 
 
 
Polyclonal 
 
Antibody detects Cdk5 protein 
of mouse, rat and human 
origin 
 
 
Yes 
 
 
p35/p25 
 
 
total protein 
 
 
Rabbit 
 
 
Polyclonal 
 
Detection of p25 and p35 
regulatory subunits of Cdk5 of 
mouse, rat and human origin 
 
 
 
Yes 
 
 
Table 4.1. Antibodies to assess Cdk5 substrate phosphorylation by IHC require antigen retrieval by 
heat induced epitope retrieval (HIER). Optimised antigen retrieval conditions with antibody 
specificity information.  
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4.2.2.3 Optimal Antibody Concentrations 
In the previous validation studies, all antibodies tested displayed compatibility with 
IHC on primary neurons and were shown to favour antigen retrieval. Subsequently, 
the optimal antibody concentration was determined for each of these antibodies prior 
to screening of human tissue. Heat induced epitope retrieval (HIER) was performed 
before each antibody was incubated on sections of primary neurons in stepwise 
increases to determine the optimal antibody dilution for IHC. Initially, antibody 
dilutions were preformed at 1:333 followed by increases in the dilutions from 1:1000 
to 1:3000 to 1:9000.   
 
Following the initial dilution series, sections were examined under a light microscope 
to assess the level of staining and the requirement of additional dilutions based on the 
level of staining observed. The following antibodies: pCRMP2 Ser522, total tau, and 
pTau Thr205 showed strong staining at all concentrations above 1:3000 however the 
staining became weaker at a dilution of 1:9000, therefore several dilutions were 
preformed between this range to determine the optimal antibody concentration. 
Intense staining was observed for pTau Ser235 at all antibody dilutions therefore 
further dilutions of up to 1:20,000 were preformed with this antibody to establish 
optimal conditions. Good staining was seen for the p35/p25 antibody for dilutions of 
1:1000 and 1:3000 therefore a dilution of 1:2000 was performed to dictate the 
antibody dilution used for IHC. The final two antibodies to be optimised, Cdk5 and 
total CRMP2, both showed weak staining at all antibodies dilutions with the most 
intense staining observed at a dilution of 1:333. The final antibody dilutions that were 
selected for IHC can be found in Table 4.2.  
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Antibody 
 
Dilution Series 1 
 
Dilution Series 2 
 
Final Concentration for IHC 
 
 
Total CRMP2 
1:333  
1:100 
 
1:250 1:1000 
1:3000 1:250 
1:9000 
 
pCRMP2 Ser522 
1:333  
1:4000 
 
1:5000 1:1000 
1:3000 1:6000 
1:9000 
 
Total Tau 
1:333  
1:4000 
 
1:5000 1:1000 
1:3000 1:6000 
1:9000 
 
pTau Ser235 
1:333  
1:15 000 
 
1:20 000 1:1000 
1:3000 1:20 000 
1:9000 
 
pTau Thr205 
1:333  
1:4000 
 
1:5000 1:1000 
1:3000 1:6000 
1:9000 
 
Total Cdk5 
1:333  
1:100 
 
1:250 1:1000 
1:3000 1:250 
1:9000 
 
Total p35/p25 
1:333  
1:2000 
 
1:2000 1:1000 
1:3000 1:2500 
1:9000 
 
 
Table 4.2. Optimised antibody concentrations selected for IHC. Dilution series for antibodies used to 
assess Cdk5 substrate phosphorylation using IHC. Initial dilutions were performed at 1:333, 1:1000, 
1:3000, and 1:9000, followed by a second round of dilutions, before reaching an optimal antibody 
concentration.  
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4.2.2.4 Validation of Phospho-Specific antibodies 
The three phospho-specific antibodies (pCRMP2 Ser522, pTau Ser235 and pTau 
Thr205) that showed Cdk5 inhibitor sensitive staining in fixed primary neurons were 
used to interrogate the embedded neurons. To assess their ability to detect the 
phosphorylated peptide and validate each antibody as phospho-specific for use in 
IHC, primary neurons were treated at 6 DIV with either 10 µM purvalanol A, 10 µM 
roscovitine, or DMSO vehicle for 3 hrs to inhibit Cdk5 activity. After treatment, the 
cultures were fixed in formaldehyde solution and then embedded in paraffin (refer to 
methods, section 2.2.10.1). Subsequently, sections were taken from the paraffin block 
and incubated with each of the phospho-specific antibodies. Negative controls were 
also performed in which the sections were incubated with antibody diluent, without 
the primary antibody, followed by secondary antibody incubation. 
 
Subsequent to examination of immunopositive staining under a light microscope, 
antibodies were classified into two groups: antibodies for which the staining was 
reduced or lost upon inhibitor treatment (passed); or, antibodies that did not show 
reduction of staining (failed) (Figure 4.10). There was not an apparent loss or 
reduction in staining with the pTau Thr205 antibody between control and inhibitor 
treated neurons therefore this antibody was not a good measure of Cdk5 activity and 
was not taken further. There was a slight reduction in the number of primary neurons 
stained with the pTau Ser235 antibody when treated with inhibitors however the 
intensity of the stain was not reduced and therefore this antibody did not pass the 
validation step. Staining of inhibitor treated neurons with the pCRMP2 Ser522 
antibody was less intense and a reduction in the number of immunopositive cells was 
apparent, compared to vehicle treated neurons, therefore this antibody was passed for 
IHC use with human tumour samples. 
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Figure 4.10. Cdk5 inhibition reduces pCRMP2 Ser522 immunostaining in primary cortical neurons. 
Primary cortical neuron cultures (6 DIV) were treated with either 10 µM purvalanol A, 10 µM 
roscovitine, or vehicle (0.1% DMSO) for 3 hrs. Subsequently, cultures were fixed in formaldehyde 
solution and then embedded in paraffin. Sections were taken from each paraffin block and incubated 
with phospho-specific antibodies to anti-pTau Thr205, pTau Ser235, and pCRMP2 Ser522 followed by 
biotinylated secondary antibodies and then streptavidin complexed with biotinylated peroxidases which 
were visualised using DAB chromagen. Cell nuclei were counterstained with hematoxylin and mounted 
in DPX. Antibodies were then classified as passed or failed dependent on the observed staining pattern. 
Images were taken at a magnification of x 20. Scale bar = 100 µm. 
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4.2.2.5 Cdk5 substrate phosphorylation in lung carcinomas 
As described in Chapter 1, downregulation of a CRMP isoform was associated with 
poor clinical outcome in lung cancer (Shih et al., 2001), therefore investigation of 
Cdk5 substrate phosphorylation was initiated in lung carcinoma as CRMP2 was the 
major substrate under investigation. Lung tumour biopsies used in the following 
experiments were sectioned and provided by Dr. Phil Coates, Tayside Tissue Bank, 
University of Dundee.  
 
Lung biopsies from 21 different NSCLC patients were obtained and immunostained 
using antibodies to anti-Cdk5 (total) and anti-p35/p25 (total) to confirm the presence 
of both Cdk5 and its cofactors in lung tissue (Figure 4.11). Additionally, tissue 
sections were stained with an antibody to anti-CRMP2 (total) to establish expression 
of CRMP2 protein in lung tissue and, also, a phospho-specific antibody to anti-
pCRMP Ser522 in order to compare the expression and degree of CRMP2 
phosphorylation between normal and tumour tissue (Figure 4.11). Tissue section 
staining was performed as described in Chapter 2.2.10.3. 
 
Tau was previously confirmed as a Cdk5 substrate therefore lung biopsies was also 
stained using an antibody to anti-tau (total). Although the pTau Ser235 antibody did 
not fully pass the previous phospho-specific antibody IHC validation, it was included 
in this investigation with the total tau antibody as a potential read-out of Cdk5 activity 
in lung tumour cells as there was a slight reduction in pTau Ser235 immunopositive 
staining with inhibitor. Once again, these tissue sections were stained as described in 
Chapter 2.2.10.3. 
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Figure 4.11. Representative images of phosphorylated CRMP2 protein expression in lung tumour 
biopsies. Tissue sections were immunostained with antibodies to anti-CRMP2 (total), anti-pCRMP2 
Ser522, anti-Cdk5, and anti-p35/p25. Degree of staining was graded using a semi-quantitative scale 
from 0-3, with 0 representing no staining, 1 representing light brown staining, 2 representing moderate 
brown staining and 3 representing dark brown staining. Scores of 2 or 3 were interpreted as high 
expression. Images were taken at a magnification of x 20. Scale bar = 100 µm. 
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The immunostained tissue sections were independently assessed by two investigators 
(Professor Frank Carey and Dr Yvonne Woods, Department of Pathology, Ninewells 
Hospital) and the degree of staining was graded using a semi-quantitative scale from 
0-3, with 0 representing no staining, 1 representing light brown staining, 2 
representing moderate brown staining, and 3 representing dark brown staining (Table 
4.3). Those with scores of 2 or 3 were interpreted as high expression. 
 
Unfortunately, staining was not robust enough with the Cdk5, p35/p25, and total 
CRMP2 antibodies to make significant conclusions on the data with these antibodies 
(Figure 4.11). Interestingly, however, immunopositive staining with the pCRMP2 
Ser522 antibody was consistently enriched in the nuclei of tumour cells while no 
staining was detected in healthy tissue from the same biopsies (Figure 4.11).  
 
Despite detectable immunopositive staining, the pattern of staining with the tau 
antibody was unclear which made interpretation of results difficult with this antibody. 
Additionally, interpretation of results with the pTau Ser235 phospho-specific antibody 
was difficult as staining was relatively low using this antibody therefore both 
antibodies were not included in further analyses.  
 
Of potential clinical interest, pCRMP2 Ser522 immunopositive staining appeared 
more robust in squamous cell carcinoma (8/11 with a score of 2 or 3, average score = 
1.91) than within the adenocarcinoma tumour biopsies (5 biopsies, none with score 3, 
average score = 1.8) in this preliminary analysis (Figure 4.12). Nonetheless, the 
numbers of adenocarcinoma biopsies were relatively low in comparison to squamous 
cell carcinoma biopsies and therefore this result is not conclusive.  
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Table 4.3. Evaluation of immunohistochemistry. Immunostained biopsies were graded using a semi-
quantitative scale from 0-3, with 0 representing no staining, 1 representing light brown staining, 2 
representing moderate brown staining and 3 representing dark brown staining. Scores of 2 or 3 were 
interpreted as high expression, n = nuclear, c = cytoplasmic and t = more in tumour than healthy tissue. 
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Figure 4.12. Immunohistochemistry staining scores of lung tumour biopsies. Immunohistochemical 
staining of squamous cell carcinoma (SCC), adenocarcinoma (ADC), and other lung tumour biopsies 
was graded using a semi-quantitative scale from 0-3, with 0 representing no staining, 1 representing 
light brown staining, 2 representing moderate brown staining and 3 representing dark brown staining. 
Scores of 2 or 3 were interpreted as high expression. Data expressed as + SEM and the number of 
patient biopsies (n) is presented on the graph. 
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4.2.2.6 Further analysis of pCRMP2 staining in squamous cell carcinoma 
and adenocarcinoma 
Following the observation of a potential variation in pCRMP2 Ser522 expression 
between squamous cell carcinoma and adenocarcinoma, an additional 18 lung tumour 
biopsies were obtained, containing roughly equal numbers of both tumour types, in 
order to compare histologically graded staining between adenocarcinoma and 
squamous cell carcinoma. In addition, a squamous carcinoma from skin was included 
in this analysis as squamous lung carcinoma is histologically different from squamous 
carcinoma sourced from other areas of the body. 
 
Tissue sections were obtained from Dr. Phil Coates, Tayside Tissue Bank, University 
of Dundee. As described previously, the biopsies were stained using the phospho-
specific pCRMP2 Ser522 antibody and evaluated independently by two investigators 
(Professor Frank Carey and Dr Yvonne Woods, Department of Pathology, Ninewells 
Hospital). The degree of staining was graded using a semi-quantitative scale as 
described previously (refer to section 4.2.2.5).  
 
Consistent with the preliminary observation, phosphorylated CRMP2 was 
predominantly localised in the nuclei of lung cancer cells and, importantly, absent in 
healthy tissue thereby confirming the unusual nuclear localisation and association 
with tumourigenesis (Figure 4.13A). Once more, immunostaining was detected in 
both cancer types however CRMP2 phosphorylation was of a significantly higher 
intensity in squamous cell carcinoma compared to adenocarcinoma immunostaining 
(Figure 4.13B-C). 
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Figure 4.13. Phosphorylation of CRMP2 by Cdk5 is stained more intensity in squamous cell 
carcinoma compared to adenocarcinoma. A) Representative histology for adenocarcinoma and 
squamous cell carcinoma biopsies immunostained with pCRMP2 Ser522 antibody. Scale bar = 50 µm. 
B) Quantification of the average scores (from two independent pathologists) for pCRMP2 Ser522 
immunostaining of adenocarcinoma (ADC) and squamous cell carcinoma (SCC) tumours. Data shown 
as mean + S.E.M, n = 9 (ADC), 9 (SCC), t-test, **p<0.01. C) Quantification of individual scores for 
pCRMP2 Ser522 staining of adenocarcinoma (ADC) and squamous cell carcinoma (SCC) tumours. 
Data shown as mean + S.E.M, n = 9 (ADC), 9 (SCC), t-test, *p<0.05. 
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4.2.2.7 How widespread is the abnormal pCRMP2 Ser522 in cancer? 
The strong positive staining of lung tumour tissue with the pCRMP2 Ser522 antibody 
prompted a more general assessment of the reactivity of this antibody in different 
types of cancer using tissue microarrays (TMA) of human tumours, generated by Dr. 
Phil Coates in the Tayside Tissue Bank. Further optimisation and validation of 
antibodies was performed for use on the TMA platform.  
 
4.2.2.7.1 Antibody staining in whole embryo 
Prior to investigating which tumour types may exhibit pCRMP2 Ser522 staining, the 
tissue expression profile of CRMP2 and pCRMP2 Ser522 was examined in embryos 
from healthy animals. Unfortunately, as shown earlier, in contrast to work with rat 
primary neurons, the total CRMP2 antibody exhibited high background staining in 
human lung tissue. As it would be informative to have data on total CRMP2 
expression, an alternative CRMP2 antibody was sourced (Cell Signaling) and 
subjected to the antibody optimisation protocol as described previously (refer to 
sections 4.2.2.1 – 4.2.2.3). This antibody required antigen retrieval and was used at a 
concentration of 1:1000. Both CRMP2 antibodies were screened against whole 
sagittal sections of a rat fetus (for further optimisation and to establish antibody 
specificity prior to screening human tumours).  
 
Once more, the original total CRMP2 antibody (DSTT) exhibited high levels of 
background and the staining pattern was therefore not clear (Figure 4.14A). 
Negligible staining was observed with the second CRMP2 antibody (Cell Signaling) 
other than around the brain tissue (Figure 4.14C-D), which may question the 
specificity of the original CRMP2 antibody. This does suggest that the CRMP2 whole 
protein antibodies may only be of use in brain sections. 
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Figure 4.14. Total CRMP2 antibodies show a lack of tissue specificity. Rat fetus sections were 
incubated with antibodies to A) anti-CRMP2 (DSTT) and B) anti-CRMP2 (Cell Signaling), and C-D) 
corresponding negative controls. Subsequently, sections were incubated with biotinylated secondary 
antibodies followed by streptavidin complexed with biotinylated peroxidases that were visualised using 
brown DAB chromagen. Scale bar = 100 mm. 
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4.2.2.5.2 Tissue specificity of pCRMP2 S522 antibody 
To further investigate tissue specificity of the pCRMP2 Ser522 antibody, staining was 
examined in healthy rat tissue from regions that would be analysed during the planned 
tumour TMA screen. Tissue sections were provided by Dr. Phil Coates, Tayside 
Tissue Bank, University of Dundee.  
 
Sections consisting of ovary, prostate, lung, skin, thymus, and stomach tissue from 
healthy adult rats were immunostained using the pCRMP2 Ser522 phospho-specific 
antibody as described in Chapter 2, section 2.2.10.3.  
 
The pattern of pCRMP2 Ser522 antibody immunostaining appeared to be sporadic 
(Figure 4.15). Immunopositive staining was observed in the follicular cells of the 
ovary and strong staining was also apparent in the corpus luteum. The prostate 
displayed a high level, and possibly artefactual staining, around the periphery of the 
tissue, which made interpretation of results difficult. However, a degree of 
immunopositive staining was observed in some neurons. Within lung tissue, 
immunopositive staining appeared scattered throughout alveolar cells and positive 
staining was also observed in the occasional bronchus cell, the cells in which lung 
cancer is believed to originate. Staining with the pCRMP2 Ser522 antibody was 
negative in lymphocytes in the white pulp of the spleen however immunopositive 
staining was seen in myeloid cells present in the red pulp. Skin was mainly negative 
for pCRMP2 Ser522 expression however immunopositive staining was observed in 
some proliferative cells, including the basal cells of the epithelium and hair follicles. 
Finally, high intensity staining was observed in epithelial cells that line the stomach.   
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Figure 4.15. Immunohistochemical staining of rat tissue with a phospho-specific pCRMP2 Ser522 
antibody. Following immunostaining of ovary, prostate, lung, spleen, skin, and stomach sections, 
bound primary pCRMP2 Ser522 was detected using VECTASTAIN® ABC system (Vector 
Laboratories) and visualised using DAB chromagen. Nuclei were counterstained with hematoxylin. 
Images were taken with Olympus x20/0.75NA objectives on an Aperio ImageScope (Aperio 
Technologies, California, USA), with a magnified image (at x20 zoom) of the same. Scale bar = 1 mm 
and 100 µm (inset). 
 
O
va
ria
n 
pCRMP2 Ser522 Negative 
P
ro
st
at
e 
Lu
ng
 
S
pl
ee
n 
S
ki
n 
S
to
m
ac
h 
1 mm 100 µm 1 mm 100 µm 
	  
 
___________________________________________________________________________________ 
 
4. Validating tools to assess Cdk5 substrate phosphorylation in cancer 
215	  
4.2.2.8 Assessing phosphorylation of CRMP2 in human tumours by means 
of Tumour Microarray (TMA)  
Tissue microarrays enable the simultaneous analysis of multiple tissue specimens for 
a large number of markers. Similarly, the TMA technique can be applied to multiple 
selected cancers (Tumour Microarray), where these are gathered into a single paraffin 
block prior to sectioning, mounting, and screening using IHC. TMAs available for 
analysis of CRMP2 phosphorylation included a range of human tumours, such as 
colorectal adenoma, prostate, renal, ovarian cancer, and follicular lymphoma. 
 
TMA sections were stained using an antibody to anti-pCRMP2 Ser522 and visualised 
using DAB chromagen, as described in Chapter 2, sections 2.2.10.3 – 2.2.10.5. The 
immunohistochemical stained sections were graded by Dr. Phil Coates, Tayside 
Tissue Bank, University of Dundee. The degree of immunohistochemical staining was 
assessed using quick score categories that were based on both the intensity and the 
proportion of brown staining: the proportion of malignant cells staining positively 
throughout the section was assigned scores from 1-6 (1 = >0-5%; 2 = 6-20%; 3 = 21-
40%; 4 = 41-60%; 5 = 61-80%; 6 = 81-100%) and termed Category A; the average 
intensity in malignant cells was scored as 0, 1, 2, or 3, corresponding to the presence 
of negative, weak, moderate, and strong brown staining, respectively, and termed 
Category B. Negative cores were scored zero whereas positive cores were allocated 
Category A and Category B scores to form an additive quick score result. The 
observed immunohistochemical expression is depicted in TMA tissue cores punched 
from different locations on the tumour (four sample cores from each patient) (Figure 
4.16, as an example of DLBCL scores). In the event that sample cores did not contain 
tumour cells, this was excluded from the analysis as an unrepresentative sample. A 
tumour sample was considered negative when all sample cores were negative, 
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whereas > 2 positive cores was considered a positive result. The results of pCRMP2 
Ser522 immunohistochemical staining are presented in Figure 4.17. 	  
 
There was only a single positive score for the control tissue TMAs (and that was the 
lowest quick score possible) therefore control tissue was deemed negative for 
pCRMP2 Ser522 staining. Likewise, ovarian, renal, prostate and colorectal cancers 
were almost completely negative for pCRMP2 Ser522 staining, with less than 1.7% of 
TMAs expressing immunopositive staining. Positive staining was observed in breast 
TMAs, however positive staining constituted only 8% of total patient samples and 
these were all only a quick score of 3 (4/48). 
 
Interestingly, a greater number of sample cores taken from lymphomas were positive 
for pCRMP2 Ser522 staining. One in every ten of follicular lymphoma cores was 
positive for phosphorylated CRMP2, while a higher proportion of immunopositive 
cells were observed in samples cores from diffuse large B-cell lymphoma (DLBCL), 
with almost half (48.1%) of patient cases scoring positive and half of those with a 
quick score >3 (Figure 4.16). This data suggests that pCRMP2 Ser522 is present in 
more than just lung carcinoma. 
 
Consistent with the data in individual sections of lung tumours (Section 4.2.2.6), 
positive staining was predominantly localised within the nuclei of tumour cells 
(Figure 4.18). Furthermore, positive staining of tumour cells was more apparent in 
squamous cancers and less consistent in adenocarcinoma across these TMAs 
(Personal communication, Dr. Phil Coates). 
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Figure 4.16. Diffuse Large B-Cell Lymphoma (DLBCL). Heat-map of TMA scoring for DLBCL 
cases. Each panel illustrates the scoring, observed for different cases of follicular lymphoma following 
immunohistochemistry with the pCRMP2 Ser522 phospho-specific antibody, in terms of A) staining 
intensity (scale of 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining) and B) 
percentage of stained cells (scale: >0-5%; >5-20%; 21-40%; 41-60%; 61-80%; 81-100%, represented 
by increasingly darker shades of blue). Patient cases are represented numerically. Dark grey shading 
refers to the absence of a core for that patient case. 
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A 
Quick Score 
Category A (score for proportion staining) Category B (score for intensity staining) 
0 = no staining 0 = no staining 
1 = >0 – 5% 1 = weak staining 
2 = 6 – 20% 2 = moderate staining 
3 = 21 – 40% 3 = strong staining 
4 = 41 – 60%  
5 = 61 – 80%  
6 = 81 – 100%  
Total Score = A+B = 0 to 9 
 
B 
 Quick Score (A+B) 
1 2 3 4 5 6 7 8 9 Cases 
 
Controls 
 
 
0	    1	    0	    0	    0	    0	    0	    0	    0	    14 
Ovarian 
 
0	   0	   0	   1 0	   0	   0	   0	   0	   79 
Kidney 
 
0 0 1 2 0	   0	   0	   0	   0	   181 
Prostate 
 
0	   1 1	   0	   0	   0	   0	   0	   0	   25 
Breast 
 
0	   0	   4 0	   0	   0	   0	   0	   0	   48 
Colorectal Adenoma 
 
0	   0	   0	   2 0	   0	   0	   0	   0	   127 
Follicular Lymphoma 
 
0	   2 1 2 0	   0	   0	   0	   0	   46 
Diffuse Large B-Cell 
Lymphoma 
0	   9 10 13 5 0	   0	   0	   0	   77 
 
 
 
 
Figure 4.17. Frequency of additive quick scores in TMA result subsets. TMAs immunostained with 
pCRMP2 Ser522 antibody were scored using the quick score grading system. A) Quick score was 
determined by adding the scores for the proportion of cells stained (Category A) and the intensity of 
staining (Category B). Quick scores ranged from 0 to 9. B) Number of positively stained TMA quick 
scores for ovarian, kidney, prostate, breast, colorectal adenoma, follicular lymphoma, and diffuse large 
B-Cell lymphoma. The numbers in the table represent the total number of positive patient cases for the 
tumour specified while the case value represents the total number of patient samples for each TMA 
screen.   
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Figure 4.18. Immunohistochemical evaluation of pCRMP2 S522 protein expression in tissue 
microarrays of Diffuse Large B-Cell Lymphoma (DLBCL). Representative images of Diffuse Large 
B-Cell Lymphoma cores stained using pCRMP2 Ser522 illustrating A) negative expression of 
pCRMP2 Ser522 and B) positive (scored 2x2) expression of pCRMP2 Ser522. Images were taken with 
Olympus x20/0.75NA objectives on an Aperio ImageScope (Aperio Technologies, California, USA), 
with a magnified image (at x20 zoom) of the same. Scale bar = 100 µm. 
 
 
 
Negative Positive 
100 µm 100 µm 
	  
 
___________________________________________________________________________________ 
 
4. Validating tools to assess Cdk5 substrate phosphorylation in cancer 
220	  
4.2.3 Does phosphorylation of CRMP2 at Ser522 occur in the nucleus of 
tumour cells in culture? 
The immunostaining of the nucleus of lung tumour cells with the anti-pCRMP2 
Ser522 antibody was an unexpected result as there is very limited evidence that 
CRMP2 enters the nucleus of cells (at least in neurons where CRMP2 has mostly been 
studied). Therefore it was worthwhile to investigate whether CRMP2 protein 
expression could be detected in the nucleus of lung cancer cell lines. 
 
4.2.3.1 Cdk5 and its cofactor are expressed in human lung cancer cell lines 
Three human lung cancer cell lines representing each class of NSCLC were obtained 
to investigate CRMP2 phosphorylation and localisation; namely, the EBC-1 cell line 
derived from human lung squamous cell carcinoma, the A549 which is used as a cell-
based model of adenocarcinoma, and, finally, the NCI-H460 cell line which serves as 
a model of large cell carcinoma. 
 
Protein lysates of the three cell lines were subjected to SDS-PAGE and 
immunoblotted with antibodies to anti-CRMP2 (DSTT) and anti-pCRMP2 Ser522. 
The SHSY5Y human neuroblastoma cell line was included as a positive control. 
CRMP2 positive protein bands corresponding to the molecular weight of CRMP2 (62 
kDa) were detected in all lines and the pSer522 phosphospecific antibody also 
detected a band at this same molecular mass (Figure 4.19). Indeed, the ratio of 
pCRMP2 Ser522 to total CRMP2 appeared in the same range to that found in 
SHSY5Y cells. Similarly, all cell lines contained Cdk5 and p35, as judged by IB 
using selective antibodies, however the lung lines appeared to contain less p25 than 
the SHSY5Y cells (Figure 4.19). This data confirms that these cell models of lung 
carcinoma express CRMP2 and p35/Cdk5 and CRMP2 is phosphorylated at Ser522. 
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Figure 4.19. CRMP2 phosphorylation at Ser522 is recapitulated in NSCLC cell lines positive for 
CRMP2 and Cdk5 protein expression. Western blot analysis was performed to confirm CRMP2 and 
Cdk5 expression in three human immortal lung cancer cell lines representing each class of NSCLC. 
A549, EBC-1, and H460 cell lines were subject to SDS-PAGE and Western immunoblots probed with 
the following antibodies: anti-CRMP2, anti-pCRMP2 Ser522, anti-Cdk5, and anti-p35/p25. The 
SHSY5Y cell line was used as a positive control known for endogenous CRMP2, Cdk5 and cofactor 
protein expression. Western blots are representative of three independent experiments.  
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4.2.3.2 Fractionation of NSCLC cell lines reveals nuclear localisation of a 
potential CRMP2 isoform  
CRMP proteins are reported to be predominantly cytosolic protein however 
investigation of lung tumour biopsies identified a nuclear epitope recognised by the 
phosphospecific pCRMP2 Ser522 antibody (section 4.2.2.5). This raises the 
intriguing possibility that the presence of phosphorylated CRMP2 in the nucleus is a 
cause or consequence of tumourigenesis and could provide diagnostic or mechanistic 
insight into lung carcinoma. 
 
To obtain additional experimental evidence that CRMP2 truly exists in the nucleus, 
subcellular fractionation of the cancer cell lines that expressed phosphorylated 
CRMP2 protein was performed (Figure 4.20), and the resultant nuclear and 
cytoplasmic protein lysate fractions immunoblotted using total CRMP2 (DSTT) and 
pCRMP2 Ser522 antibodies. Cell lines were fractionated (as described in Chapter 2, 
section 2.2.7.4.) to generate cytoplasmic, membrane, nuclear (soluble), and nuclear 
(chromatin-bound) protein lysates. Fractionation efficiency was assessed by 
immunoblot using an antibody to anti-GAPDH (cytoplasm) and anti-histone H4 
(nuclear (chromatin-bound)) (Figure 4.20).  
 
CRMP2 protein expression (62 kDa) was found only in the cytoplasmic fraction for 
all cell lines (Figure 4.20A-D), however an apparent larger form of CRMP2 was 
detected in the soluble nuclear fraction. This band corresponded to the molecular 
mass of a known isoform of CRMP2 (CRMP2A) (75 kDa) that has an N-terminal 
extension due to alternative splicing (Figure 4.20A-D). This same band of apparent 
mass 75 kDa was also detected using the anti-pCRMP2 Ser522 antibody giving 
greater confidence that this is truly the CRMP2A isoform and indicating that 
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phospho-CRMP2 does exist in the nucleus. Interestingly, the shorter cytoplasmic form 
of CRMP2 (CRMP2B) was detected by the pCRMP2 Ser522 antibody, and this may 
be responsible for the weak cytoplasmic signal seen in the IHC studies above. This 
data suggests that alternative splicing of CRMP2 may contribute to its ability to 
localise to the nucleus and both isoforms of CRMP2 are regulated by phosphorylation 
at Ser522. 
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Figure 4.20. Identification of phosphorylated CRMP2 in nuclear fraction. Subcellular fractionation 
of A) A549, B) EBC-1, C) H460, and D) SHSY5Y cell lines. Cells were fractionated into cytoplasmic, 
membrane, soluble nuclear and chromatin-bound nuclear fractions, subjected to SDS-PAGE and 
immunoblots probed with the following antibodies: anti-CRMP2, anti-pCRMP2 Ser522, anti-Cdk5 and 
anti-p35/p25. Antibodies to anti-GAPDH and anti-histone H4 were used as subcellular markers for the 
cytoplasm and chromatin-bound nuclear fraction, respectively. Western blots are representative of three 
independent experiments.  
Mr  
(x103) 
IB: Cdk5 
IB: p35/p25 
Cy
top
las
m 
IB: pCRMP2 S522 
IB: CRMP2 
Me
mb
ran
e 
Nu
cle
us
 
(so
lub
le)
 
Nu
cle
us
 
(C
hr
om
ati
n) 
IB: Histone H4 
64 
51 
64 
51 
39 
28 
39 
28 
39 
28 
IB: GAPDH 
19 
14 
Mr  
(x103) 
IB: Cdk5 
IB: p35/p25 
Cy
top
las
m 
IB: pCRMP2 S522 
IB: CRMP2 
Me
mb
ran
e 
Nu
cle
us
 
(so
lub
le)
 
Nu
cle
us
 
(C
hr
om
ati
n) 
IB: Histone H4 
64 
51 
64 
51 
39 
28 
39 
28 
39 
28 
IB: GAPDH 
19 
14 
A B
Mr  
(x103) 
IB: Cdk5 
IB: p35/p25 
Cy
top
las
m 
IB: pCRMP2 S522 
IB: CRMP2 
Me
mb
ran
e 
Nu
cle
us
 
(so
lub
le)
 
Nu
cle
us
 
(C
hr
om
ati
n) 
IB: Histone H4 
64 
51 
64 
51 
39 
28 
39 
28 
39 
28 
IB: GAPDH 
19 
14 
Mr  
(x103) 
IB: Cdk5 
IB: p35/p25 
Cy
top
las
m 
IB: pCRMP2 S522 
IB: CRMP2 
Me
mb
ran
e 
Nu
cle
us
 
(so
lub
le)
 
Nu
cle
us
 
(C
hr
om
ati
n) 
IB: Histone H4 
64 
51 
64 
51 
39 
28 
39 
28 
39 
28 
IB: GAPDH 
19 
14 
C D
	  
 
___________________________________________________________________________________ 
 
4. Validating tools to assess Cdk5 substrate phosphorylation in cancer 
225	  
4.2.3.3 Nuclear expression of CRMP2 isoform confirmed by Mass 
Spectroscopic fingerprint analysis  
It remained possible that the signal detected by the pCRMP2 Ser522 antibody in the 
nuclear fraction and IHC was unrelated to CRMP2 therefore Mass Spectroscopic 
(MS) analysis was performed to obtain additional evidence supporting nuclear 
CRMP2A localisation as this technique is independent of antibody specificity.     
 
The EBC-1, HeLa, and HEK293 cell lines were subjected to subcellular fractionation 
to isolate the cellular nuclear fraction. Duplicate samples of these protein lysates were 
separated by SDS-PAGE before the gel was subsequently split into two, each half 
containing one sample from each cell line. One half of the gel was subjected to 
immunoblotting to confirm the presence and molecular mass of an anti-P-Ser522 
CRMP2 reactive protein; whereas, the second half of the gel was Coomassie stained 
and each band equivalent to pCRMP2 Ser522 staining (approx. 75 kDa) was excised, 
digested by trypsin, and sent to the Dundee Proteomic Service for MS fingerprint 
analysis, searching solely for tryptic peptides from human CRMP2 isoforms.  
 
MS analysis of the HEK293 nuclear fraction positively identified three peptides that 
corresponded to either isoform of CRMP2 (Figure 4.21). Additionally, a fourth 
peptide that corresponded to the N-terminal extension region only found on CRMP2A 
was identified, providing compelling evidence that CRMP2A is present within the 
nucleus, at least in HEK293 cells. Unfortunately, CRMP2 peptides were not detected 
to a significant level in HeLa and EBC-1 nuclear lysates suggesting that expression is 
relatively low in these cell lines, therefore it would be worth repeating this analysis 
starting from a larger number of cells and possibly including analysis of additional 
proteins with known nuclear expression levels as an internal positive control. 
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Figure 4.21. Identification of peptide corresponding to CRMP2A identified in HEK293 nuclear 
fraction. Schematic representation of MS analysis results following isolation of HEK293 nuclear 
component, SDS-PAGE, and excision of band of interest to depict A) the position of identified peptides 
within CRMP2A and B) the amino acid sequence of each peptide (highlighted) within the full protein 
sequence.  
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4.3 DISCUSSION 
Recent studies have linked abnormal expression of Cdk5 in many malignancies, 
including prostate cancer, lung cancer, and glioblastoma (Strock et al., 2006; Hsu et 
al., 2011; Feldmann et al., 2010; Eggers et al., 2011; Demelash et al., 2012; Liu et al., 
2011); however, the association of Cdk5 activity with tumourigenesis still remains 
controversial. Therefore, the work described in this chapter attempted to develop 
protocols to quantify the degree of Cdk5 substrate phosphorylation in human tumours 
as a surrogate for Cdk5 activity. Ideally a panel of protein sites that are very 
specifically regulated by Cdk5, with optimised and highly selective phosphospecific 
antibodies, would provide the most useful assay for Cdk5 action in tumourigenesis. 
This chapter presented characterisation of two potential substrates as initial members 
of such a panel, namely CRMP2 and tau. In addition, evidence for the first time was 
provided that abnormal phosphorylation of CRMP2, at a site that is sensitive to Cdk5 
inhibition or deletion (Ser522), is enriched in human tumour cells. Uncharacteristic 
for CRMP2, this abnormal phosphorylation is present in the nucleus of tumour cells 
and may represent a specific isoform of CRMP2. Hence, this work implicates 
abnormal Cdk5 activity as a cause or consequence of specific cancers and further 
investigation of the mechanism that leads to this abnormal epitope may provide 
diagnostic or therapeutic value. 
 
4.3.1 Cdk5 substrate phosphorylation is apparent in human tumours 
The biological function of CRMP2 is modulated by phosphorylation at residues 
Ser509 through Ser522, with phosphorylation of Ser522 acting as the priming 
mechanism that leads to the other modifications (Fukata et al., 2002, Brown et al., 
2004, Uchida et al., 2005, Yashimura et al., 2005, Cole et al., 2007). Consistent with 
previous findings inthe laboratory (Cole et al., 2006), evidence presented in this study 
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confirms that Cdk5 is both necessary and sufficient for phosphorylation of CRMP2 at 
Ser522. Furthermore, this work shows for the first time that Ser522 phosphorylated 
CRMP2 is present in lung tumour cells, with no detection in healthy lung tissue in the 
same sections. Phosphorylated CRMP2 was predominantly localised in the nuclei of 
lung tumour cells and may therefore be a distinctive characteristic of highly 
proliferative cells. If so, this would support the notion that abnormal CRMP2 
phosphorylation by Cdk5 may be associated with lung cancer development. Of 
course, it remains possible that an alternative Ser522 kinase is enhanced in tumours, 
or that the phosphatase responsible for dephosphorylation of Ser522 is lost. The 
identification of additional Cdk5 substrates for inclusion in these analyses would help 
dissect these possibilities. What appears likely, however, is that CRMP2 function is 
altered in lung tumours compared with surrounding healthy tissue.  
 
Until very recently, a role for the CRMP family in cancer biology had not been 
proposed however during this study of CRMP2 phosphorylation in tumours, two 
groups reported abnormal CRMP2 phosphorylation in human tumours (Oliemuller et 
al., 2013; Shimada et al., 2013). Firstly, total CRMP2 protein expression was 
increased in NSCLC tissue compared to healthy tissue, and phosphorylated CRMP2 
was predominantly detected in tumours cells and absent in healthy tissue (Oliemuller 
et al., 2013). The second group reported phosphorylated CRMP2 predominantly in the 
nuclei of breast cancer cells, and not in healthy mammary tissue, despite a significant 
decrease of CRMP2 mRNA and protein expression in the breast cancer tissue 
(Shimada et al., 2013). Although the role of CRMP2 protein expression remains 
unclear (increased CRMP2 expression in lung; decreased CRMP2 expression in breast 
cancer), possibly due to the poor quality of total CRMP2 antibodies, both groups 
report increased expression of phosphorylated CRMP2 predominantly localised in the 
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nuclei of tumour tissue. Of importance, these groups used a different phosphospecific 
CRMP2 antibody to the current work, although the epitope was overlapping with 
Ser522. They used an antibody that recognises a multiply phosphorylated peptide 
(pThr509, pSer518, and pSer522) and suggest an association of GSK3 to cancer 
progression as our lab have reported Thr509 and Ser518 as targets for this protein 
kinase. However this clearly provides further confidence that it is truly CRMP2 that is 
being detected in these different studies. Hence, the results described in this chapter 
add to a growing body of evidence recognising abnormal CRMP2 in tumour cells and 
implicating the modulation of CRMP2, potentially through Cdk5 activation, as an 
important aspect of tumourigenesis. It is worth noting that there are three completely 
novel aspects to the findings presented in the current study: firstly, the link with Cdk5 
rather than GSK3; secondly, the identification of the long isoform of CRMP2 as the 
nuclear form; and thirdly, the potential difference between cancer types in intensity of 
staining of pCRMP2 Ser522.  
 
4.3.2 CRMP2 phosphorylation is greater in squamous cell carcinoma compared 
to adenocarcinoma 
Two separate studies of lung tumour cells with the pCRMP2 Ser522 antibody 
identified both adenocarcinoma and squamous cell carcinoma, and both suggested 
that staining was significantly more intense (p = 0.03, student’s t-test) in squamous 
cell carcinoma, exhibiting a higher histological grade in comparison to 
adenocarcinoma. This data may indicate increased CRMP2 phosphorylation in 
squamous cell carcinoma as a result of increased Cdk5 activity however an 
assessment of Cdk5 activity would be required to confirm this.  
 
While immunohistochemistry is emerging as a useful resource in the subtyping of 
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non-small cell carcinoma, it is important to emphasise that the majority of 
adenocarcinoma and squamous cell carcinoma can already be distinguished based on 
standard morphological criteria, with immunostains required in only a subset of cases 
(Rehktman et al., 2011; Righi et al., 2011; Lou et al., 2010; Edwards et al., 2010). 
Therefore, immunostaining with pCRMP2 Ser522 antibodies may not provide added 
diagnostic value as a marker for differentiating between adenocarcinoma and 
squamous cell carcinoma however an immunopositive pCRMP2 Ser522 stain might 
be able to distinguish a metastatic squamous cell carcinoma of primary lung origin 
from an origin in alternative sites. Of course, this would need to be confirmed by 
future more directed studies. Additionally, dissecting the role of Cdk5 and/or CRMP2 
in the mechanism of tumourigenesis in the tumour subtypes may provide novel 
targeted cancer therapeutic strategies. Interestingly, in the study by Oliemuller and 
colleagues, a significant correlation between phosphorylated CRMP2 and poor 
outcome in NSCLC patients was proposed (Oliemuller et al., 2013). Such an analysis 
was not possible in the present work but would be worth investigating using our more 
specific antibody. It is worth noting that adenocarcinoma and squamous cell 
carcinoma have variable rates of growth, therefore the staining intensity may 
potentially be linked to the rate of progression of the disease.  
 
4.3.3 Phosphorylated CRMP2 in other cancers 
Phosphorylated CRMP2 was not a common feature of all cancers, suggesting that the 
phospho-specific CRMP2 antibody is not simply identifying a general upregulation of 
proliferation, rather a more specialised property of a few cancer types (e.g. lung, 
lymphoma, and breast). In all cases, immunopositive staining was localised 
predominantly in the nuclei and not found in surrounding healthy tissue. Furthermore, 
immunopositive staining was not detected in all tumour cells providing confidence 
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that the nuclear staining was not background noise but rather indicative of some 
selective mechanism that could provide diagnostic or therapeutic value. 
 
Oliemuller et al., proposed that CRMP2 participates in cell division in a 
phosphorylation-dependent manner (Oliemuller et al., 2013). It has been known for 
some time that CRMP2 phosphorylation impairs its ability to bind tubulin structures 
therefore, these researchers extrapolate that knowledge to suggest phosphorylated 
CRMP2 could delay spindle assembly and entry into the metaphase of the cell cycle; 
conversely, non-phosphorylated CRMP2 would increase microtubule stabilisation and 
interfere with cell cycle progression into anaphase. During cell division, the mitotic 
spindle, a highly specialised and dynamic structure that mediates the alignment of 
replicated chromosomes to the equatorial plane and their subsequent transmission to 
daughter cells, is formed by microtubules (Rovini et al., 2011). Microtubules are 
dynamic polymers formed by tubulin heterodimers, in continuous equilibrium 
between growth and destruction (Downing et al., 1998) and the concurrent activity of 
microtubule-associated proteins (MAPs), including the CRMP family, are required to 
achieve microtubule formation. MAPs contribute to the transport, localisation, and 
regulation of microtubule components (Bhat & Setaluri, 2007). CRMP2 has been 
detected in the mitotic spindle of transformed mouse and human cells (Tahimic et al., 
2006) and, recently, it was demonstrated that CRMP2 binds to tubulin during mitosis, 
whereas its depletion leads to destabilised anaphase microtubules and altered spindle 
position (Lin et al., 2011). This suggests that CRMP2 plays an important role in 
mitosis and CRMP2 phosphorylation defects may result in important defects during 
cell cycle progression, which is often present in cancer cells enabling uncontrolled 
cell proliferation. However, this would not explain the selective pCRMP2 staining 
across different tumour types and requires further study.  
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4.3.4 CRMP2 nuclear localisation in cancer cell lines 
The CRMP family have always been considered cytosolic proteins as they are 
predominantly expressed in the neurites and cell bodies of neurons, and when the 
predominant isoform (CRMP2B) is transfected into COS cells, the recombinant 
protein localises to the cytoplasm ((Goshima et al., 2009), data not shown). Therefore 
it was surprising to observe pCRMP2 Ser522 expression in the nuclei of tumour cells. 
 
4.3.4.1 CRMP2A is observed in the nucleus of cancer cell lines 
CRMP2 is alternatively spliced to generate two subtypes (A and B; long- and short-
form, respectively) (Bretin et al., 2005; Minturn et al., 1995; Goshima et al., 1995; 
Inagaki et al., 2001; Fukata et al., 2002), derived through an N-terminal extension 
(Yuasa-Kawada et al., 2003). When total cell lysates are analysed by IB for CRMP2 
expression both isoforms are usually detected, the major isoform (CRMP2B) with 
apparent molecular mass of 62 kDa and a second long-form at 75 kDa (CRMP2A). 
Interestingly, subcellular fractionation of multiple immortalised cell lines revealed 
CRMP2B protein expression only in the cytoplasmic fraction, while CRMP2A was 
detected solely in the nuclear fraction. This isoform specific localisation has never 
been previously reported and additional mass fingerprinting data from HEK293 cells 
supported this finding. 
 
There is evidence to suggest that post-translational modifications of CRMP2 can alter 
its cellular localisation. For example, post-translational processing of CRMP2 into a 
58 kDa isoform has been reported to alter the spatio-temporal localisation (Hao et al., 
2006). CRMP2 is thought to contain a nuclear localisation signal (NLS) within 
residues Arg171 – Lys472 that becomes unmasked after C-terminal clipping. It is 
possible that the N-terminal extension in CRMP2A either unmasks this NLS or 
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contains an alternative NLS. Clearly, mutation of the central NLS within CRMP2A or 
addition of the N-terminal extension to fluorescent proteins could uncover the relative 
importance of each region to the nuclear localisation of CRMP2A. It would also be 
worth investigating whether polymorphisms in the N-terminal region of the CRMP2A 
gene are associated with cancer genesis, progression, or prognosis. Of note, the N-
terminal extension of CRMP2A contains an additional proline-directed 
phosphorylation site with some aspects of a Cdk5 consensus sequence. 
 
4.3.4.2 A novel role for the long form of CRMP1 in tumourigenesis 
There are some lines of evidence implicating the long-form of a related CRMP 
protein in cancer (Pan et al., 2010, Pan et al., 2011, Wang et al., 2012). Pan and 
colleagues reported that the long-form of CRMP1 (LCRMP1), which undergoes a 
similar N-terminal exon 1 splice event as CRMP2A, has a positive correlation with 
lung cancer cell invasiveness using both in vitro and in vivo invasion assays (Pan et 
al., 2010). Furthermore, high LCRMP1 mRNA expression was associated with poor 
overall and disease-free survival in NSCLC patients.   
 
4.3.5 Developing additional readouts of Cdk5 activity in vivo 
The original aim of this chapter was to develop a panel of validated Cdk5 substrates 
that could simultaneously provide quantitative information on overall Cdk5 activity in 
human tissue. A major hurdle in this quest was the development of a suitable cell 
model system in which to validate Cdk5 substrates and further investigate the 
relationship between preferred substrate sequence determinants and degree of 
substrate phosphorylation.  	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4.3.5.1 Inefficiency of the triple transfection system 
Despite successful overexpression and generation of active Cdk5 complexes in 
HEK293 cells, triple transient transfection in these cells proved unreliable. It is known 
that co-transfection of large copy numbers of multiple different gene promoters can 
‘squelch’ key transcription factors, resulting in reduced activity of one or more of the 
gene promoters. However, substantial experiments comparing different ratios of 
expression constructs did not overcome the problems. HeLa cells presented a 
reasonable alternative as they were reported to express endogenous Cdk5 and would, 
therefore, only require a double transfection (cofactor and substrate), while allowing 
direct comparison of p35 with p25 (as neither was thought to be present in these 
cells). Unfortunately, Cdk5 expression was not sufficient to allow induction of 
endogenous activity by transfection with p35 or p25. Future development of a suitable 
cell system may require the use of targeted stable insertion of inducible Cdk5 and 
cofactor genes, permitting subsequent single transient or stable transfection with 
substrates of interest. 
 
4.3.6 Conclusions 
The results described in this chapter present four major advances: firstly, they provide 
additional evidence that abnormal CRMP2 phosphorylation occurs in the nuclei of 
multiple tumour types; secondly, they implicate abnormal Cdk5 activity in lung 
cancer, breast cancer, and lymphoma; thirdly, they identify the long isoform of 
CRMP2 (CRMP2A) for the first time as the nuclear form of this protein and the one 
linked to tumourigenesis; and finally, they provide preliminary evidence that the 
intensity of staining of pCRMP2 Ser522 varies between adenocarcinoma and 
squamous cell carcinoma. 
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Overall, the data will serve as a platform to improve mechanistic insight into 
tumourigenesis in specific forms of cancer that will hopefully guide additional 
diagnostic and therapeutic strategies for cancer in the near future. 	  
4.4 SUMMARY 
In summary, cell-based and immunohistochemical techniques were utilised in order to 
validate substrates and develop tools to investigate Cdk5 substrate phosphorylation in 
human cancer. Work in this chapter generated evidence that CRMP2 phosphorylation 
at Ser522 reduced when Cdk5 was inhibited in primary cells, and increased when 
Cdk5 was overexpressed. This gave confidence that phosphorylation of Ser522 on 
CRMP2 was a reasonable surrogate for Cdk5 activity in intact cells and tissue. In 
NSCLC and DLBCL, pCRMP2 Ser522 was predominantly observed in the nuclei of 
tumour cells but absent in normal cells, thereby implicating Cdk5 activity and 
modulation of CRMP2 as an important aspect of tumourigenesis. Other groups 
recently published related findings, which gave confidence that this phosphorylation 
event is a potential marker of an aspect of tumourigenesis. 
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5.1 RESEARCH QUESTIONS SURROUNDING CDK5 
The initial discovery of Cdk5 was made due to its strong sequence homology to Cdk1 
and Cdk2 and added a new member to the Cyclin-dependent kinase family, albeit an 
apparently uncharacteristic member with no association with known cyclins. The 
majority of studies have since focused on the functions of Cdk5 in the development of 
the nervous system and in differentiated neurons where it appears enriched. More 
recently, however, the physiological functions of Cdk5 are being reassessed due to an 
increasing number of proposed substrates not involved in neuronal functions. 
Collectively, these substrates do not appear to have a specific consensus sequence 
differentiating them from substrates of other Cdks, making it even more vital to 
validate physiological and pathophysiological targets. Cdk5 has previously been 
associated with malignancy however this remains extremely controversial. The role of 
Cdk5 in disease is further complicated by the proposal that proteolytic cleavage of the 
Cdk5 activator, p35 results in altered subcellular localisation, dysregulation of kinase 
activity and altered substrate profile, with this process contributing to the 
pathophysiology of multiple diseases including neurodegenerative disease and cancer. 
In order to provide evidence for or against the proposed role of Cdk5 in disease, the 
work in this thesis aimed to further characterise Cdk5 substrate selection at the 
primary sequence level, determine whether or not proteolytic cleavage of p35 to p25 
alters the specificity of the Cdk5 complex to specific substrates, and, finally, 
investigate whether abnormal phosphorylation of Cdk5 substrates was present in 
tumour cells.  
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5.2 MAIN CONTRIBUTIONS OF THE THESIS 
The present study systematically defined a consensus sequence for Cdk5 substrate 
recognition, validated Cdk5 substrates using specific assessment criteria to establish 
whether they could act as a read-out of Cdk5 activity in cells and tissues, and 
examined substrate phosphorylation in human tumours. A major outcome of this work 
was the identification of an abnormally phosphorylated Cdk5 substrate in lung 
tumours suggesting that abnormal Cdk5 substrate phosphorylation may contribute to 
an aspect of the disease process or serve as a clinical diagnostic. There were two 
unusual and novel aspects to this abnormal tumour associated phosphorylation event: 
firstly, that the substrate, CRMP2 was phosphorylated at Ser522 only in the nucleus 
of the tumour cells; and secondly, that it appeared to be a minor isoform of this family 
of proteins.  
 
5.2.1 Abnormal Cdk5 phosphorylation in cancer 
CRMP2 was characterised as a substrate specifically regulated by Cdk5 in neurons 
therefore abnormal phosphorylation of this site was investigated as a read-out of 
altered Cdk5 activity in tumour cells. As a result, this is the first study to associate 
Cdk5 regulation of CRMP2 in tumourigenesis. Interestingly, studies published 
towards the end of the current work reported abnormal CRMP2 phosphorylation at 
Thr509, Ser518, and Ser522 in both breast and lung cancer (Shimada et al., 2013; 
Oliemuller et al., 2013). However, they did not link Cdk5 to this event, rather the 
downstream regulator GSK3, therefore they may have missed the key regulatory 
pathway in this process as Cdk5 phosphorylation of Ser522 is a rate-limiting step for 
GSK regulation of CRMP2. Both of these studies identified abnormal CRMP2 
phosphorylation in the nuclei of tumour cells. Detection in breast tissue suggests that 
abnormal Cdk5 phosphorylation is more widespread than lung tumours and this work 
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found immunopositive staining in a few cancer types but not all, suggesting this is not 
just a marker of general upregulation of proliferation. Furthermore, the current work 
provides preliminary evidence that CRMP2 phosphorylation appeared to be more 
intense in squamous cell carcinoma compared to adenocarcinoma. 
 
The abnormal CRMP2 phosphorylation was enriched in the nuclei of tumour cells in 
direct contrast to neuronal CRMP2 where it only exists as a cytosolic protein. This 
work suggests that it is the long-form of CRMP2, which was not investigated in the 
recent reports of CRMP2, GSK and tumourigenesis. 
 
In summary, the work presented in this thesis implicates abnormal Cdk5 regulation of 
CRMP2 as a cause or consequence of specific cancers, and presents a potential new 
pathway to serve as a platform to enhance mechanistic insight into tumourigenesis in 
specific forms of cancer. Additionally, further investigation of the mechanism that 
leads to abnormal phosphorylation of CRMP2 may present new opportunities for 
diagnostic and therapeutic strategies.   
 
5.2.2 Towards a Cdk5 consensus sequence and the role of p35 cleavage 
In the present study, in vitro peptide analysis revealed an unanticipated, extremely 
selective peptide substrate profile for Cdk5 leading to the conclusion that Cdk5 
substrate selection is defined, at least in part, at the primary sequence level. 
Subsequently, P-K-S-P-R-K was proposed as the optimal sequence consensus for 
Cdk5 substrate phosphorylation from the examined peptide combinations. In support 
of this consensus, a previous publication determined the consensus sequence of 
optimal substrates by sequencing the mixture of products generated during a brief 
reaction with a kinase of interest and established the optimal consensus for p35/Cdk5 
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as H/P-K-S-P-K/R-H/R/K  (Songyang et al., 1996). Expanding on these findings, the 
current work showed that the N-terminal -2 residue appears to be crucial for peptide 
substrate phosphorylation and residues surrounding the phosphoacceptor residues 
affect the rate of substrate phosphorylation, signifying the importance of primary 
sequence for Cdk5 substrate selection. Unfortunately, an optimal consensus sequence 
for substrate recognition is not sufficient to identify all bona fide substrates, as 
substrate phosphorylation in vivo does not rely solely on primary sequence for 
recognising substrates. However, this information provides an evidence base to 
examine proteins for this motif and investigate whether Cdk5 phosphorylates these 
proteins.  
    
It is often reported that the catalytic ability of Cdk5 is significantly increased when 
complexed to p25, in comparison to p35; therefore conversion of p35 to p25 is 
believed to induce Cdk5 ‘hyperactivity’ contributing to pathophysiology (Tsai & 
Cruz, 2004) however very few studies have rigorously demonstrated relative 
hyperactivity of the p25/Cdk5 complex. In the present study, there were no clear 
differences in substrate phosphorylation rates for the two major complexes in vitro 
using peptide or protein substrates, leading to the conclusion that inherent activity was 
similar for both complexes. Consequently, cellular toxicity of p25/Cdk5 in vivo 
cannot be attributed to simple differences in the catalytic parameters between the two 
complexes. Although a previous publication proposed that truncation of p35 resulted 
in increased phosphorylation of tau, the difference was at a single point in the rate 
curves and was not overly convincing (Hashiguchi et al., 2002). Other publications 
have also failed to detect differences in specific activity of the two complexes 
(Peterson et al., 2002; Kusakawa et al., 2000; Sukaue et al., 2005). Therefore, 
truncation of p35 does not alter the substrate specificity of Cdk5 nor the catalytic 
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efficiency measured in vitro. 
 
This finding is perhaps not that surprising as the Cdk5 activation domain on p35 lies 
between residues 138 – 291, consisting of three domains essential for interaction and 
activation (Pant et al., 2003), and cleavage of p35 by calpain at residues 98 and 99 
does not interfere with the activation domain structure. However it is important to 
note that both Cdk5 complexes were compared using a soluble assay system and as 
cleavage removes the membrane localisation domain of p35 this may affect the 
inherent structure of the Cdk5 interaction domains. Although it is perhaps more likely 
that the cleaved p25 cofactor exposes Cdk5 to a distinct substrate pool or alters its 
stability and this promotes altered Cdk5 activity in intact cells. Further studies are 
required to distinguish between these possibilities and could help develop strategies to 
selectively inhibit the p25/Cdk5 complex as a potential therapeutic target.      
 
5.3 FUTURE DIRECTIONS 
The work described in this thesis has presented a consensus sequence motif specific to 
Cdk5 that may aid in the identification of novel Cdk5 substrates and provided 
evidence to implicate abnormal Cdk5 phosphorylation of CRMP2 in tumourigenesis. 
However, the mechanisms underlying the nuclear localisation and isoform selective 
actions of CRMP2 and Cdk5 in tumours are still to be uncovered. Additional 
functional and mechanistic studies to further elucidate the role of Cdk5 in 
tumourigenesis would extend the work described here and are necessary to pave the 
way to more clinically relevant findings.  
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5.3.1 Identification of novel Cdk5 substrates 
The consensus sequence proposed for Cdk5 in this study could be used in future 
studies to search for and identify novel substrates of Cdk5, extending understanding 
of the physiological relevance of Cdk5. The predicted Cdk5 consensus sequence 
extends the minimal SP motif and introduces specificity-determining residues that 
may be utilised in silico to identify potential in vivo substrates of Cdk5. 
Computational analysis using the proposed consensus substrate phosphorylation motif 
could be used to identify novel substrates that harbour the P-K-S-P-R-K consensus 
phosphorylation motif by employing short peptide sequences as specificity 
determinants specific to Cdk5 and searching protein and phosphorylation-site 
databases for proteins containing the specificity-determining consensus sequence 
motif. The use of short peptide motifs are large enough to confer specificity however 
they are also small enough to cover a broad spectrum of proteins, therefore 
introducing the use of physiologically relevant filters such as protein structure and 
accessibility of the catalytic site as well as subcellular localisation could be applied to 
refine the substrates identified as potential substrates of Cdk5. Potential substrates 
would then be analysed further to substantiate the screening results through substrate 
validation experiments, such as immunoprecipation kinase assay of full-length 
proteins and site-directed mutagenesis of the target motifs. Alternatively, the proposed 
Cdk5 consensus sequence could be used in conjunction with Stable Isotope Labelling 
of cultured Cells (SILAC)-type experiments coupled with mass spectrometry to 
identify novel substrates of Cdk5.  
 
5.3.2 Investigating the role of Cdk5 in Cancer 
The present study presented evidence that implicated altered Cdk5 activity as an 
important aspect of tumourigenesis, presenting Cdk5 as a potential therapeutic target, 
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therefore future studies should focus on confirming altered Cdk5 activity in tumours. 
Expanding the current research by examining a greater panel of confirmed in vivo 
substrates of Cdk5 for enhanced phosphorylation in tumours at sites specifically 
regulated by Cdk5 using optimised and highly selective phosphospeciifc antibodies 
would provide further evidence of potentially altered Cdk5 activity in tumour cells. 
Additionally, the use of murine models could be used to examine the effect of altered 
Cdk5 activity in tumourigenesis. For example, strategies to transfer tumour cells or 
injecting mice with viruses that can induce lymphomas could be used to investigate 
the impact on tumourigenesis in Cdk5 knockout models and examine the role of Cdk5 
in tumour formation. Furthermore, future studies are required to fully elucidate the 
role of Cdk5 in tumourigenesis and determine if altered Cdk5 activity is associated 
with invasion, migration, and metastasis of cancer cells and determine if inhibiting 
Cdk5 activity can reduce metastasis and offer Cdk5 as a potential therapeutic target. 
Therefore, work evaluating the role of Cdk5 in tumours should focus on migration 
regulation and the potential for changes in invasion and metastasis in cancer. The use 
of knockdown or overexpression vectors, or small molecule Cdk5 inhibitors coupled 
with migration and invasion assays may help establish the role of Cdk5 in metastasis.  
 
5.3.3 Mechanistic Studies 
Further work with CRMP2-receptor fusion proteins would help evaluate the role of 
the isoform specific N-terminus of CRMP2 in its localisation and phosphorylation by 
Cdk5, both in healthy cells and tumours. Similarly, development of cell systems with 
strong pCRMP2 Ser522 nuclear staining would enable the dissection of upstream 
regulation (for example, Cdk5 dependence) and investigation of the role of cell cycle 
regulation in its appearance. Furthermore, the use of CRMP2 mutants in such systems 
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(for example, S522A or tubulin binding deficient) would help establish the 
importance of CRMP2 regulation in the survival and proliferation of the tumour cells. 
 
5.3.4 Clinical Utility 
If altered Cdk5 regulation of CRMP2 is associated with initiation, invasion, 
migration, and/or metastasis of specific cancers then this antibody may provide some 
diagnostic value on prognosis, while Cdk5 would become a potential therapeutic 
target. The tumour profile of pCRMP2 Ser522 and differential intensity in squamous 
cancer compared to adenocarcinoma requires further investigation as this may provide 
additional clinical utility for this marker. A greater proportion of immunopositive 
cells with higher intensity was observed for the faster growing, more aggressive form 
of non-Hodgkins lymphoma (double large B-cell lymphoma) compared to the 
indolent form of non-Hodgkins lymphoma (follicular lymphoma) raising the 
hypothesis that staining intensity of the pCRMP2 Ser522 antibody may be related to 
the proliferation rate and/or aggressiveness of the tumour. The two types of NSCLC 
have variable rates of growth however differences in biological aggressiveness 
between squamous cell carcinoma and adenocarcinoma of the lung are not well 
understood and the staining intensity may potentially be linked to the rate of 
progression and/or aggressiveness of the disease. Further investigation may uncover 
the use of this antibody as a biomarker to distinguish between aggressive versus non-
aggressive cancer. Furthermore, this antibody may be useful in providing information 
about the origins of secondary tumours. Cancers of epithelial origin invade local 
tissues and metastasise to distal sites forming secondary tumours therefore a phospho-
CRMP2 stain might be able to distinguish a metastatic squamous carcinoma of 
primary lung origin from an origin in other sites however this would require further 
investigation. 
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5.4 CONCLUSION 
These studies have provided novel insight into Cdk5 activity and one of its substrates 
in cancer and will hopefully provide greater impetus to investigate Cdk5 activity as a 
therapeutic or diagnostic target in cancer.  
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